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Preface
This thesis is the culmination of philosophical confluences from complexity, informatics, and system
science. As such, it might not come as a surprise to the reader that this author inherits his views
from a lineage of scientists sharing the goal of understanding common principles of organization
in nature. A domain-agnostic view where more important than the things (T ) under scientific
scrutiny, are the relations (R) among the things themselves; and, by means of a discretionary
resolution, the higher-order relations among things-of-things, all of which are often hidden in the
simple definition of a system [21], as S = {T,R} .
Systems thinking influences from the early 20th century Cybernetics group—or the later System’s
Movement, as these scientists are often refereed to—are embedded onto every discipline practiced
today in science: from biology to architecture to the social sciences. Today, this field is known
as Complex Systems. True to its post-war origins, it encompasses scientists from a diverse range
of backgrounds, often scattered across walled-in institutional domains. Recently, however, there
has been a return for methodologies developed by the movement, as seen by the growing number
of grant calls and awards specifically aimed at transdisciplinary science. A example, is the U.S.
National Science Foundation Research Traineeship (NRT), awarded to Indiana University to train
dual-domain PhD students in complex networks and systems, and another domain of application.
My interests in systems thinking and transdisciplinary science comes from much earlier and
through a non-linear academic path towards my doctoral training. This path encompasses the
management information systems undergraduate—for which later, inspired by von Bertallanfy [22],
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I taught General Systems Theory (GST) courses—to organizational systems during my business
management masters degree. Aside from teaching GST at Universidade Regional de Blumenau
(FURB), practical knowledge came from managing the Technology Development and Transfer Lab-
oratory (LDTT, in portuguese), a transdisciplinary enterprise bridging academia, government, and
private sector, with a mission to help address societal issues through technological research. There,
I helped develop a city-wide electronic health record system, which later enabled data science ques-
tions addressed in this thesis (in chapter 3). Indeed, if one were to trace the academic distance from
the Cybernetics group to this author through his advisor, one would soon realize a much smaller
distance path than Milgram, in his average six-degree of separation, would have predicted.
As much as the Systems Movement were a constant throughout my academic training, in this
thesis the reader will only get a glimpse of a much broader research agenda. An agenda grounded
in the same philosophy, of transdisciplinary, collaborative research, with an added personal vision
of societal impact.
Figure 1: The Social Symbiome. Physical, mental,
and social well-being is influenced by multi-level com-
plex networks. Reproduced from Pescosolido [23] and
Pescosolido et al. [24].
The main experimental setting, or better yet,
the domain of inquiry of this thesis, is pharma-
coepidemiology. Still, the complex network meth-
ods and the advances in these methods we present,
are orthogonal to any specific domain of applica-
tion, a unique characteristic of systems science. Af-
ter all, the network is a ubiquitous representation
of a system. Additionally, this author is concerned
with the societal impact of complexity science and
the real-world outcomes from his research. This
may be evident from some of the questions we
tackle in this thesis. After all, the cybernetic his-
torical background help us well remember the war
effort by which the scientists were pulled together
in the first place.
In this thesis we study the DDI phenomena, the
increase in adverse reactions caused by the co-administration of drugs known to interact. From a
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system’s perspective, the DDI phenomena is a public health issue caused by solutions to previous
problems: the development of drugs to treat diseases affecting human health. These paradoxical
influences—e.g., increased hospitalization and health debilitation from overly administration of med-
ications that should make patients healthy—are common in systems science, where achievements in
the individual part can cause problems at the whole system level. The task of the complexity scien-
tist is then to visualize the system as a whole and its parts, to uncover a signal that can influence the
system, disrupting it towards desired outcomes. In our case, possibly discovering still unknown DDI
and lowering their levels in the whole population. Finding and leveraging such signal is like finding
an tapping into a hidden collective intelligence of the system. The complex systems problem then,
is that factors affecting human health occur at several scales, from gene and protein interactions,
to the cellular, tissue, organism, and social levels (see fig. 1). Thus, understanding and controlling
human health is especially complex due to the inter-level interactions that cannot be integrated
away and thus form true control hierarchies [25]. Therefore my research agenda—initiated with
this thesis—is a transdisciplinary approach towards the understanding of the multi-level
complexity in human health, spanning from micro biological to macro population levels.
During my doctoral training I contributed of a variety of interdisciplinary projects. Not all
were accommodated into this thesis as complete chapters. For instance, early in my studies I
collaborated with Kwan Nok “Norbert” Chan, a political scientist, to predict discourse polarization
in the US Congress [RBC1, RBC2, RBC3], and predict conflict in social unrest using social media
and machine learning methods [RBC4]. Since then, most of my research shifted to human health.
For example, in Correia, Gates, Wang, and Rocha [RBC5] we describe the development of a
Python package to study control and redundancy in Boolean networks as models of biochemical
regulation. This work pertains to the biological, molecular level of my overall research agenda
and was published in the journal Frontiers of Physiology. Then, in this thesis, Chapter 3 is a
city-wide pharmaco-epidemiological study on factors explaining the dispensation of known drug-
drug interactions. This work is currently under review, but a pre-print version can be seen in
Correia, Araújo, Mattos, Wild, and Rocha [RBC6]. Similarly, a previous version of chapter 4 was
published in the Pacific Symposium in Biocomputing (PSB). There, we determined the potential of
Instagram for public health monitoring and surveillance of DDI, ADR, and behavioral pathology at
large. We demonstrated that Instagram contains much drug- and pathology specific data and that
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complex network analysis provided an important toolbox to extract health-related associations. This
work was later selected by renowned scientist Russ Altmann in his American Medical Informatics
Association (AMIA) Translational Bioinformatics Year in Review 2016 [26]. An expanded version
of this work, containing additional digital-cohorts of interest and data from Twitter, is presented
hereinafter. In order to study an additional level of the complex problem of DDI & ADR affecting
human health, in chapter 5, including data from the FDA’s Adverse Report System and the scientific
literature (PubMed), we offer a preliminary glimpse into whether social media mentions of DDI and
ADR precede those occuring in official channels. This latest work is upcoming as an independent
journal paper.
As with most—if not all—transdisciplinary work, the present thesis includes collaboration with
additional authors that I would like to note. Chapter 3 was co-written with Luciana P. de Araújo,
Mauro M. Mattos, and Luis M. Rocha [RBC6]. Chapters 4 and 5 were co-written with Luis M.
Rocha [RBC7]. Also, chapter 5 utilizes PubMed data generated by Ian Wood. Finally, in chapter 2
there are passages co-written with Alexander Gates and Xuan Wang [RBC5].
Thank you for taking the time to read this thesis. It is my hope that you enjoy the reading just
as much as I enjoyed the writing.
–Rion Brattig Correia,
April 12th, 2019. Bloomington, IN.
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Rion Brattig Correia
PREDICTION OF DRUG INTERACTION AND ADVERSE REACTIONS, WITH DATA
FROM ELECTRONIC HEALTH RECORDS, CLINICAL REPORTING, SCIENTIFIC
LITERATURE, AND SOCIAL MEDIA, USING COMPLEXITY SCIENCE METHODS
Human health conditions, such as adverse drug reactions (ADR) caused by drug-drug interactions
(DDI), are too complex to be tackled effectively by a single domain of expertise. Their associated
wide range of data sources, from electronic health record (EHR), social media, to the published
scientific literature, requires an interdisciplinary approach common to complexity science and its
sub-fields of data and network science. We divide our work in three parts. Using city-wide public
health care dispensation records from Blumenau—a mid-size city in southern Brazil—we report
primarily on the large number of major DDI being prescribed, with women having a 60% increased
risk of DDI when compared to men—the increased risk becomes 90% when only major DDI are
considered; this DDI risk also increases with age, with patients age 70-79 having a 34% risk of
DDI when they are dispensed two or more drugs concomitantly; and our ability to correctly classify
patients with DDI using machine learning techniques. Then we study and predict DDI and ADR
from social media data. We focus on different cohorts of interest, for which we build networks from
Instagram and Twitter timelines. The network analysis uncovers population-level associations of
drugs and symptoms, useful for public health surveillance, as well as affords a means to identify
edges to predict putative known and unknown DDI and ADR. Lastly, we present a preliminary
study of the timing of DDI observation across different data sources such as social media, clinical
reports, and the scientific literature on DDI. We select a set of DDIs and show that social media
measurements of DDI and ADR mentions may precede scientific literature when large longitudinal
social media data is available. We exemplify with the case for the co-administration of opioids
and benzodiazepines. Overall, the results we present in this thesis have important consequences
for private and public health policy and regulation, further demonstrating that the methods of
complexity science are very useful for studying DDI in particular and public health in general, to
the benefit of society.
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Chapter One
Motivation
“Very abstract and general questions, are not directly
amenable to an experimental test. They have to broken
down into more specific terms, terms directly translatable
into experimental procedure”
Arturo Rosenblueth, 1945 (with Norbert Wiener)
Mexican Physiologist
1.1 Complex systems science & public health
It is estimated that every year the United States spends between $30.1B and $136.8B because
patients had a serious reaction to a drug they took [27]. For Canada this number is $35.7M, or
about $1 per capita [28], affecting 6.7% of all hospitalized patients [29]. More than 30% of so
called Adverse Drug Reactions (ADR) are caused because patients took two or more drugs that
had a Drug-Drug Interaction (DDI) [30]. DDIs are a threat to public health worldwide [RBC6,
31, 32, 33], with physicians often prescribing drugs that may lead to DDIs out of habit or lack of
information [34]. Patients are increasingly prescribed more drugs, i.e. polypharmacy, so the odds
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of DDIs continues to grow. This is particularly the case in aging populations, as patients are more
likely to have multiple health conditions. Despite the magnitude of the problem, the incidence of
DDIs in primary care is largely unknown. New resources for DDI discovery could help prevent large
human suffering and financial losses. In this thesis we study the DDI phenomena from multiple
data sources, using data from electronic health records, clinical reporting, scientific literature, and
social media. We do so with an interdisciplinary approach using methods from data and network
science, two sub-fields of complexity science.
From a public-health perspective, the concomitant administration of drugs with adverse interac-
tions is of great concern [35, 36, 37]. Better identification and prediction of administration of known
DDIs in primary- and secondary-care could reduce the number of patients seeking urgent care in
hospitals, resulting in substantial savings for health care systems worldwide [33, 38, 39]. However,
most efforts to measure the scale of ADR from DDI focus on hospitalizations and emergency room
visits [28, 36, 37, 38, 40, 41, 42] or literature meta-analysis that aggregate other studies [33, 35,
43]. Few studies [30, 44, 45, 46] so far have been able to characterize the DDI problem in primary
and secondary care settings. Lack of access to longitudinal data from Electronic Health Records
(EHR) of large populations continues to be the main barrier to measuring the prevalence of DDIs
and characterizing the phenomenon in medical care [39, 47, 48]. In this thesis we study possible
prescription biases, costs, and the predictability of the DDI phenomenon by analyzing EHR of pa-
tients prescribed drugs in primary- and secondary-care of an entire city in southern Brazil for 18
months (see Problem 1). To the best of our knowledge, this is the first study of DDIs we are aware
of that follows an entire city longitudinally for more than 3 months.
Complementary to EHR, social media data provides access to the discourse of a large number
of users. The analysis of such discourse can provide early warnings about potential DDIs, and also
identify under-reported, population-level pathology associated with DDIs. Social media analysis of
DDIs can contribute to increased population health, particularly in the case of conditions associated
with perceive social stigma, such as mental disorders [49]. In this thesis we analyze social media as a
source of large-scale data that can help identify DDIs and ADRs in ways that have not been hitherto
possible. Our study focus on three cohorts of interest: depression, epilepsy, and opioid-based drugs
that are currently being abused in the US. From social protest [50] to stock market prediction [51],
social media shows great promise in studying collective human behavior [49, 52, 53, 54, 55], including
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monitoring of public health [56, 57, 58, 59, 60]: from dengue [61] and influenza spread [62, 63, 64],
measurements of depression [65, 66, 67] and, in particular, the potential for DDI and ADR discovery
[30, 68, 69, 70, 71, 72]. Social media research has been enabled by the ability to record self-reports
from a large number of human subjects [62]. These windows into collective human behavior could
also be useful to study the use, the potential interactions, and the effects of natural products—
including cannabis. The pharmacology of such products constitute an array of DDIs and ADRs
very poorly explored by biomedical research so far, and thus an arena where social media mining
could provide important novel discoveries and insights. While social media and online health-care
communities have been used for DDI [68, 69], and ADR [71, 73, 74] discovery, methods exploring
whether social media discourse contains known DDI or ADR co-mentions in relevant populations are
still lacking (see Problem 2). Additionally, most work on social media pertaining to public health
monitoring that we are aware of has relied on data from Twitter or Facebook. However, Instagram is
an increasingly important platform, with high availability of posts with geolocation coordinates, and
images and video to supplement textual analysis. While Instagram has been used to qualitatively
observe the type of content people post regarding health situations, such as Ebola outbreaks [57],
its potential for large-scale quantitative analysis in public health was first established with our own
work [RBC7]. Instagram currently has more than 1 billion active users, with 100 million only in the
United States, where it has a 52% penetration rate among internet users [75]. It surpasses Twitter
(40%) for preferred social network among teens (12-24) in the US, only behind Facebook (76%) and
Snapchat (79%). A majority of its users worldwide, or 61%, are between 18 to 34 years old, and
in the US, 64% are adults (18-29) [76]. Although Twitter has a much smaller footprint, it reaches
262.7 million users worldwide [77], with the strong advantage of having an open API for public data
collection. In this thesis we use both Twitter and Instagram as social media data sources in the
study of the DDI phenonomena.
A variety of factors may lead to increased levels of DDI, for both cities and individuals: the
availability of drugs, the prescribing habits of physicians, the biological differences due to age and
gender, possible social processes, or even biases. All these interconnected factors characterize a
complex problem. Complex problems often cannot be solved by walled-in traditional scientific
disciplines [78]. They require an interdiciplinary view of science. The field of complexity science
has a long held tradition of crossing disciplinary boundaries to solve complex problems [21, 79]. In
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this thesis we analyze our heterogeneous data sources with methods such as machine learning, data
mining algorithms, time series analysis, knowledge graphs, and semi-metric closure. These methods
come from two sub-fields of complexity science: data science and network science.
Data science allows us to investigate the DDI phenomena and draw inferences from large scale
data sources. By drawing from additional fields, such as statistics and informatics, data science is
enabled by big data processing, computing power, and the analysis of real-world complex problems,
such as the DDI phenomena we study. The field has shown its importance in marketing [80],
economics [81], supply-chain management [82], logistics [83], life sciences [84], and many others.
While companies have adopted data science in key processes [83], its use for public institutions—
aiming to enhance the quality of life of citizens as we do in this thesis—is still largely unexplored [85],
specially in the public health care setting [86]. In this thesis, we aim to contribute to improve this
situation using data science methods to study the extent to which known DDI are being prescribed
to patients in primary and secondary care of an entire city public health-care system—as well as
study biases, costs, and the predictability of the DDI phenomena.
Network science is the field devoted to the canonical form to study relations among a set of
things, such as interactions between drugs. In this thesis we extract networks from social media
discourse and use text mining methods to automatically characterize and extract signals of DDI and
ADR in our cohorts of interest. In the networks we extract from social media, the prediction of a
DDI is analogous to the problem of link prediction in graphs [87]. Similarly, uncovering population
level discourse and possible co-morbidities are equivalent to modularity detection [88]. Both link
prediction and modularity detection are domain agnostic methods. These are characteristic of
complexity scientists, who are often interested in the pattern of relations among a set of objects (or
their organization), rather than in the objects themselves [21]. This orthogonal view to traditional
science [89], where problems are organized by domain of application (e.g., physics, biology, etc),
is well captured by the sub-domain of complex systems known as complex networks [90, 91, 92].
Graph-theoretical approaches to study the connected organization of complex systems have been
used successfully in a variety of fields [21, 79, 93, 94, 95, 96, 97, 98, 99, 100, 101], such as social
network analysis [87, 102, 103], metabolic networks [104], brain networks [105], food webs [106],
power grids [107], epidemic [108] and knowledge [109] spread, and others. Most importantly, complex
networks research has contributed to the advance of many other domains of science [110, 111, 112].
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Our study of the DDI phenomena using complex networks is based on weighted networks built
from word co-occurrence to represent knowledge in a semantic space. These networks have shown
to be useful for automated fact-checking [113], protein-protein interaction extraction [114, 115]
and recommender systems [116]. We explore population-level associations of DDI and ADR in
these networks where nodes are terms associated with drugs, symptoms, natural products, or even
cannabis. We also rely on the distance closure of these networks and its metric and semi-metric
edges [117]. In previous work we have show that so-called metric edges—edges that do not break the
triangle inequality—are useful in predicting the spread of diseases in social processes [118, RBC8].
Thus, we hypothesize that metric edges of our knowledge networks could be used to predict known
DDI and ADR. Additionally, edges for which we have only indirect evidence from the network
topology, denoted semi-metric edges, could in turn be used to predict yet unknown DDIs. Most
importantly, the role of semi-metric edges in link prediction is currently an open question in the
complex network literature. In this thesis we explore both cases, whether metric, high ranking
edges, can be used to predict known DDIs and ADRs, and whether semi-metric edges are indicative
of still unknown DDIs.
Novel data sources to study the DDI phenomena, such as social media data, can potentially lead
to new discoveries of ADR, thus increasing the quality of life of patients. However, it is currently
unknown whether social media discourse predict the discovery of unknown DDI with sufficient ac-
curacy, and if it is better or complementary to existing measurements, such as clinical reporting
or mining the scientific literature (see Problem 3). If social media predicts official reporting, the
role of social media data for public health monitoring and pharmacovigilance would change. Health
agencies worldwide would have to ensure social media historical data is easily and safely available
for public health research, similarly to what was done to clinical reporting (i.e. FAERS) in the
1960’s [119]. However, answering this question requires an additional hurdle. We lack comprehen-
sive information of when DDIs were first discovered in any data source, and specially for different
evidence types—such as in vitro, in vitro, and clinical. Similarly, there is no temporal discovery
information on ADR. A timeline for each individual drug of when discoveries about interactions or
adverse reactions were discovered. This prevents temporal comparisons of DDI and ADR discovery
in diverse data sources. Also, temporal information on different evidence types of DDI could help
elucidate knowledge gaps in the literature, while at the same time driving DDI research and invest-
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ments. For instance, by knowing that in vitro evidence is the only piece of knowledge missing for
a certain DDI, the National Institutes of Health could open a specific grant call to fill this gap. In
this thesis we build this DDI and ADR timeline using machine learning and text mining methods
from drug co-mentions in three different data sources: clinical reporting, scientific publications, and
social media data. We also use time series analysis to investigate whether social media discourse
precedes clinical reporting or scientific evidence of DDI. Furthermore, we provide a roadmap to the
investigation the temporal patterns of DDI discovery, in different data sources and evidence types,
towards predicting important knowledge gaps in the DDI literature.
In summary, in this thesis we study the prevalence and prediction of known DDI and ADR in
a variety of heterogeneous data sources—electronic health records, social media, clinical reporting,
and the scientific literature. Furthermore, we also attempt to shine light into possible unknown
DDIs. Our interdisciplinary approach, using methods from complexity science and its sub-fields of
data and network science, allows us to investigate the DDI phenomena in innovative ways. The
results we present constitute novel contributions to both biomedical informatics and public health
in general. Furthermore, our study of the role of metric and semi-metric edges in the prediction of
DDI and ADR from social media data constitutes a unique contribution to the complex networks
literature.
1.2 Thesis structure & summary of results
In order to provide readers a separation from necessary background and results, we have condensed
the diverse background literature on subsections of chapter 2. Readers familiar with these topics,
may choose to skip this chapter or its subsections altogether.
In chapter 3, we present a large-scale longitudinal study (18 months) of the DDI phenomenon
at the primary- and secondary-care level using electronic health records (EHR) from the city of
Blumenau in Southern Brazil (pop. ≈ 340, 000). This is the first study of DDI we are aware of
that follows an entire city longitudinally for more than 3 months. In summary, we found that
181 distinct drug pairs known to interact were dispensed concomitantly to 12% of the patients in
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the city’s public health-care system. Further, 4% of the patients were dispensed DDI combinations,
likely to result in major adverse reactions with costs estimated to be larger than previously reported
in smaller studies. The yearly estimated cost for Blumenau of these major DDI is at least $2 per
capita, after adjusting for inflation and exchange rates—though for less stringent assumptions it can
be as high as $7 per capita. DDI results are integrated into associative networks for inference and
visualization, revealing key medications and interactions involved in the DDI phenomenon. Analysis
of the large EHR data set reveals that women have a 60% increased risk of DDI as compared to men;
the increase becomes 90% when only major DDI are considered. Furthermore, DDI risk increases
substantially with age. Patients aged 70-79 years have a 34% risk of DDI when they are dispensed
two or more drugs concomitantly. In contrast, this risk is less than 10% for patients under 40
years of age and negligible for children under 14. Interestingly, a null model demonstrates that age-
and women-specific risks from increased polypharmacy fail by far to explain the observed risks of
DDI in those populations. This suggests that social and biological factors are at play. Finally, we
demonstrate that machine learning classifiers accurately predict patients likely to be administered
DDI given their history of drug dispensations, gender, and age (MCC=.7,AUC=.97). These results
demonstrate that considerable gender and age biases exist, but that accurate warning systems for
known DDI can be devised for health-care systems and public-health policy management, to reduce
DDI-related adverse reactions and health-care costs.
In chapter 4 we determine the potential of Instagram and Twitter for public health monitoring
and surveillance for DDI, ADR, and behavioral pathology at large. Three coherent cohorts were
collected from Instagram and Twitter based on user mentions of drugs known to treat: depression,
epilepsy, and opiod drugs that are currently being abused in the US (e.g., oxycodone). Using
drug, symptom, and natural product dictionaries for the identification of the various types of DDI
and ADR evidence, we report on the development of a monitoring tool to easily observe user-level
timelines associated with drug and symptom terms of interest, and population-level behavior via the
analysis of co- and tri-occurrence networks computed from individual timelines. Analysis of these
networks further reveals drug and symptom direct and indirect (latent) associations with greater
support in user timelines, as well as clusters of symptoms and drugs revealed by the collective
behavior of the observed population. For instance, the co-mention network of our depression cohort
on Instagram found 12 (out of the top 25 ranked edges) to be are known or very like ADR. Also,
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subnetworks extracted via spectral methods further reveal population-level associations, such as
network modules of drugs and symptoms associated with the psoriasis pathology. We also found
metric edges of tri-mention networks not to help in the prediction of known DDI and ADR, when
these were automatically validated from DrugBank and SIDER. Nonetheless, the large number of
known DDI and ADR uncovered by our methods demonstrates that Instagram and Twitter are
data sources of potential benefit in the monitoring of public health and for pharmacovigilance.
Importantly, our work shows that complex network analysis provides an important toolbox to
extract health-related associations and their support from large-scale social media data.
In chapter 5, we present a preliminary study of the temporal behavior of DDI and ADR discovery.
Our temporal analysis is given by time-resolved drug and symptom co-mentions extracted from
social media, clinical databases, and the scientific literature. Specifically, co-mention time-series are
constructed from social media mentions in Twitter and Instagram—based on chapter 4—, clinical
reporting from physicians and the general public to FAERS, and the scientific literature from paper
abstracts available in PubMed. To limit the amount of abstracts we inspect, we use only relevant
papers classified as having at least one type of DDI evidence—in vivo, in vitro, and clinical—a
result that builds upon previously developed work in our group [120, 121]. We select a set of
DDIs (e.g., those involving one of the drugs known to treat epilepsy) and show that social media
measurements of DDI mentions may precede scientific literature. We exemplify with the case for
the co-administration of opioids and benzodiazepines (Diazepam, Hydrocodone), a DDI discovered
after the existence of social media data. We found co-mention evidence in social media up to 7 years
before any in vivo or in vitro evidence, and 5 years before the FDA released a safety announcement
of the DDI. However, possibly due to limited temporal social media data, this is the only pair we
found that match this criteria. We then perform a systematic analysis of the temporal patterns of
co-mention of DDIs in physician reports and scientific evidence and discover the significant temporal
order to be: first in clinical reporting to FAERS, then in scientific literature evidence of in vivo,
then clinical, and finally of in vitro type.
In addition to the three main parts outlined above, this thesis presents a web tool that was
built to provide the community access to the data, the networks, and the analysis we performed
(details in section 4.2.1 of chapter 4). This may prove important for other scientists, physicians, or
public health analysts, interested in specific DDI, ADR or conditions associated with terms in our
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networks.
Finally, chapter 6 closes this thesis by discussing a future research agenda in multi-level com-
plexity of human-health.
1.3 Problems, questions & hypotheses
For clarity, this section details problems (P) and questions (Q) we address in this thesis, together
with associated hypotheses (H) to be tested. These are numbered and prefixed with their respective
initial letter below.
P.1 It is currently unknown to which extent primary and secondary care patients are
being co-administered drugs that are known to interact.
Experimental setup:
• Data Sources: public health care system of Blumenau, southern Brazil.
• Analysis Methods: increased risk, statistical analysis, and machine learning.
Q.1 What is the prevalence of prescribed known DDI in primary and secondary care for the
public health care system of a city like Blumenau?
Q.2 What are the characteristics of patients being prescribed known DDI?
H.1 Women are at significant increased risk of DDI when compared to their male coun-
terparts.
H.2 Lower education level patients are at significant increased risk of DDI when compared
to more educated patients.
H.3 The increased risk of DDI grows linearly with patient age after adjusting for number
of administrations.
Q.3 How homogeneous is the Blumenau public health system across neighborhoods in terms
of drug dispensations and DDI?
H.4 Lower income neighborhoods have higher number of drugs dispensed per capita.
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H.5 High income neighborhoods have lower numbers of DDI per capita.
H.6 Higher crime neighborhoods have higher number of DDI per capita.
Q.4 Can we predict which patients are likely to be prescribed a known DDI using machine
learning methods?
H.7 Age and gender are sufficient to predict the number of DDI per patient.
H.8 Age, gender and dispensed drugs are sufficient to classify patients with at least one
DDI.
P.2 It is currently unknown if social media discourse contains known DDI or ADR
co-mentions in relevant populations, and whether complex network methods can
help the prediction of unknown DDI and ADR.
Experimental setup:
• Data Sources: Instagram and Twitter user timelines.
• Analysis Methods: Social media minig, text-mining, proximity and distance graphs, dis-
tance closure.
Q.5 Does Instagram contain DDI and ADR evidence in user timelines as co-mentioned terms?
Q.6 Does Twitter contain DDI and ADR evidence in user timelines as co-mentioned terms?
Q.7 To what extend does the semi-metric topology of drug- and symptom-related term co-
mention networks predict DDI and ADR associations?
H.9 Terms associated with specific health conditions tend to cluster in the knowledge
networks.
H.10 Metric edges are likely to be of known DDI and ADR.
H.11 Semi-metric edges are likely to be of still unknown DDI and ADR.
P.3 It is unknown whether social media discourse may precede clinical reporting or
scientific literature evidence of DDI
Experimental setup:
• Data Sources: Instagram and Twitter for social media, FAERS for clinical reporting and
PubMed abstracts for scientific literature.
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• Analysis Methods: Text-mining, time series, and statistical analysis.
Q.8 In which data source does DDI evidence is first seen? Social media, clinical reporting by
physicians or various types of evidence in the scientific published literature?
H.12 Social media evidence of DDI precedes both clinical reporting and scientific literature
evidence.
H.13 Clinical evidence of DDI and ADR precedes literature evidence.
H.14 In the literature, clinical evidence precedes both in vivo and in vitro evidence types.
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Chapter Two
Background 1
“For we always pay for generality by sacrificing content,
and all we can say about practically everything is almost
nothing.”
Kenneth E. Boulding, 1956
American Economist
2.1 Drug-drug interaction & adverse drug reactions
Adverse drug reactions (ADR) are unintended harmful, noxious, or unpleasant reactions resultant
from the use of a medicinal product [119, 122, 123]. Their occurence warrants different drug
treatment, alteration of the dosage regimen, or complete withdrawal [122]. The history of ADR
goes thousands of years back [124], with mentions in The Odyssey and the Hippocratic Oath as well
as in the Old Testament. Modern interest, however, started around 1930, with peaks in publication
1Passages in this chapter can be found in Correia, Gates, Wang, and Rocha [RBC5], Correia, Gates, Manicka,
Marques-Pita, Wang, and Rocha [118], Correia, Barrat, and Rocha [RBC8], and Gates, Wang, Correia, and Rocha
[RBC9]. These have also been presented in Rocha, Gates, Manicka, Pita, andCorreia [RBC10], Correia, Ratkiewicz,
and Rocha [RBC11], and Gates, Wang, Correia, and Rocha [RBC12].
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on the topic between 1976-1985. In September 1971, the World Health Organization held a meeting
in Geneva, to discuss the role of national centers in global drug monitoring [119]. The meeting
concluded with recommendations for national centers on data collection—from individual private
practice to hospital settings—, the need for a systematized monitoring of populations and other
sources of ADR data, and effective analysis of such data.
At the time, problems with reporting were already evident. For instance, some adverse effects
remain undetected because patients or doctors may fail to report them [125]. Conversely, over-
reporting of evident symptoms can suggest non-existent associations. Usually, suspected signals
detected in clinical reports are investigated in the laboratory. For example, the association between
haemolytic anemia and long-term administration of methyldopa was confirmed with laboratory
tests [126]. Additionally, rare ADR require a larger number of patients to statistically assert the
association. For instance, our current knowledge between the association of estrogen-containing oral
contraceptives and venous thromboembolism is well established [127], however, it was not until the
1960s, after careful epidemiological survey, that a strong relation between oral contraceptives and
death from pulmonary embolism or cerebral thrombosis was found [125, 128]. However, possibly the
worst tragedy was that of thalidomide (Contergan R©), a drug tested for spasmolitic, local anesthetic,
and anticonvulsive effects with supposed antihistamine and antiergotropic activity [129]. In post-
marketing it was discovered it caused embryopathy, a severe developmental defect in embryos.
Thalidomide was launched in German markets in 1957 and later in several other countries, including
Brazil. It was withdrawn from German markets in December 1961, and in Brazil it was widely sold
until June 1962. It is estimated to have caused 4,400 cases with a 40% mortality rate [129]. Since
then, several ADR from drugs commonly prescribed were and continue to be discovered. A list of
recent ADR discovered can be seen in table 2.1; note the temporal distance between the time of
when it was highlighted/communicated to when supporting evidence was established.
Historically, research on adverse reactions only involved single-drug approaches [131]. It was
only after the discovery of the cytochrome P450 (CYP450) enzyme family in 1940s-1960s, and
its importance in drug metabolism, that possible drug-drug interactions (DDI) started to be in-
vestigated [132]. The first reports of unexpected DDI started late 1970s, for instance, in 1978
between digoxin and quinidine [133] and in 1981 with phenobarbital and valproic acid [134]. In the
late 1990s the FDA released its first drug interaction guidances, the Guidance for Industry, Drug
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Table 2.1: Drugs, their suspected ADR, and timeframe from when they were highlighted by quantitative screening
of individual reports, communicated to national pharmacovigilance centers and pharmaceutical companies, and sup-
ported by scientific publications or changes were made to the official product safety information. Reproduced from
[130].
Drug Suspected ADR Highlighted Communicated Supported
Topiramate Glaucoma 2nd quarter 2000 April 2001 October 2001
Infliximab Vasculitis 2nd quarter 2000 September 2002 August 2004
Infliximab Pericardial effusion 4th quarter 2001 December 2002 August 2004
SSRIs Neonatal convulsions 4th quarter 1999 December 2001 May 2005
Abacavir Myocardial infarction 2nd quarter 2000 May 2005 April 2008
SSRI = Selective Serotonin Reuptake Inhibitor.
Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro (1997) and
the Guidance for Industry, In Vivo Drug Metabolism/Drug Interaction Studies–Study Design, Data
Analysis, and Recommendations for Dosing and Labeling (1999). The first was aimed at conducting
drug metabolism and drug interaction studies while the second suggested an integrative approach,
moving to in vitro, early, and definitive clinical studies. An excellent review of the unfolding events
at the time can be found in Huang [132].
As human bodies are complex organisms, drugs administered undergo several timed processes
until a therapeutic effect is observed. The study of such processes, such as drug absorption, dis-
tribution, metabolism and excretion, is defined as Pharmacokinetics (PK). Orally administered
drugs are commonly absorbed in the intestine, metabolized in the liver and distributed by the
bloodstream into tissues and sites of action. A drug effect is modulated by its PK concentration
at specific action sites. However, measuring drug concentrations at these receptor sites are often
impractical, as they can be in inaccessible tissues, such as the myocardium. Instead, measures of
drug concentration in blood or plasma, urine, saliva and other easily sampled bodily fluids are often
used. Such measurements are key in determining therapeutic and toxic drug concentrations in the
body as well as in tissues and targets [135]. Complementary, pharmacodynamics (PD) studies the
physiologic effect of drugs, the response—both desired or undesired—produced in relation to the
drug concentration levels [136]. The effect of a drug is then determined by its binding capacity
with a specific receptor. Examples include receptors present on neurons, as is the case with opiate
receptors; on cardiac muscle, affecting intensity of contraction; or even within bacteria, targeted to
disrupt maintenance of the bacterial wall [135]. Various factors may change the drug concentration
at the action site, directly affecting the drug’s effect. Examples include the density of receptors on
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the cell surface, the mechanism by which a signal is transmitted into the cell (called second messen-
ger), the regulatory factors that control gene translation and protein productions (as is the case for
several CYP targeting drugs), the concomitant administration with another drug (DDI), and even
certain consumed foods [135]. DDI, therefore, can happen at both the PK and PD phases [131].
PD interactions happen when one drug increases or decreases pharmacological effect, influencing
drug efficacy or causing adverse reactions. PK interactions can be due to changes in absorption,
distribution, metabolism and elimination. Metabolic pathway overlap is a common example of PK
DDI, where metabolites either compete for binding sites, causing apparent overdosing, or induce
metabolism, resulting in decreased clinical response [135]. It is also important to stress that some
drug interactions are intentional, as are the case of several HIV and cancer treatments. Readers
interested in further biochemical details of DDI should see references Tannenbaum and Sheehan
[131] and Rodrigues [136].
Gene polymorphism may also amplify DDI and its potential risk for drug toxicity or inactivity.
Inherited genetic variations have been identified in approximately 20 genes that affect about 80
medications [137]. Pharmacogenotyping, the identification of individual gene variability in disease
treatment, held great promises for precision medicine. However, in practice only a handful of genetic
tests are routinely used in the clinic today, for example those that are mandatory for certain types
of chemotherapy [138]. A praised example of pharmacogenetics is the uncommon hypersensitivity
to the antiretroviral drug abacavir, used in HIV treatment. The life-threatening adverse reaction is
found in certain groups with a variant of the immune-system gene HLA-B [139]. This gene variant
is predominant in Caucasians, giving them a 50% chance of hypersensitivity. Fewer than 3% of
African and East Asian populations carry the variant [138]. Variations in the CYP[2D6] gene also
display phenotypical characteristics of pharmacological importance for DDI. For example, subjects
with multiple copies of the gene, characterized as ultrarapid metabolizers, should avoid codeine
therapy, an opioid analgesic, due to potential toxicity [140]. As the CYP[2D6] gene is responsible
for the metabolism and elimination of approximately 25% of clinically used drugs with significant
polymorphisms [141], there is increased concern of its role in DDI.
Today, there are myriad research approaches to study DDI, which include researchers from
varied backgrounds [131, 149, 150, 151]. These approaches include: system approaches in mining
published pharmacological data; mining of spontaneous clinical reports of adverse drug events (e.g.
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Table 2.2: Some of the current DDI and ADR data sources
Source Link
DrugBank[142, 143, 144] drugbank.ca
SIDER[145] sideeffects.embl.de
Drugs.com◦ drugs.com
FDA† fda.gov
DailyMed dailymed.nlm.nih.gov
MedlinePlus medlineplus.gov
Bulário ANVISA portal.anvisa.gov.br
Vigibase• who-umc.org
MED-File & Medi-Span• wolterskluwercdi.com
EudraVigilance ema.europa.eu
Vigibase• who-umc.org
DIDB• druginteractioninfo.org
◦ non-crawlable dataset; • private dataset; † Includes Labels[146], MedWatch[147] & FAERS[148].
FAERS or Vigibase [152]); biomedical literature mining [120, 153]; mining of electronic health care
(patients records) [RBC6]; In vitro studies using freshly isolated or cryopreserved human hepato-
cytes, Caco-2 cells, microsomal protein fractions, or recombinant systems to investigate molecular
interaction mechanism inside the cell; In silico simulation of PK parameters; In vivo studies of of
PK parameters; population study of PK data obtained through the course of clinical care; pharma-
coepidemiological studies of clinical outcomes; development and evaluation of approaches to avoid
DDI or manage their risks in clinical settings; and possibly others. These approaches have produced
various types of analysis and results. Combining such results into actionable insight is a necessary
major challenge [151]. Overall, DDI identification can have different starting points, resulting ulti-
mately in drug interaction warnings, drug label change, or complete withdrawal from the market.
The first and foremost are those DDI and ADR identified early in drug development, although at
this stage knowledge of the adverse effect profile is provisional and likely to change [130]—since
pre-marketing clinical trials are often too limited to account for small, long-term or rare reactions
[154]. Additionally, due to the variety of ways drugs can interact [155, 156] it is unfeasible to test
every possible combination in the laboratory. To overcome this problem, researchers are now using
big-data hypothesis-driven mechanistic models of pharmacokinetics simulation [157]. These in silico
methods enable the screening of a large variety of compounds for potential interactions.
In post-marketing, surveillance is done primarily by voluntary reporting. Reporting may come
from physicians [158] or the general public and reporting is usually concentrated in governmental
health organization—Food and Drug Administration (FDA) in the U.S; European Medicines Agency
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(EMA) in the EU; Anvisa in Brazil—or private companies that can aggregate data from multiple
countries. However, voluntary reporting suffers from under-reporting and limited coverage biases
[71].
Databases and services such as DrugBank [159] and SIDER [145] were built in order to help DDI
and ADR research, either expanding the current knowledge or connecting multiple data sources (see
Table 2.2 for a non-exhaustive list). DrugBank includes chemical, pharmacological and pharmaceu-
tical information on drugs, including DDI validation; SIDER includes ADR validation on drugs and
it was built via natural language processing (NLP) of drug labels from different english-speaking
countries. While these are useful tools, no database exists to provide a historical time-series of when
DDI and ADR were first reported, communicated, or supported. This prevents some scientific ques-
tions involving the evolution of our knowledge about DDI or their prediction from alternative data,
such as social media. Publicly available resources from which such historical time-series could be
built are: (a) the online interface on unstructured drug labels from the FDA [146], (b) the database
on clinical reports of ADR (FAERS) [148], and (c) the published scientific literature, largely avail-
able on PubMed [160]. However, the sheer size and continuous updating of these resources exceeds
the capacity of any human to read. While text-mining and information retrieval methods have been
proven important for biochemical knowledge extracting from large scale resources [70, 161], such
historical time-series are not available, despite their scientific importance.
2.2 Data science for public health
Data science is concerned with the extraction of generalizable extraction of knowledge from data
[162]. The skills and tools of a data scientist are drawn from a variety of other domains, such
as statistics, computer science, linguistics, sociology, epidemiology, and others. Data used in this
science are increasingly heterogeneous and unstructured, a combination of text, images and videos,
upon which scientific questions can be formulated and answered. Recently enabled by the availability
large data sets and available computing resources, the use of data and computers to solve scientific
problems is not new. In fact, the cybernetic group [79] was already working with machines that
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were to store, process and analyze what at the time was large amounts of data, mostly devoted
for prediction, insight gathering, and knowledge extraction. However, these machines were mostly
designed for war efforts, such as nuclear testings. A general methodological approach to this science
was pioneered with Klir’s General System Problem Solver [163]. Today, there are several specialized
research sub-fields within the field of data science, each providing their own contributions. Some
of these include, machine learning, knowledge discovery in databases (KDD), text- and literature-
mining, information retrieval, and so forth. Similar to systems science, data science is a domain
agnostic field, as its methods can be applied seamlessly to data from any other discipline.
Public health is a specific domain of science, concerned with the health and well-being of large
numbers of individuals, specially in promoting the prevention of diseases and conditions [164]. These
are often seen as methods and technologies applied through public policies. Examples include the
eradication of contagious diseases through vaccinations, and the prevention of injuries through
education and regulation policy—such as promoting smoke-free indoors and the use of seat-belts.
Recently, these two concepts—data science and public health—were linked through the definition
of precision public health. Initially described as the “ability to prevent disease, promote health, and
reduce disparities in populations by applying emerging methods and technologies for measuring
disease, pathogens, exposures, behaviors, and susceptibility in populations” [165], precision public
health can be simply defined as the “practice to more granularly predict and understand public
health risks and customize treatments for more specific and homogeneous sub-populations” [166].
This practice is achieved by gathering insights from large scale datasets, including transportation
data, electronic health records, mobile phone & social media data, clinical reporting, and so forth.
Early attempts using single data sources have produced misguided results, commonly exemplified by
the Google Flu project [167]. Since then, we have seen a new drive to integrate heterogeneous data
sets into hybrid systems to support an increasingly precise public health, aimed at better decision
making and knowledge discovery [168, 169, 170, 171].
It is important to distinguish precision public health from precision medicine. While the latter
is focused on individualized clinical treatments requiring genetic, lifestyle and environmental data;
the former is focused on increased accuracy and granularity in defining public cohorts, discovering
signals that can be used to infer increased risks in populations, as well as developing different target
interventions [166]. When coupled with machine learning methods (loosely refereed to as artificial
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intelligence; more in section 2.3) precision medicine and precision public health are also known as
population health intelligence and personalized health intelligence, respectively [172]. A variety of
studies has demonstrated the usefullness of the intersection of big data, machine learning, and public
health. Examples include the use of sensors to monitor city-wide air quality [173, 174, 175], regional
antimicrobial resistance from online data sources [176], the use of social media and internet searches
to predict disease outbreaks (e.g., cholera [177], dengue [61, 178], influenza [63], lyme disease [179],
measles [180], and whooping cough [181]), drug safety [RBC7, 182], and the monitoring of food
intake [183]. For a recent review article, see Dolley [166].
In this thesis we use data and network science methods towards achieving a more precise public
health. We demonstrate the impact of such approach in our large-scale analysis of the DDI phe-
nomena using data from electronic health records, clinical reporting and social media data. We
demonstrate that an integrated data- and network-science approach to public health can help pre-
vent ADR and thus lead to a significant impact on the quality of life of citizens and finances of both
private and public-health care systems. In fact, a recent review article [166] identified our paper
on DDI discovery using Instagram—detailed and expanded in chapter 4—as an example where big
data has added value to precision public health efforts.
In the next sections we survey the literature on the main data sources and algorithmic methodol-
ogy used in this thesis: electronic health records (EHR), clinical reports, social media (e.g., Twitter,
Instagram & Facebook), and the published scientific literature (e.g., PubMed). As all these topics
are quite broad, and it is not the focus of this thesis to list every paper published in these areas,
at times we will restrict our literature review to areas within our domain of application: precision
public health, drug-drug interactions and adverse drug reactions. We also briefly discuss two addi-
tional data sources, from different levels of human health complexity: logical models of biochemical
regulation, and contact networks. Although not concerned with DDI directly yet—and thus not
included in this thesis as complete chapters—this author has contributed to both topics, which are
expected to be useful to precision public health and DDI in future work. We discuss such possibility
in section 6.2 of chapter 6.
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2.2.1 Logical models of biochemical regulation 2
Mathematical and computational modelling of biological networks promises to uncover the fun-
damental principles of living systems in an integrative manner [184, 185]. In particular, Boolean
Networks (BN), a class of discrete dynamical systems, provide an effective framework to capture
the dynamics of interconnected biological systems without the need for detailed kinetic parameters
[186, 187]. BN have been used to model and predict biochemical regulation in genetic networks
[188], cell signalling [189], chemical reactions in metabolic networks [190], anticancer drug response
[191], action potentials in neural networks [192], and many other dynamical systems involved in
biomedical complexity [193].
Two reasons contribute to the success of BN models: (1) the reduction of complex multivariate
dynamics to a graph revealing the organization and constraints of the topology of interactions
in biological systems, and (2) a coarse-grained treatment of dynamics that facilitates predictions
of limiting behavior and robustness [194]. However, more than understanding the organization
of complex biological systems, we need to derive control strategies that allow us, for example,
to intervene on a diseased cell [195], to revert a mature cell to a pluripotent state [196], or to
simulate cell fate when subject to a multiple drug schedule. Recently, several mathematical tools
were developed to enhance our understanding of BN control by removing redundant pathways,
identifying key dynamic modules [197], and characterizing critical driver variables [198].
InCorreia, Gates, Wang, and Rocha [RBC5] we presented CANA3, an open-source and publicly
available python package to study redundancy and control in BN models of biochemical dynamics
[RBC13]. CANA provides a simple interface to access computational tools for three important
aspects of BN analysis and prediction:
1. Dynamics. Python classes are included to enumerate all attractors and calculate the full
state transition graph (STG) of BN.
2. Canalization. The redundancy properties of automata functions have been characterized as a
2This section was adapted from Correia, Gates, Wang, and Rocha [RBC5], Correia, Gates, Manicka, Marques-
Pita, Wang, and Rocha [118], and Gates, Wang, Correia, and Rocha [RBC9]. These have been presented in Correia,
Gates, Manicka, Marques-Pita, Wang, and Rocha [118] and Rocha, Gates, Manicka, Pita, and Correia [RBC10]
3CANAlization: Redundancy & Control in Boolean Networks. For documentation and tutorials see github.
com/rionbr/CANA.
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form of canalization [199], particularly when used to model dynamical interactions in models
of genetic regulation and biochemical signalling [197, 200, 201]. At the level of individual
Boolean transition functions (network nodes), canalization is observed when not all inputs are
necessary to determine a state transition (a formal definition is presented in Correia, Gates,
Wang, and Rocha [RBC5]). CANA can be used to calculate all measures of canalization that
derive from removing dynamical redundancy via two-symbol schemata re-description [197]:
effective connectivity, input redundancy and input symmetry. At the network level, CANA
also calculates the effective graph, a weighted and directed graph whose edge weights denote
their effective contribution to node transitions, as well as the dynamics canalizing map, a
parsimonious representation of the necessary and sufficient state transitions that define the
entire dynamics of BN. All canalization measures and network representations are applicable
to synchronous and asynchronous BN models.
3. Control. From a subset of driver variables (nodes that act as the loci of control interventions)
CANA computes the controlled state transition graph (CSTG), as well as the controlled at-
tractor graph (CAG) capturing all controlled transitions between attractors possible via driver
variable interventions [198]. CANA also computes measures of controllability that depend on
the CSTG and CAG: mean fraction of reachable configurations, mean fraction of controlled
configurations, and mean fraction of reachable attractors. Currently, control analysis in CANA
is applicable only to synchronous BN models.
Additionally, CANA provides an interface to load logic models directly from the Cell Collective
repository [202], a collaborative platform with more than 80 publicly available biological models,
allowing for an extensive analysis of control and canalization in complex biological systems.
In a follow up paper [RBC9], utilizing the aforementioned methods in CANA, we formally
introduced the effective graph, a weighted subgraph of the original interaction graph of every BN,
where edge strength denotes how effective an input is at controlling the state of a receiving variable.
The effective graph is rooted in the concept of automaton canalization, reflecting the fact that not
all inputs are equally important for determining its state transition [200].
We follow Marques-Pita and Rocha [197] by quantifying canalization through the amount of
logical redundancy present in the automata. Specifically, we use the Quine-McCluskey Boolean
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minimization algorithm [203] to identify those inputs of an automaton which are redundant given
the state of its other inputs, thus reducing its look-up-table (LUT) to a set of prime implicants. The
prime implicants are in turn combined to create wildcard schemata, F ′ ≡ {f ′υ}, in which the wildcard
or “Don’t care” symbol, #, denotes an input whose state is redundant given the state of other
necessary input states. In this process, the original LUT F (see fig. 2.1-A) is re-described by a more
compressed set of schemata F ′ as illustrated by the example in fig. 2.1-B. Every wildcard schema
f ′υ ∈ F ′ re-describes a subset of entries in the original LUT, denoted by Υυ ≡ {fα : fα f ′υ} ⊆ F ;
 means ‘is re-described by’.
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Figure 2.1: Constructing the effective graph. (A) The structural interaction graph of a 3-input automata
(blue node), x4, and the corresponding look-up-table (LUT). (B) The effective graph of automata x4 is built from
the wildcard redescription of the LUT, F ′. The Arabidopsis Thaliana biological model. (C) The structural
graph. (D), The effective graph. For the effective graphs, edge thickness denote their effective connectivity, eji, with
fully canalized edges shown in dashed red in B; node size denote its effective connectivity; and gray shading denote
its effective out-degree (see legend).
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The extent of canalization present in the LUT of an automaton can be quantified by statistical
measures. For instance, the input redundancy, kr(x), measures the number of inputs that on average
are not needed to compute the state of automaton x. This is quantified by tallying the mean number
of wildcard symbols present in the set of schemata F ′(x) that re-describe the LUT F (x) by
kr(x) =
∑
fα∈F
avg
υ:fα∈Υυ
(
n#υ
)
|F | , (2.1)
where n#υ is the number of inputs with a # in schema f ′υ; avg is the average operator. The input
redundancy can be compared to the true number of inputs k(x) to derive the effective degree,
ke = k(x)− kr(x), the number of inputs that are on average necessary to compute the automaton’s
state. Whereas k(x) is the number of inputs to automaton x present in the BN, ke(x) is the
minimum number of such inputs that are on average necessary to determine the state of x.
Since the effective degree and input redundancy are defined for each automata, the above pre-
sentation has implicitly made use of the idea that each input individually has a varying affect on the
automata transition. To formalize this concept, we compute the effective connectivity, eji ∈ [0, 1],
of the input from automaton xj in determining the truth value of automaton xi, by counting the
average number of schema in which input xj is specified by a wildcard symbol:
rji =
∑
fα∈Fi
avg
υ:fα∈Υiυ
(
j  #
)
υ
|Fi| , eji = 1− rji (2.2)
where (j  #)υ is a logical condition that assumes the truth value 1 (0) if input xj is (not) a
wildcard in schema f ′υ; avg is the average operator. Naturally, kr(xi) =
∑
j rji and ke(xi) =
∑
j eji.
The effective graph is then E ≡ (X,E), where X is the set of automata and E is a set of
weighted directed edges eji as defined in eq. (2.2). Note that when the interaction is fully-canalized,
the effective connectivity will be zero, eji = 0; we remove all fully-canalized edges completely from
the effective graph but retain them for emphasis in the visualizations (see red edges in fig. 2.1-B&D).
To illustrate the full strength of the effective graph for BN, we used the 15 variable Boolean
network underlying the cell-fate determination during floral organ specification in the flowering
plant Arabidopsis thaliana (TBN) [204, 205]. The structural graph and effective graph for the TBN
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model are shown in fig. 2.1-C&D respectively. Note that there are three fully canalized (red) edges
in the model which, when removed, alter the global structure of interactions. These modifications
have strong effects in the definition of control variables (a.k.a driver nodes) while also impacting the
spread of dynamical perturbations in the system. For a more detailed analysis of how the effective
graph impacts control and dynamics, see Gates, Wang, Correia, and Rocha [RBC9].
2.2.2 Electronic health records
Technological advances in data storage and computing power also meant that medical records,
previously kept on paper, are now being stored in computer servers. In fact, not so long ago
medical residents were performing their research by browsing piles of medical records, physically
stored in hospital basements. The digitalization of medical records and the inclusion of more
health professionals onto a broader human health framework have since renamed health records to
electronic health records (EHR). The value of health records, however, for both medicine and public
health has not diminished [206]. Arguably, much knowledge is still to be discovered as access to
EHR is scarce and new technologies to sort and process this data requires interdisciplinary teams to
be effectively transformed onto useful insights [48]. Even Google’s new EHR deep learning models,
despite advancing the prediction of hospital performance measures, is still limited on knowledge
generalization and medical insight [207].
The ability to include laboratory, pharmacological [208] and genomic [209, 210] data to EHR has
also extended the possibilities of data integration. This large-scale heterogeneous data integration
can both provide a more holistic approach to human health as well as better focus on specific health
conditions [211]. Recently, EHR have been used to predict longitudinal risk patterns in depression
cohorts using rule-based inference [212], along with internet searches in influenza forecasting [169],
to identify disease trajectories in comorbidities [213, 214, 215, 216, 217, 218, 219], and risks in
drug-drug interaction administration [RBC6].
Most of the current work on ADR from DDI focuses on hospitalizations and emergency visits
[28, 36, 37, 38, 40, 41, 42] or meta-analysis [33, 35, 43]. Very few studies so far have been able to
characterize this problem in primary and secondary care settings, mostly due the lack of data. Access
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to longitudinal EHR data of large populations continues to be the main barrier to the study of DDI
[39, 47], which will likely increase with recently new data privacy regulations [220]. The large-scale
analysis of primary- and secondary-care data from an entire city we describe in chapter 3 is a novel
opportunity to understand the prevalence of and biases in the prescription of known DDI outside
of hospital settings. We found only four articles that included primary or secondary care data in
their DDI analysis, but in limited contexts. Molden et al [44] searched 43,500 patients in pharmacy
databases in south-eastern Norway, focusing only on DDI from CYP inhibitor-substrate drugs only.
Pinto et al [45] studied DDI prevalence on a small cohort of forty elderly hypertensive patients in a
primary health care unit in Brazil. Iyer et al [30] mined 50 million clinical notes from STRIDE [221]
— a private and integrated EHR database — to identify signals of unknown potential DDI from
clinical text. While STRIDE contains EHR from multiple care levels, this analysis did not focus
on characterizing the concomitant prescription of pairs of drugs with known DDI in primary- and
secondary-care. Lastly, Guthrie et at [46] did a repeated 84 days cross-sectional comparison (1995
& 2010) of polypharmacy and DDI of the Tayside region of Scotland (pop. 405,721) mapping DDI
in drug classes from the British National Formulary, a private publication. This study estimated
that 13% of adults (≥ 20) were prescribed a “potentially serious” known DDI in 2010, and that the
number of drugs dispensed was the characteristic most predictive of DDI, with patients dispensed
15+ drugs having a 26.8 increased odds of DDI over those dispensed 2-4 drugs. However, by using
only 84-day windows, this analysis missed potential co-administrations from separate prescriptions
made outside of the relatively short windows; using larger windows provides a more thorough study
of the DDI phenomenon, which we pursue with the Blumenau data.
Other studies have focused on tertiary care or emergency rooms. Let us first attend to compa-
rable work in Brazil, where are own analysis was located.
Okuno, Cintra, Vancini-Campanharo, and Batista [37], analyzed a sample of 200 prescriptions
at the Emergency Department of the Hospital São Paulo. They found 526 interactions (109 major,
354 moderate & 63 minor), worth noting the concomitant use of Haloperidol+Fluconazole with 3
instances, and Omeprazole+Phenytoin with 24 instances. The former DDI pair leads to an increased
risk of ventricular arrhythmias including torsade de pointes and sudden death [222, 223]. The latter
pair, increases the risk of toxicity and symptoms of drowsiness, visual disturbances and changes in
mental state, seizures, nausea, or ataxia [222, 224].
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In a study at a public university hospital in Campinas, specialized in women health, a sample
of 36 prescriptions from the intensive care unit (ICU) and 274 from joint accommodations (JA)
were analyzed for interactions [42]. At the ICU they found 105 major, 171 moderate and 18 minor
interactions. In the JA, they found 64 major, 64 moderate and 4 minor interactions. This work
also notes the necessity of multidisciplinary teams to minimize the risk of DDI in hospital settings.
Carvalho, Reis, Faria, Zago, and Cassiani [225] did a cross sectional study with 1,124 adult
patients in seven intensive care units of teaching hospitals across Brazil. They used information on
drugs administered at 24 and 120 hours of hospitalization, obtained from prescriptions. Worrisome,
they found that +70% of all patients had at least one drug interaction. Midazolam, Fentanyl,
Phenytoin and Omeprazole were the drugs with higher frequency of DDI, from which only the
latter is available in primary care. They note that moderate and severe DDI were more prevalent,
and an integrative approach to patient care should be able prevent such large number of DDI.
Also from Blumenau, where our own work was performed (see Chapter chapter 3), but fo-
cusing on diabetic and hypertensive elderly (> 60), Codagnone Neto, Garcia, and Santa He-
lena [226] in 2006 interviewed 318 patients and compared their prescribed drugs. They found
295 DDI where a majority (93.2%) were of moderate severity. At the top of their list were 22
co-administrations of Acetylsalicylic Acid+Glyburide, 10 of Digoxin+Spironolactone and 10 of
Digoxin+Hydrochlorothiazide. They also found patients were co-administering on average 6.6 drugs,
with patients reporting having physical discomfort while on these medications, possibly ADR due to
DDI. This work shows that attempts to measure DDI prevalence were already in place in Blumenau,
however in a smaller and focused scale then what we pursue in chapter 3.
In the neighboring and also state’s largest city of Joinville, Hannes and colleagues [227] analyzed
1,069 prescriptions from 140 patients in an intensive care unit. They found that 87,9% of these
patients were exposed to some form of DDI. Patients with DDI had higher mean length of stay
and greater number of administrations. Interestingly, these patients also had greater number of
prescribing professionals.
In 2004, Cruciol-Souza and Thomson [228] evaluated 1,785 prescriptions with multiple drugs in a
Brazilian hospital. They found that 49.7% contained evidence of DDI. For 30 of these prescriptions
they followed patient records and, in 17, found evidence of ADR, including digitalis toxicity with
the co-administration of Amiodarone or Hydrochlorothiazide with Digoxin.
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Miyasaka and colleagues[229] focused on DDI where an antidepressant was involved. Their study
was performed in a public hospital in São Paulo from 1993 to 1995. At the time, 169 patients were
identified from which 36 (21.3%) had drug interactions.
From similar studies in other countries, Sutherland, Daly, Liu, Goldstein, Johnston, and Ryan
[34] identified co-prescription trends in the NHANES dataset from the Center of Disease Control
and Prevention in the United States. They analyzed 672 unique drug pairs from 10,537 subjects
who self-reported their drugs usage in surveys between 1999-2010. They found that the number of
interactions rose proportionally with the number of co-prescribed medications, from 3.3 in patients
prescribed 5 medications to 11.7 in patients prescribed 10 medications, with higher numbers among
the elderly (≥ 65). They also found co-prescribed SSRIs and tricyclic antidepressants, a major
interaction also present in our work. Furthermore, they found low agreement between co-prescription
rate and co-discussion in the literature, concluding that pairwise approaches to assessing DDI may
be inadequate for predicting real world outcomes.
In Norway, a study in three primary pharmacies—comprising 43,500 patients in a 6 month
period—focused on assessing the frequency of CYP(3A4 and 2D6) inhibitors co-prescribed with
their respective enzymes substrates, an important DDI mechanism [44]. CYP3A4 inhibitors include
drugs like fluconazole and erythromycin while their substrate include quetiapine, simvastatin and
carbamazepine. CPY2D6 inhibitors include fluoxetine with its substrate including amitriptyline,
haloperidol and nortriptyline.
In a similar study, prescriptions for 236 patients in adult wards and 87 in functional elderly
wards in a British city were analyzed [31]. A substantial proportion of patients were receiving
interacting drugs, many of which were known to produce clinically important interactions, including
fluoxetine+nortriptyline, fluoxetine+carbamazepine and omeprazole+diazepam.
Leeuwen and colleagues in The Netherlands assessed the prevalence and seriousness of DDI
among ambulatory cancer patients on oral anticancer treatment [230]. Of the 898 patients the
authors analyzed, 46% had potential interactions. The most frequent drug class involved were
coumarins and opioids and the majority of cases concerned central nervous system DDI.
Lastly, a retrospective study in a Swiss hospital assessed the frequency of DDI and ADR associ-
ated with antifungal drugs in patients with hematopoietic stem cell transplantation [231]. From 36
patients analyzed, 32 had ADR. The authors concluded that in 9 cases these were probably related
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to antifungal-drug interaction.
Is is clear from these studies that there are large variability in the number of DDI patients are
prescribed and administered. Few studies have focused on primary- and secondary-care, and only
one have analyzed patients timelines in a longitudinal way. Our longitudinal analysis of the EHR
data from the entire city of Blumenau, with a population of about 340 thousand people, for a period
of eighteen months (see section 3.1), allows us to study the DDI problem in primary and secondary
care in greater detail and for a longer period of time than what has been hitherto possible.
2.2.3 Clinical reports
The identification of ADR in drug post-marketing has been primarily done through spontaneous
reporting systems. However it was not until the famous thalidomide case [129], that governments
began to push for a systematic reporting system. Spontaneous reporting may come from physicians
or the general public and is usually concentrated in governmental health organization—Food and
Drug Administration (FDA) in the U.S; European Medicines Agency (EMA) in the EU; Anvisa in
Brazil—or private companies that can aggregate data from multiple countries, like the Uppsala Mon-
itoring Centre (UMC) for the World Health Organization (WHO). In the U.S., the FDA aggregates
reports from physicians, patients, and drug manufacturers on a free and publicly available resource,
the FDA FAERS [148]. Reports can be sent by healthcare professionals (e.g., pharmacists, nurses,
physicians), consumers (e.g., patients, lawyers, family members), and drug manufactures. Impor-
tantly, drug manufactures are required to submit reports from patients, as clinical trials advance
and potential adverse reactions surface [148, 232]. From 1968 to December 2017, FAERS received
more than 14 million reports. Since 2004, data has been publicly released quarterly. There are,
however, multiple hurdles in handling this large data set. For instance, fields are not normalized,
and records can be duplicated. Further, from September 2004 to August 27, 2012 data is provided in
a legacy format, denoted LAERS [232]. LAERS and FAERS have slightly different data structures,
which encompasses an additional hurdle. In 2009, a Nature Biotechnology editorial listed major
issues with the data, requesting that the FDA should place high priority in an “immediate overhaul
of its antiquated Adverse Event Reporting System” [233].
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The difficulty in dealing with FAERS data has motivated several efforts, including privately
developed software, scientific work made publicly available, and even software made available from
the FDA. Shortly after the published editorial, Pratt and Danese [234] released FDAble (fdable.
com/), the first “free” public search-engine for AERS data. However FDAble users are charged for
the creation and delivery of a customized electronic document with query results. FDAble is based
on open-source software and built upon a relational database with a web-based search engine that
queries the database. Data spans September 1997 to the most recent FDA data release. Currently,
FDAble only lists the top 30 case results and users need to order a US$270 report to view all query
results.
Critiquing FDAble for not being free of charge, Böhm, Höcker, Cascorbi, and Herdegen [235] then
releases OpenVigil, the first open-source FAERS search engine under GNU General Public License
(GPL). The authors report that their search engine enables fine tuning queries before submission
to VigiBase [236], a paid database from the World Health Organization (WHO) containing reports
from several countries. OpenVigil is still being developed, and like our approach in chapter 4, drugs
and symptom terms were standardized using standard medical dictionaries, such as MedDRA [237].
On a recent approach, Banda, Evans, Vanguri, Tatonetti, Ryan, and Shah [232] developed and
freely provided a curated and standardized version of FAERS that removes duplicated case records,
applying standardized vocabularies with drug names mapped to RxNorm and outcomes mapped
to SNOMED-CT concepts, which are standardized term dictionaries hosted by the U.S. National
Library of Medicine [238]. The latest data release was in June 2015, but additional database scripts
were provided so that users can process additional data. This standardized version of FAERS
is focused on providing populated contingency tables, a standard format to calculate a series of
epidemiological measures [239], including risk and odd ratios. However, a key data structure is
missing in their data release, the date of events, thus limiting longitudinal studies as we report
in chapter 5. Also, given that the authors have released PostgreSQL scripts, it became less time
consuming to simply process the raw LAERS/FAERS data with custom-built python scripts.
In an effort to enhance the accessibility to FAERS, the FDA also recently released a Public
Dashboard. In the dashboard users can visualize absolute numbers of reports and detailed informa-
tion on drugs on a Business Intelligence type web interface [240]. The system, however, does not
enable uses to drill down on specifics or submit queries.
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The burden of manipulating FAERS data described above should not underestimate its impor-
tance or deter people from using it for ADR discovery. For instance, in a 1998-2005 analysis of
FAERS, Moore, Cohen, and Furberg [241] saw an 2.6-fold increase in serious ADR reports, and a
2.7-fold increase in fatal ADR reports. Serious events increased 4 times faster than the total number
of outpatient prescriptions during the same period; and, in a subset of 51 drugs with 500+ reported
cases, drugs related to safety withdrawals accounted for 26% of reported events in 2009, declining
to <1% in 2005. An analysis of post-marketing reports provided evidence, along with pharmacoki-
netic and electrophysiological data, that the drug cisapride was associated with the occurrence of
QT prolongation and torsade de pointes [242]. Its risk of fatal arrhythmia lead to the drug’s discon-
tinuation in the United States. In Raschi, Poluzzi, Koci, Caraceni, and De Ponti [243], the authors
mined FAERS data to assess live injury associated with antimycotics. The authors reviewed eleven
systemic antimycotics (including ketoconazole, voriconazole and posaconazole) and found it to be
significantly associated with drug-induced liver injury. Mining FAERS also elucidated the associa-
tion between finasteride—a drug widely used to treat hair loss due to androgenetic alopecia—and
sexual dysfunction, despite low incidence reported in clinical trial. In Gupta, Carviel, MacLeod, and
Shear [244], the authors found a significant association in the reporting of sexual dysfunction with
the use of finasteride, independent of prescribed indication. However, as these examples highlight
the importance of FAERS, others have called for caution in its interpretation, and caution for its
lack of associated data, small samples, and differing definitions of ADR [245].
Small sample issues can be overcome by supplying additional data sources. For instance, in
Xu and Wang [246] the authors applied a variety of epidemiological methods on drug-ADR pairs
extracted from both FAERS and Medline article abstracts. They report an overall low but increased
F1 score (from .045 to .14) when mentioned pairs extracted from Medline abstracts are included.
To validate their method, they manually curated a subset of drug-cardiovascular events associated
with anticancer drugs. In this smaller set they had a .52 precision score, demonstrating that if a
drug-cardiovascular event appeared in both FAERS and Medline, it is highly likely to be a true ADR
signal. In a similar effort to boost ADR signals, Harpaz et al. [247] combined FAERS data with
Electronic Health Records (EHR). They combined 4 million FAERS reports with 1.2 million EHR
narratives. The authors report a significant improvement over only using FAERS, with the average
improvement ranging from 31% to almost 200% in different evaluation criteria. Most importantly,
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they found a new association between rasburicase and acute pancreatitis, which was supported by
clinical review. FAERS and EHR data combined has also been used to find uncommon effects in
combined drug therapy. For instance, in Tatonetti et al. [248], the authors found a sinergistic effect
on blood glucose with combined therapy of the antidepressive paroxetine (an SSRI) and the lipid-
lowering agent pravastatin. These two drugs are among the most widely prescribed in the world.
These studies above show the promise of a combined use of data sources in ADR discovery, a similar
effort that we pursue in chapter 5.
2.2.4 Contact Networks
Another level in our general approach towards understanding multi-level complexity in human health
comes from epidemiology. Epidemiology of infectious diseases is one of the public health fields in
which network science has led to the most concrete advances [249]. Examples include the targeted
immunization strategies derived from non-homogeneous connectivity patterns in scale-free networks
[250, 251], the prediction of policy decisions [252] and vaccine stocks [253] for influenza containment,
and the development of real-time forecasts of the global spreading of emerging health threats [254].
Most of these achievements rely on statistical simulations of disease spread based on census data,
characterized by the fine-grained topological information on population, migration patterns and
multi-modal transportation networks [255, 256, 257], often simulating entire populations down to
the single individuals or households [253, 258, 259].
In contrast to these large-scale simulations, contact networks are real-world, instantaneous
recordings, of person-to-person interactions. These are temporal networks representing a simplified
model of social interactions, where nodes are real people and edges are their interactions throughout
the experiment. These contact networks are then used to model how infectious disease could spread
in a given population. The structure of the contact network plays a crucial role in disease spread,
with heterogeneous networks strongly favoring the spread [94]. Contact networks are recorded with
wearable proximity sensors—devices often based on Radio-Frequency Identification, RFID, technol-
ogy. These devices are worn by individuals in a specific social setting, where their proximity to
others is recorded with a certain preset minimum distance (e.g., 1 meter).
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In one of our papers [RBC8, RBC11]—not included as complete chapter in this thesis as it
does not pertain to the DDI domain—we computed the metric backbone for nine different contact
networks (a formal definition of the metric backbone is provided below in section 2.4). We showed
that the metric backbone preserves the social structure of the original network even after removal
of 94% to 80% of the network edges. It also provides much improved results in the simulation of
epidemic spread when compared to thresholding methods.
Importantly, these results were consistent across data sets, although with some variability in
the backbone size due to the context in which the data was collected. Six of the networks analyzed
belong to the SocioPatterns project [260], a catalog of contact networks in different social settings
recorded in Europe, including an office [261], a primary [262] and high school [263], a scientific
conference [264], a hospital [265], and an art exhibit [264]. The other three networks we analyzed
were gathered from independent work and included an elementary, a middle and a high school in
the USA [266, 267]. These data sets contained duration of contact between pairs of individuals (via
wearable sensors), and were used in models of epidemic spread to evaluate containment policies
[268, 269].
Similar to results obtained in chapter 4, we showed that all contact networks analyzed were very
redundant, with the proportion of semi-metric edges (those not in backbone) ranging from 52-94%—
eight of the nine networks with larger than 80% redundancy (see table 2.3). This means that all
shortest paths can be computed with fewer than 48 to 6% of the edges (which comprise the metric
backbone). For instance, fig. 2.2 shows the primary school contact network [262] and its metric
backbone, which contains only 9% of the edges in the original network. The Figure also shows that
the social structure of the contact network is preserved in the backbone subnetwork—in the figure,
the community structure of the backbone subgraph was recomputed after edge removal, but main
student communities (10 classrooms), and community pairs (5 grades) did not change significantly
from those in original network, neither did the teacher nodes. The preservation of community
structure in the metric backbone is observed in all the other networks. Importantly, we also show
that alternative methods for removing edges (e.g. thresholding) break the community structure of
the original networks after removal of fewer edges than those removed with the computation of the
metric backbone.
Further results and details in the transformation of the temporal contact network into weighted
32
graphs used in the analysis can be seen in Correia, Barrat, and Rocha [RBC8].
Figure 2.2: Primary School contact network on social normalization. Original graph (left) and metric backbone
(right). Colors represent student grade and class: 1st grades in cyan, 2nd in green, 3rd in orange, 4th in blue, and 5th
in red; lighter and darker shades of the same color separate classes within grade; teachers are shown in gray. Plotted
with Gephi [270] using the ForceAtlas2 layout algorithm [271].
Network Location Social context Nodes Edges Metric Semi-metric
Fr-Ho [265] Lyon, France Hospital 75 1,139 217 (19.05%) 922 (80.95%)
It-SC [264] Turin, Italy Scientific Conference 113 2,196 308 (14.03%) 1,888 (85.97%)
Ir-Ex [264] Dublin, Ireland Exhibit 200 714 283±166 (48±9%) 14,219±13,013 (52%)
Fr-Wo [261] Paris, France Workplace 232 4,274 745 (17.43%) 3,529 (82.57%)
Fr-PS [262] Lyon, France Primary School 242 8,317 790 (9.50%) 7,527 (90.50%)
Fr-HS [263] Marseille, France High School 327 5,818 603 (10.36%) 5,215 (89.64%)
US-ES [266] Utah, USA Elementary School 339 16,546 1,128 (6.82%) 56,163 (93.18%)
US-MS [266] Utah, USA Middle School 591 56,867 3,521 (6.19%) 170,824 (93.81%)
US-HS [267] USA High School 788 118,291 9,275 (7.84%) 300,803 (92.16%)
Table 2.3: Contact Networks and their metric backbone Networks used in this analysis and their respective
number and percentage of nodes, edges, metric, and semi-metric edges. For the Exhibit dataset, values are the mean
± standard deviation over the 69 days for which data were gathered.
2.2.5 Social Media
The analysis of social media data has recently allowed us to gain unprecedented access to collective
human behavior. The new field of Computational Social Science has brought together Informatics
and Complex Systems methods to study society via social media and online data in a quantitative
manner not previously possible. Its importance have been demonstrated through the study of social
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protest [50], human sexual cycles [272], the spread of fake news [273, 274], and the prediction of
the stock market [51]. Most of the work has been focused on Twitter, though recently other social
networks have received attention, including Facebook [54], Flickr [52], and Instagram [53].
Social media analysis has also shown great promise for precision public health [166], given the
ability to measure the online behavior of a very large number of human subjects. It has been shown
to predict the onset of depression [65, 275], the forecasting of smog-related health hazards [175],
and a series of disease outbreaks, such as influenza [62, 63, 64], dengue [61], cholera [177], and
Zika [171]. For instance, in the 2015-2016 Latin American outbreak of Zika, a combined data set
including Google searches and Twitter data was able to predict estimates of weekly suspected cases
with up to three weeks in advance of the official publications [171].
Although the use of social media to pharmacovigilance is new, it has received increasing atten-
tion in the last years. A review paper in 2015 found 24 studies distributed between manual and
automated methods for postmarketing drug surveillance [276]. Another review paper [277], also in
2015, gathered 22 studies and reported on the difficulties in comparison due to the scarcity of pub-
licly available annotated data. This lead to a shared task workshop and the “Social Media Mining
for Public Health Monitoring and Surveillance” session, hold during the 2016 Pacific Symposium on
Biocomputing, where our group presented the work described and expanded in chapter 4 [RBC7].
Detecting signals of ADR from social media is challenging [278]. Prior to the analysis of main-
stream social media sites, such as Twitter and Facebook, most of the work on mining ADR from
social media came from specialized health forums and message boards [278, 279, 280, 281, 282,
283]. One of the first groups to analyze social media data for ADR signals is that of Graciela H.
Gonzales, at Arizona State. In Leaman, Wojtulewicz, Sullivan, Skariah, Yang, and Gonzalez [279],
they analyzed user comments in DailyStrength, a health-focused site where users discuss personal
experiences with drugs, demonstrating that comments contained drug safety information. In this
paper, the authors used a lexicon and rule-based system to detect ADR. Then, in Nikfarjam and
Gonzalez [280], the group proposed a new method to automatically extract ADR from user com-
ments using association rule mining, a supervised machine learning method, to extract mentions of
ADRs in user reviews of DailyStrength.
There have been previous attempts to understand online drug discussions through the use of data
visualization techniques. Chee, Karahalios, and Schatz [284] provided a qualitative interpretation
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of user posts and drug mentions, using natural language processing and networks. The same group,
in Chee, Berlin, and Schatz [285] used LIWC, a sentiment analysis tool, to demonstrate the ability
to track trends in people’s sentiment regarding particular drugs over time. Both studies used data
from Yahoo Health Groups.
Benton et al. [281] used co-occurence statistics of ADR present in breast cancer message boards
sites and compared them to package labels of 4 different drugs. They found that 75-80% of these
ADR were documented on drug labels, while the rest were previously unidentified ADR for the
same drugs. Sampathkumar, Luo, and Chen [282] treated the task of identifying drugs and their
side effects from social media forums as a sequence labeling problem, using a Hidden Markov Model
to predict their relationship. Data came from Medications.com and were annotated using dictio-
naries of drug names, side-effects and interaction keywords. They report an F -score of .864 when
predicting an ADR on an automatically annotated set. In Yang, Yang, Jiang, and Zhang [286], the
authors used association mining and proportional reporting ratios to mine the association between
drugs and their ADR. Their experiment used only ten drugs and five ADR, with data mined from
MedHelp. The authors report being able to effectively retrieve ADR for these drugs. At Georgetown
University, Yates and Goharian [283] mined user reviews for five commonly used breast cancer drugs
in three different social media sites (askapatient.com, drugs.com, and drugratingz.com). Their main
contribution was developing ADRTrace, a synonym set with a mining engine, to retrieve expected
and unexpected ADR. Gonzales’ group then in Patki et al. [278] explored a probabilistic model for
drug categorization using a two-step approach. Patient posts and comments on DailyStrength were
used for analyses. The analysis first classified whether a comment included a mention of an ADR,
and then inferred whether the combined comments for the drug indicated a disproportionately large
number of other ADR. They report high accuracy (82%) for the classification of ADR comments
with the ADR class F -score of .652. Focusing on web forums of the website MedHelp, Yang, Kiang,
and Shang [287] proposed an automated ADR related post filtering mechanism using text classi-
fication methods. They leveraged Latent Dirichlet Allocation (LDA) and a partially supervised
classification approach to propose a pharmacovigilance system. By selecting only drugs with more
than 500 threads of discussion in their analysis, they report ADR found for three drugs: biaxin,
lansoprazole and luxox.
A common thread in these studies is the difficulty in extracting ADR from social media due
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to language inconsistency. To resolve some of the informal language patterns used in social media,
Nikfarjam, Sarker, O’Connor, Ginn, and Gonzalez [288] introduced ADRMine, a machine learning-
based concept extraction system that uses conditional random fields to learn language patterns in
uncovering ADR mentions. Their system leverages the use of word clusters and word semantic
similarities (word2vec), a deep learning method of word embeddings. The authors applied their
system to both Twitter and DailyStrenght. They report outperforming several baseline systems
by achieving an F -measure of 0.82 in correctly extracting ADR. Nguyen, Larsen, O’Dea, Phung,
Venkatesh, and Christensen [289] also applied word2vec to estimate the prevalence of ADR on
Twitter, Reddit, and LiveJournal. Rates of ADR estimated from social media discussion were
compared to the SIDER database of ADR. They found that word2vec leveraged variants of ADR
terms, thus improving correlation coefficients on a chosen sample of 10 psychiatric drugs (with
values between .08 and .50 increasing to .29 and .59). A main drawback of deep learning methods,
however, is the need for a large training corpus to guarantee accurate results, which may bias results
to commonly prescribed drugs and their ADR.
Bridging both social media and electronic health records, Topaz et al. [290] compared the reports
of patients and those of clinicians of ADR regarding aspiring and atorvastatin, a drug used to treat
high cholesterol. They found that the most frequently reported ADR in EHR matched the most
frequent patient’s concerns on social media. However, several less frequently reported reactions were
more prevalent on social media, with aspirin-induced hypoglycemia only being discussed in social
media. Their results indicates the advantage of combining other data sources with social media
data. We pursue a similar multi-data approach in chapter 5.
In France, from a more information system development perspective, Bousquet et al. [291] devel-
oped ADR-Prism, an information system for ADR monitoring through web scraping. The authors
reported guarantee of data privacy, taking into account pharmacovigilance expert requirements,
domain-specific knowledge resources through the lexicon, and a component-based architecture that
allows storage of big data and accessibility by third-party applications.
The body of work we presented above has been focused on detecting signals for single drugs
and their adverse reactions. Few so far have been focused on detecting DDI signals from social
media data. In fact, a group at Drexel University was among the first to propose the use of
social media data to detect DDI signals [69]. In their approach they used association mining on
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thirteen drugs and three DDI associations. Their source of data was MedHelp, PatientsLikeMe and
DailyStrength. They used DrugBank as their gold standard and reported being able to effectively
detect DDI. Subsequently, the group expanded their work to use heterogenous networks, formulating
the prediction of DDI from online health communities as a network link prediction problem [292,
293], an important task in network analysis. In their work they use a heterogeneous network
approach, where nodes and edges can be of different type. For instance, nodes can represent “users”,
“drugs” or “ADR”, while edges can be an inference of “cause” or “treatment”, informing relational
information between nodes. In this study they report being able to correctly classify DDI (F1 = .91)
using a set of topological network features.
Recently, due to the opioid epidemic aﬄicting the U.S., there has been increased interest in
understanding opioid abuse, including its discussion in social media. Despite that, some online
behavior, such as posting to Facebook, has been shown not to predict self-reported illicit drug use
[294]. Social media has been shown of great importance in drug abuse research. Studies have
analyzed licit [295], illicit [296, 297], and controlled substances [72, 298, 299] in diverse social media
sites. For instance, Chary, Genes, Giraud-Carrier, Hanson, Nelson, and Manini [300] used Twitter to
demonstrate that the geographical variation of posts mentioning prescription opioid misuse strongly
correlates with official government estimates. In Hanson, Cannon, Burton, and Giraud-Carrier [301]
the authors monitored Twitter and selected 25 users who discussed topics indicative of prescription
drug abuse. In their sociological analysis of posts and social circles surrounding these selected
users, they found that users who discuss prescription drug abuse online are surrounded by others
who also discuss it—an abuse discussion reinforcement with others of like mind. Through keyword
categorization they were able to identify users seeking, trading, and buying prescription drugs, an
important mechanism of drug redirection. In a different example of the opioid abuse discussion
on social media, Daniulaityte, Carlson, Brigham, Cameron, and Sheth [302] performed a web-
based study about the use of buprenorphine in the self-treatment of opioid withdrawal symptoms.
Buprenorphine is a semi-synthetic opioid effective in the treatment of opioid dependence. The
authors extracted relevant posts from an undisclosed web-forum that allows free discussions on illicit
drugs, between 2005 and 2013. The authors report on an increase of buprenorphine-related posts
over time, and that users discussed ways buprenorphine use may compromise opioid dependence
treatment. Noteworthy, they also report that mentions of concomitant use with other psychoactive
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substances was commonly reported, which may present significant health risk of ADR from DDI.
Readers interested in the use of social media for drug abuse research should refer to the recent
critical review of Kim, Marsch, Hancock, and Das [303].
2.2.6 Scientific literature
The volume of scientific publication has increased rapidly [304]. At this point, no individual scientist
can physically keep up with the body of scientific literature. Even within specialized domains, such
as chemistry, it is increasingly difficult to keep up with the rate of publications [161]. This problem
has led to diverse efforts to automate information retrieval and knowledge extraction from published
literature, commonly referred to as literature text-mining.
The biomedical domain offers one such example. Since 2004, the BioCreAtIvE competition has
provided common datasets of scientific literature for informaticians to collectively tackle information
extraction problems within the biological domain. Its first meetings [305] dealt with two tasks:
(a) the extraction of gene or protein names from text, and their mapping into standardized gene
identifiers for three model organism databases (fly, mouse & yeast); and (b) the identification of
short text passages that supported Gene Ontology annotations for specific proteins, provided by full
text articles. Since then, BioCreAtIvE issued a variety of collaborative initiatives [306, 307, 308,
309, 310, 311, 312], with tasks ranging from gene identification, extraction of drug and chemical
name, and extraction of protein-protein interaction evidence. Our own group has contributed to
these efforts, and in some cases ranking among the top teams [115, 308, 313, 314].
Literature mining usually contains the following workflow. Relevant documents are retrieved
from literature sources (e.g., PubMed) via keyword searching. Textual information often comes
from article abstracts, however recently, full-text article mining has shown to outperform abstract
only in some tasks [315]. In large-scale knowledge discovery approaches, a machine learning model
may be trained on a small annotated set of documents and then deployed to the whole source
to retrieve additional documents (more on machine learning in section 2.3). Using named entity
recognition (NER) on selected documents, single or multi-word tokens are extracted and mapped
to entities and their predefined categories (e.g., drug, disease, symptom). Biomedical ontologies are
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frequently used to automate the detection of such entities, in practice mapping synonym tokens
to the same entity (i.e., generic and trade drug name). Additional NER methods are used when
entities are unknown or need to be enriched. These span from early use of rule-based [316] to
current machine-learning and conditional random field methods [317, 318, 319, 320], with deep
learning receiving recent attention [321]. Once identified, relevant entities are then used as input
for methods of information extraction and knowledge discovery. The goal in this step is to find
existing and possibly unknown relations between (or among of) entities. For instance, the type of
relationship (e.g., expresses or inhibits) between two genes. A commonly used technique is term
co-occurrence, where a relationship is established if two terms occur together in the same predefined
linguistic space (i.e., a sentence, a paragraph, or an abstract). As directionality is an issue with
co-occurrence, in practice this simple method may provide high recall but poor precision [319]
(precision and recall are formally introduced in section 2.3). More sophisticated methods to retrieve
token relationship include leveraging linguistic grammar and syntax. Examples include the use of
word stemming, lemmatization, part-of-speech (POS) tagging, and also syntax trees. Needless to
say, even though parsing and tagging methods are expected to provide better performance, they are
also computationally intensive, specially in large corpora such as PubMed.
Readers interested in a comprehensive introduction to text-mining technologies applied to chem-
istry and biomedical literature, should see Krallinger, Rabal, Lourenço, Oyarzabal, and Valencia
[161] and Shatkay [322], respectively. Similarly, a recent review in biomedical text-mining can be
seen in Fleuren and Alkema [323].
Some tasks in biomedical literature text-mining are more complex than others. For instance,
extracting gene and protein names from biological literature is challenging, as genes are often de-
scribed rather then referred to by gene symbol, and one gene name may refer to different genes
[324]. To collaboratively address these difficulties, several tools have been developed by the bioin-
formatics community. In a recent review, Fleuren and Alkema [323] listed 31 different text mining
applications for the biomedical domain. Most are focused on retrieving similar studies, thus pro-
viding some sort of recommender system (more about recommender systems in section 2.4), while
others return connected concepts, or highlight parts of text. Only four applications were active and
had network-like capabilities (see table 2.4). In chapter 5 we also build a network using literature
text-mining, however including time and additional sources of data, beyond scientific literature. We
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now provide some background on these studies.
Chen and Sharp [325] built Chilibot (chip literature robot), which constructed content-rich
relationship networks between genes, proteins, drugs and biological concepts. Raw data came from
Medline abstracts. Chilibot also annotated the sentence and network edges depicting the nature of
the relationship found in the text (e.g., inhibitory versus stimulative).
Douglas, Montelione, and Gerstein [326] developed PubNet, a system to visualize literature
derived networks. The focus of their work is to enhance literature knowledge discovery by linking
authors and Medical Subject Headings (MeSH) terms. The rationale is that a network visualization
of search queries enable researchers to easily find and compare similar articles or authors working
with specific genes or proteins.
botXminer, was a publicly available tool to search XML-formatted MedLine data [327]. A
graphical interface allowed queries to be visualized as a network where edges connected term to
papers where they were co-mentioned. In their website, the authors indicate that botXminer is no
longer updated, directing users to ToTeM [328]. Upon inspection, ToTeM seems to have the same
capabilities of botXminer, but no reference was found with its description.
In Plake, Schiemann, Pankalla, Hakenberg, and Leser [329], the authors describe AliBaba, an
interactive tool for graphical summarization of search results from PubMed. The tool parses ab-
stracts selected from a user query and presents extracted information on biomedical entities and
their relationships as a graphical network. Extracted entities include cells, diseases, drugs, proteins,
species and tissues, with filter options allowing focused searches. Unfortunatelly, the URL provided
by the authors is no longer active.
Taking a visual data exploration approach, Xuan et al. [330] developed PubViz, a tool to explore
and visualize scientific literature from PubMed. It was developed in Adobe Flex 2.0, with a graph-
ically rich interface focusing on usability. The tool allowed users to explore association networks
between genes, citations, and MeSH terms. The URL provided by the authors is also no longer
active.
More than 14 years have passed since the first BioCreAtIvE, and literature text-mining is as rel-
evant to the biomedical domain is it was then. As we have shown, several tools and databases have
been built along the years. Pioneers in the field described the path forward with both literature and
biological databases being fused through text-mining methods [331]. STRING is one such example.
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Focusing on protein-protein interactions, STRING [332] is a database holding information on more
than 2,000 organism. As it focuses on interactions, a query of protein or gene names results in a
network of interactions. Importantly, it includes both direct (physical) and indirect (functional)
associations. Network edges can be investigated for different types of evidence building the con-
nection, ranging from text-mining (term co-occurrence in literature) to experimental evidence. Our
group has established a pipeline to work with STRING while this author was on sabbatical at the
Instituto Gulbenkian de Ciência (2017-2018). Along with Paulo Navarro Costa, we are investigating
evolutionary conserved genes that can shed light into male infertility using controllability methods
in Boolean Networks [RBC5]. As this research line does not pertain to DDI, it was not included in
this thesis.
Table 2.4: Biomedical literature mining tools deriving network results.
Name Active Link Description
Chilibot [325] Y chilibot.net Graph visualization between genes, pro-
teins, drugs and biological concepts from
mined literature.
PubNet [326] Y pubnet.gersteinlab.org Visualization of literature mined networks.
ToTeM [327, 328] Y botdb-abcc.ncifcrf.gov Comention network representation of XML-
formatted MedLine data. Formely known
as botXminer.
AliBaba [329] N alibaba.informatik.hu-berlin.de Network representation of biomedical enti-
ties from PubMed query.
PubViz [330] N brainarray.mbni.med.umich.edu Interactive Medline (graph) visualization
with active external content retrieval.
String [332] Y string-db.org Protein-protein interaction database rep-
resenting literature and experimental evi-
dence as a network.
2.3 Machine Learning
The large-scale amount of health data discussed in the last sections calls for methods that enable the
extraction of insights and knowledge from data sources. Machine learning is a mixture of computer
science, statistics & cognitive science. Also called computational statistics, or statistical learning, it
provides a set of automated methods that can detect (statistical) patterns in data, and then use the
uncovered patterns to predict future data [333]. It is beyond the scope of this section to provide a
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complete discussion on the etymology of machine learning, or what it means to have machines that
can learn, thus being often depicted as intelligent. However, it is often useful to state our stance and
provide some background on what we mean when describing computational intelligence, specially
for readers outside of complex systems & machine learning research.
The field of machine learning grew out of the ambition of early cyberneticians to find common
principles in understanding living, cognitive and social systems. Early research in developing ma-
chine intelligence attempted to build machines that could mimic humans and their ability to learn,
a central feature of human intelligence. Machine learning belongs to a more broadly defined field of
Artificial Intelligence (AI), which includes robotics and automonous agents. Alan Turing is consid-
ered the modern AI pioneer. Turing, in his 1936-37 seminal paper, described a machine capable of
computation analogous to that of the human brain [334], abstracting the task of a ‘human computer’
to perform a calculation into a formal machine that manipulates symbols on an infinite paper tape
[335]. Inspired by human neurophysiology, in the 1943 seminal work [336], Warren McCulloch and
Walter Pitts defined the theory underlying machine learning through the use of neural networks.
That the “all-or-none” nature of firing neurons could be modeled as logical propositions and thus
used for computation as logic gates. After suffering from hardware and data limitations in the
1980’s, neural networks made a comeback in recent years contributing to major advances in natural
language processing, machine translation and computer vision with its new “deep” architecture.
Both the symbol and network view on machine intelligence as surrogates for human intelligence
are underlined by a large philosophical debate among those who accept a computational nature of
the mind [337]. On the symbolic side, represented by Allen Newell and Herbert Simon, the physical-
symbol hypothesis, where scientists argue that a symbol manipulation system has the necessary and
sufficient means for intelligence [338]. On the network side, and represented by Paul Churchland
[339], a connectionist view which encompasses parallel distributed processing and artificial neural
networks [337]. This networked view of human intelligence is possibly best illustrated by the famous
Perceptron [340, 341] and later with the back-propagation learning algorithm [342]. Recent views
on the nature of the mind and intelligence, specially drawn from robotics, depict a holistic view
that the brain is not the single most important computational device, but instead computation is
distributed through a coupled brain-body-environment system [343].
Despite advances in AI in these 80+ years, and its sharp increase since the 1980’s, much of
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the early promises of artificial intelligence are still not delivered. Strong AI, defined as conscious,
sentient machines, capable of solving problems in a wide ranges of application, are still far from
being built, in defiance of recent results of IBM Watson and Google AlphaGo. Today, Weak AI
(also called narrow AI) is everywhere, with home and smartphone assistants being the most natural
example.
Below we provide a formal description of machine learning methods used throughout the next
chapters of this thesis. The notation follows lecture notes from Prof. Predrag Radivojac, Bishop
[344] and, specially the probabilistic approach, Murphy [333], unless otherwise noted.
Machine learning methods are usually divided into two main types, a predictive (or supervised
learning) and a descriptive (or unsupervised learning). In the first, the goal is to learn a mapping
from inputs x to outputs y, given a labeled set of input-output pairs D = {(xi, yi)}ni=1, where
xi ∈ X and yi ∈ Y. Here, D is called a training set, and n is the number of training examples. We
usually assume that X = Rk, in which case xi = (xi1, xi2, . . . , xik) is a k-dimensional vector called
data point (or example). Each dimension of xi is typically called a feature or an attribute. In the
descriptive type, also called knowledge discovery, we are only given inputs, D = {xi}ni=1, and the
goal is to find “interesting patterns” in the data. There is also a third type of machine learning,
known as reinforcement learning, where machine errors and successes in a task elicit a feedback of
reward or punishment, which in turn helps the machine to learn. Due to the scope of this thesis we
will not describe reinforcement learning in any greater detail.
The machine learning literature usually distinguishes two different types of prediction problems:
regression and classification. In general terms, we have a classification problem when yi is categorical
and a regression problem when yi is real-valued. In the classification problem the objective is to
learn a mapping from inputs x to outputs y, with |Y| being the number of classes. Whenever
|Y| = 2, this is called a binary classification. If |Y| > 2, this is called a multi-class classification. In
this thesis we will only concern ourselves with problems where |Y| = 2. The machine learning task
is then formalized as a function approximation. We assume y = f(x) for some unknown function
f , and the goal of learning is to estimate the function f given the labeled training set, and then
predict yˆ = f(x) from previously unseen instances of xi. The regression problem works in similar
form, however the goal is to approximate a target value y as close as possible, where usually yi ∈ R.
A machine learning predictor is then a function map, f : X → Y. Both regression and classifica-
43
tion models will be realizations of knowing or learning a posterior distribution p(y|x,D). In simple
terms, this means learning the probability of a certain class, say y = 1, given the input vector x and
the training set D. This task can be solved in different ways, but a straightforward approach is to
assume a functional form for p(y|x,D), say p(y|x,D,θ), where θ is a set of weights or parameters
that can be learned from the data. For example, in a linear model θ = (α, β), where α and β
represent the intercept and the slope parameters of a line.
Above we presented data points x = (x1, x2, . . . , xk) using k-tuples. However, it is often ben-
eficial to consider an algebraic notation, where each data point x is a column vector in the k-
dimensional Euclidean space. In the algebraic notation x = [x1, x2, . . . , xk]T , where T is the trans-
pose operator. A linear combination of features and some set of coefficients w = (w1, w2, . . . , wk) ∈
Rk
k∑
i=1
wixi = w1x1 + w2x2 + . . . wkxk (2.3)
can be expressed using the inner (dot) product of column vectors wTx. This notation is specially
important for learning parameters w and implementation, as vector form are optimized in most
programming languages. We can also use an n-by-k matrix X = (xT1 ,xT2 , . . . ,xTn ) to represent the
entire set of data points, and y to represent a column vector of targets. For example, the i-th row
of X represents data points xTi . Finally, the j-th column of X, denoted as fj , is an n-by-1 vector
which contains the values of feature j for all data points.
To simplify formalism in the following sections, we have added x0 = 1 to each data point
xi. This extends the input space to X = Rk+1 but, fortunately, it also leads us to a simplified
notation and guarantees that the intercept (in the case of linear models) is not required to pass
through the origin. Then, the predictor decision boundary in Rk can be written as wTx = 0, where
w = (w0, w1, . . . , wk) is a set of weights and x = (x0 = 1, x1, . . . , xk) is any element of the input
space.
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2.3.1 Regressors
We now introduce the formalism for different type of regressor models used in the next chapters.
Specifically, these are simple regression (SR), polynomial regression (PR), ordinary multiple regres-
sion (OMR), and linear mixed model (LMM).
Finding the best parameters of w whenever the target function is modeled as as linear com-
bination of features and parameters is referred to as a linear regression problem. The regression
problem can be presented as a probabilistic modeling approach reduced to a parameter estimation,
an optimization problem where some cost criteria between the target values {yi}ni=1 and the pre-
dictions {f(xi)}ni=1 is minimized. This is why it is generally said that regressions work by fitting a
line (a plane, or a hyperplane in the case higher order regressions) through a series of data points.
A common performance measure to find w is the sum of the squared errors
SSE(w) =
n∑
i=1
(
yi − f(xi)
)2
=
n∑
i=1
e2i . (2.4)
A simple regression (SR) is a linear regression model with one-dimensional data xi = (x1), or a
single explanatory variable, with the fit
f(x) = w0 + w1x+  , (2.5)
where x is the data point, w = (w0, w1) is the weight vector (intercept and slope, respectively), and
 is the residual error. Similarly, a polynomial regression (PR) is a regression where the data point
is fitted with a n-th degree polynomial
f(x) =
p∑
j=0
wjx
j +  , (2.6)
where x is the data point, w = (w0, w1, . . . , wp) is the weight vector, p is the degree of the poly-
nomial, and  is the residual error. The ordinary multiple regression (OMR) is a widely used type
of regression for predicting yˆ from the value of a set of features. It works by fitting a hyperplane
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through the data
f(x) = wTx+  =
k∑
j=0
wjxj +  , (2.7)
where x = (x0, x1, . . . , xk) is the data point, w = (w0, w1, . . . , wk) is the weight vector, and  is
the residual error. We also often assume that  has a Gaussian or normal distribution, N (µ, σ2),
where µ is the mean and σ2 is the variance. However in practice, a zero-mean Gaussian N (0, σ2)
is often used. With some manipulation it can be shown that f(x) also follows a Gaussian distri-
bution, where its conditional probability density is p(y|x,w) = N (wTx, σ2(x)). This will be useful
when we describe Logistic regression further below, a generalization of the linear regression to the
classification problem.
The linear mixed model (LMM; also known as multilevel, mixed effects, random effects, or
hierarchical linear model) can be seen as extensions of the OMR where instances of the data belong
to certain groups—like children in classrooms or cities in states. In the case shown in chapter 3,
they are patients in specific neighborhoods. Individual levels are usually defined as level-1 (within-
group), and level-2 (between-group) for a two level model. Separate l level-1 models (e.g., patients)
are developed for each m level-2 (e.g., neighborhoods). Considering only one feature, level-1 models
take the form of simple regressions:
f(x)lm = β0m + β1m xlm (2.8)
where β0m is the intercept for the m neighborhood, and β1m is a coefficient (slope) associated with
data point xlm. Note that instead of w = (w0m, w1m) we wrote w = (β0m, β1m), as it is convention
[345]. In the level-2 models, the level-1 regression coefficients (β0m and β1m) are used as outcome
variables and are related to each of the level-2 predictors,
β0m = γ00 + γ01 gm , β1m = γ10 + γ11 gm , (2.9)
where gm is the level-2 predictor, and γ00 and γ10 are the overall mean intercept adjusted for g. γ01
(γ11) is the regression coefficient associated with g relative to level-1 intercept (slope). A combined
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two-level model is created by substituting eq. (2.9) into eq. (2.8):
f(x)lm = γ00 + γ10 xlm + γ01 gm + γ11 gm xlm (2.10)
The combined model incorporates the level-1 and level-2 predictors (xlm and gm) and a cross-level
term (gmxlm). Single and composite errors were omitted for clarity. In practice, LMM parameters
are estimated using maximum likelihood methods. For further details on LMM see Woltman,
Feldstain, MacKay, and Rocchi [345].
Evaluation of regressor performance is usually given by the amount of variance in the data that
the model can explain, typically measured by R2,
R2 ≡ 1− SSE
SSTO
, SSTO =
n∑
i=1
(yˆi − y¯)2 (2.11)
where y¯ is the mean of the observed target values. In other words, a sum of distances of how far off
the fitted line the points are located.
2.3.2 Classifiers
Predictors where the target class is discrete are called classifiers. In the case where there are only two
classes (a binary classifier), f : Rk → {0, 1}, we are interesting in finding the relationship between
inputs and outputs by constructing a function that splits Rk into two half-regions. Each region then
acts as a decision function, separating the two classes. However, the method by which the classifiers
builds the decision surface may vary. For example, in linear classifiers, the algorithm may optimize
a line (or plane, or hyperplane depending on the size of k) in order to minimize the number of data
points placed in the wrong region. Conversely, the algorithm may attempt to estimate the posterior
distribution p(y|x), in which case it is more likely to perform parameter estimation by maximizing
the likelihood of the parameters.
In chapter 3 we leverage Support Vector Machine (SVM) [346] and Logistic Regression (LR)
[347] to learn a model that predicts patients with at least one drug-drug interaction, given the
medications they were previously prescribed. SVM and LR are two standard and reliable machine
47
learning algorithm for such binary classification problem. Below we provide some details about both
classifiers.
As hinted in the section above, the logistic regression is a generalization of the linear regression
to the binary classification problem. It works by replacing the Gaussian distribution for y with a
Bernoulli distribution p(y|x,w) = Ber(y|sigm(wTx)). Here sigm refers to the sigmoid function,
also known as the logistic or the inverse logit function, defined as
sigm(wTx) =
1
1 + exp(wTx)
=
ew
Tx
ewTx + 1
. (2.12)
Such model trained to learn posterior probabilities can be seen as a function g : X → [0, 1]. The
conversion from g to f then is a straightforward application of the maximum a posteriori (MAP)
principle: the predicted output is 1 (positive class) if g(x) ≥ 0.5 and 0 (negative class) if g(x) < 0.5.
In practice, parameters in the logistic regression classifier are often estimated using gradient descent,
a first order iterative optimization algorithm for finding a function minimum.
Support Vector Machine (SVM) is a kernel-based sparse vector machine. Intuitively, it works
by learning a set S of support vector—hence its name—that maximizes the concept of a margin,
defined to be the smallest distance between the decision boundary and any of the data points.
SVM is a powerful predictor in practice, as it can generalize high dimensional data with only a few
support vectors—hence being called a sparse machine. The maximum margin solution is found by
solving the following optimization problem
(w∗, w∗0) = argmax
w,w0
{
1
||w|| mini
[
yi
(
wTφ(xi) + w0
)]}
(2.13)
where φ(xi) denotes a fixed feature-space transformation. The predictive function, after some
manipulation, can be shown to be
f(x) =
∑
xi∈S
αi yi κ(x,xi) + w0 (2.14)
where αi are Lagrange (dual problem) multipliers with αi > 0 for all support vectors xi ∈ S, and
κ(x,xi) is the kernel function. The kernel function is a real-valued measure of similarity between two
arguments, κ(x,xi) ∈ R. Kernel functions are specially useful when objects are not easily translated
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Table 2.5: A contingency table, also called a confusion matrix.
True positive True negative
Predicted positive TP FP
Predicted negative FN TN
to fixed-size feature vectors, possibly due their variable size (e.g., text document, protein sequence,
etc). Is is therefore useful to define a generative model for the data, and use the inferred latent
representation of this model as features, which can in turn be fed to standard learning methods, as
seen above. In our case we used a linear kernel, defined as κ(x,xi) = xTxi. Linear kernels are useful
for high dimensional data where individual features are informative and the classification task is
some linear combination of these features.
An important property of SVM is that the determination of the model parameters corresponds to
a convex optimization problem, where any local solution is also a global optimum. Additionally, as
it is a decision machine, it does not provide posterior probabilities. SVM were originally developed
for binary classification, but can be extended to regression and multi-class classification.
These classification models need to be evaluated for how well they perform with previously
unseen data. In most settings, this is achieved using a standard 4-fold cross-validation method,
albeit in practice any number can be used. This means data points D are split 4 times into two
subsets, Dtrain and Dtest. Using a different shuﬄe for each fold, a model is trained using Dtrain
and tested on Dtest. This guarantees that the model is not “cheating” by using the same data for
learning and evaluation.
Different measures can be used to evaluate classifier performance. These are usually derived
from a confusion matrix, also called a contingency table [348]. The confusion matrix contains four
categories: true positives (TP ), which are examples correctly labeled as positive; false positives
(FP ), examples incorrectly classified as positive; true negative (TN), examples correctly labeled as
negative; and finally, false negatives (FN), positive examples mislabeled as negative. A contingency
table example can be seen in table 2.5.
From the confusion matrix one can calculate a variety of measures, such as
Precision =
TP
TP + FP
, Recall =
TP
TP + FN
& Accuracy =
TP + TN
TP + FP + TN + FN
.
(2.15)
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Precision (also called positive predictive value) is the fraction of examples correctly predicted as
positive, among all examples predicted as positive. Recall (also called sensitivity) is the fraction
of examples correctly predicted as positive, among all true positive examples. Lastly, accuracy is
the fraction of correctly classified instances over the total number of examples. Also frequently
computed is the True Positive Rate (TPR) and False Positive Rate (FPR) as
TPR =
TP
TP + FN
, FPR =
FP
FP + TN
, (2.16)
where TPRmeasures the fraction of positive examples that are correctly classified and FPRmeasures
the fraction of negative examples incorrectly classified as positive. These basic measures enables the
plotting of the Receiver Operator Characteristic (ROC) and the Precision and Recall (P/R) space.
In ROC space we plot FPR against TPR while in P/R space we plot Precision against Recall.
These plots are typically generated to evaluate the performance of machine learning algorithms,
and to enable system users to inspect the trained algorithm’s precision at a specific recall level, for
example. From both ROC and P/R curves we compute their respective interpolated area under the
curve (AUC) [348].
From Precision and Recall we can also compute F1-score (also called F -score or F -measure) as
F1 = 2× Precision× RecallPrecision + Recall . (2.17)
Finally, we also compute Matthew’s Correlation Coefficient (MCC)[349], which is regarded as
an ideal measure of the quality of binary classification in unbalanced scenarios [350], as
MCC =
TP × TN − FP × FN√
(TP + FP ) + (TP + FN) + (TN + FP ) + (TN + FN)
. (2.18)
2.3.3 Dimensionality reduction
Whenever we have unlabeled data, meaning there is no target value y, we resort to methods that can
find patterns in the data. This can be seen as a bottom-up approach—as compared to a hypothesis
driven top-down approach—, that can build intuition and direction so that plausible hypothesis
50
about relations in the data can be formulated. Some of these widely used methods include singular
value decomposition (SVD) and principal component analysis (PCA). However, other methods, such
as clustering, latent Dirichlet allocation (LDA), Gaussian mixture models, and non-negative matrix
factorization (NMF) can all be seen as methods of dimensionality reduction. In other words, these
methods are attempting to find a faithful representation of the data with a smaller number of
dimensions. In this section we follow Murphy [333] and Wall, Rechtsteiner, and Rocha [351] in
defining both SVD and its relation to PCA. In this thesis we use PCA in chapter 4 when analyzing
social media data.
We start with our data points, defined as a (real) n × k matrix X, where n ≥ k. This matrix
can be decomposed as follows
X︸︷︷︸
n×k
= U︸︷︷︸
n×k
S︸︷︷︸
k×k
VT︸︷︷︸
k×k
(2.19)
where U = {uj} is an n × k matrix whose columns are orthonormal, so that UTU = In with I
being the identify matrix; V = {vj} is a k× k matrix whose rows and columns are orthonormal, so
VTV = VVT = Ik; and S = diag(s1, . . . , sk) is a k×k matrix containing the r = min(n, k) singular
values σi ≥ 0 on the main diagonal, and 0 otherwise. Furthermore, sj > 0 for 1 ≤ j ≤ r, and sj = 0
for (r + 1) ≤ j ≤ k. By convention, singular vectors are listed in descending order with the highest
singular value in the upper left index of S. The columns of U are the left singular vectors, and the
columns of V are the right singular vectors. For an intuitive graphical representation of SVD see
Wall, Rechtsteiner, and Rocha [351]. Importantly, if the singular values die off quickly, a truncated
SVD can be computed with a rank l approximation of matrix X as
Xl ≈ U:,1:l S1:l,1:l VT:,1:l =
l∑
j=1
uj sj v
T
j . (2.20)
Similarly, one could choose to null the importance of a certain eigenvalue by setting sj = 0 and
recomputing matrix X. In a recent work, where data points were a distribution of emotion in the
English language over time, our group has shown that setting s0 = 0 and reconstructing matrix X
allowed for the removal of the patterns inherent of the English language, thus enhancing signals in
lower components [272].
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SVD has also a direct relation to PCA in the case where principal components are calculated
from the covariance matrix. For an arbitrary real matrix X, if X = USVT , we have
XTX = VS2VT , (2.21)
where S2 is a diagonal matrix containing the square singular values. Thus, the eigenvectors of XTX
are equal to V, the right singular vectors of X, and the eigenvalues of XTX are equal to S2, the
squared singular values. Similarly,
XXT = US2 , (2.22)
so the eigenvectors of XXT are equal to U, the left singular vectors of X. Also, the eigenvalues of
XXT are equal to the squared singular values. Summarizing,
U = evec(XXT ) , V = evec(XTX) , S2 = eval(XXT ) = eval(XTX) . (2.23)
2.4 Complex networks and systems 4
The Cybernetics group was a mid-20th century group of scientists from diverse backgrounds aimed
to invent digital computers to uncover common principles of organization in the living, cognitive and
social systems [79]. Among its members were renowned scientists, including Wiener, Shannon, Von
Neumann, and Turing [352, 353]. In his seminal 1948 paper, Weaver [354] pushes science to study
the common principles of what he called problems of organized complexity: a vacuum between prob-
lems of simplicity—consisting of few variables and easy described by Newtonian mechanics—, and
problems of disorganized complexity—consisting of large number of variables but easily described by
statistical mechanics. This drive gave rise to the Systems Movement (i.e., System’s Science, General
Systems Theory), a field of interdisciplinary scientists aiming to uncover general relationships of the
4Parts of this section draws inspiration from unpublished notes from Luis M. Rocha.
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empirical world [97, 355]. This vision did not vanish but got absorbed into domains of application
under different names, such as operations research, systems psychology, systems ecology, systems
biology, among others. The core vision and shared mindset of the systems movement is currently
known as the field of Complex Systems [21, 95, 98].
The field of complex systems started with collaboration between mathematicians, physicists,
biologists, neuroscientists and sociologists (e.g. McCulloch, Rosenblueth, Mead, Von Neumann,
Wiener, etc. see [79]) and it remains committed to an interdisciplinary agenda, successfully trans-
lating theory to solve problems in social sciences [87, 93, 356], public health [357], physics [358],
biology [187], neuroscience [101], and in a long and growing list of other fruitful examples. Common
to all these disciplines, and more, since it is useful to describe interactions in the, biochemical,
neural, environmental, technological, knowledge and social spaces we live in [87, 92, 94, 96, 99, 100,
101], is the paradigmatic and most successful general principle of complexity, the complex network.
The study of complex networks differs but heavily draws from the study of graph theory and
social networks, originally studied in mathematics and sociology [87]. Complex networks are graph
structures with non-trivial topological features, often arising when modeling real-world complex
systems [92, 359]. The widespread computing power and the availability of large data sets capturing
the rich structure of real-world systems both contributed to the study of complex networks as models
of organized complexity [21], being adopted by a variety of fields [96]. For instance, the networks of
links in Wikipedia can be used for automatic fact-checking [113], and the communication patterns
of Twitter help us understand the spread of ideas online [360], obtain collective mood states that
correlate with future stock-market fluctuations [51], and even misinformation campaigns [361].
Without disregarding the extensive body of work in social network analysis [356], perhaps two
seminal papers can be seen as major contributors to the establishment of the study of complex net-
works as the now known complex systems sub-field of network science [362]. The first was published
some 20 years ago, when Watts and Strogatz [111] described a model for ‘small-world’ in networks,
a term popularly known as ‘six-degrees of separation’ [363]. In this work they showed that merely
randomly connecting edges in a network—as in the Erdös-Rényi random network model [110]—, is
not sufficient to explain a network’s cliqueshness, a measure of the clustering coefficient of a node, or
the ratio of the number of links between a node’s neighbor and the maximum number of links. Be-
yond the initial assumption that their work was only an explanation for six degree of separation, the
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wide adoption of the model by diverse fields paved the way to explain a variety of dynamic phenom-
ena [362]. A year later, in 1999, Barabási and Albert [112] proposed the ‘preferential-attachment’
network model. This model highlighted that the distribution of edges in real world networks were
not Poisson—as the random model would predict—, but rather ‘heavy-tailed’. This latter work
brought an array of research that focused on the characterization of network edge distributions,
eliciting advancements in the computation of such ‘heavy-tails’ [364].
As networks are useful representations to study complex systems, they have been extensively
applied in the biomedical domain, as models of gene regulatory or metabolic networks [104, 365].
However, in precision public health they only recently have been adopted. For instance, in con-
junction with large-scale data integration, networks have been recently used in disease progression
[216, 217, 366], precision oncology [367], and systems pharmacology [368, 369]. In the study of DDI,
networks have been used in predicting new interactions [370], or have been integrated with machine
learning pipelines [371], either aiming at uncovering new interactions or validating new methods on
already known interactions.
2.4.1 Network link prediction
From a network perspective, predicting a new drug-drug relation (e.g., interaction) is a link predic-
tion problem. The link prediction problem attempts to either predict the existence of a link between
two nodes or to rank links based on some predefined metric, such as importance of aﬄuence. Re-
cently, the link prediction problem has also received increased attention in respect to network data
reliability, or when limited knowledge about the network is known [372, 373]. Link prediction mea-
sures are usually based on the attributes of the nodes, their neighbors, or other observed topological
or statistical information [374]. The problem has been extensively studied in sociometrics, usually
to predict social relationships [87], and the participation of actors—individuals, but also extended
to corporations, governmental agencies, or any other institutional entities [375]—in events, such as
email chains, telephone calls, scientific conferences, etc [376, 377]. Large scale computation and data
availability brought new applications to the link prediction problem, often regarded as part of the
information retrieval literature [378, 379, 380]. These studies include transactions between banks,
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links between internet pages [381, 382], epidemic spread from incomplete temporal data [373], mea-
sures of scientific impact factors [383, 384], and even the proposal of new systems of science funding
[385, 386]. In practice, a variety of measures can be used for link prediction, usually based on local
[112, 378, 387, 388, 389, 390, 391, 392, 393] or global [390, 391, 394] similarity measures, variations
of the random walk problem (drunkard’s walk [395]) [381, 382, 396, 397, 398, 399, 400], or even
probabilistic [401] and generative [87, 402, 403] models. A survey of different measures can be seen
in the works of Lü and Zhou [390], Zhou, Lü, and Zhang [393], and Liben-Nowell and Kleinberg
[404].
Below we describe in detail a few examples in closer relation to the work we develop in chapters 4
and 5. In Kastrin, Ferk, and Leskošek [370] the authors represented the process of link prediction
as a binary classification task on networks of potential DDIs. They used link prediction techniques
for predicting unknown interactions between drugs in five large-scale DDI databases: DrugBank,
KEGG, NDF-RT, SemMedDB, and Twosides. Their prediction uses unsupervised and supervised
approaches including classification tree, k-nearest neighbors, support vector machine, random forest,
and gradient boosting machine classifiers based on topological and semantic similarity features. The
supervised approach outperformed the unsupervised approach with the Twosides network having
the best prediction performance (AUC/PR: 0.93 for both random forests and gradient boosting
machine).
Shi, Shang, Gao, Zhang, and Yiu [371] presented a new methodology integrating drug proximity
networks with machine learning classifiers to predict DDI. Their assumption is that drugs with
similar profiles will often interact with the same set of drugs. Once the interaction and proximity
networks were built, they feed into three different classifiers: multi-label K nearest neighbors, regu-
larized least square classifiers, and support vector machine. The proximity network was built using
a pairwise Jaccard index. The authors report faster computation than previous methods and about
.80 P/R AUC for predicting known DDI.
In order to characterize new drugs and uncover a global picture of drug-targets, drug-drug,
and target-target interaction, Lin, Zhang, Yan, Lu, and Hu [405] analyzed data from Drugs@FDA
and DrugBank for new molecular entities (NMEs). These were NMEs approved by the U.S. Food
and Drug Administration (FDA) between 2000 and 2015. The authors modelled two molecular
interaction networks—the drug-drug interaction and the target-target interaction network and found
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that NMEs for the nerve system were not only multi-target, but also had a greater number of targets
than NMEs for other classes. Importantly, these results represent a shift from the classical drug
development paradigm of “one lock one key” model.
Based on the theory of ‘compressed sensing’, from digital signal processing, Poleksic and Xie
[406] used drug-adverse reaction bipartite networks and similarity networks to predict the occurrence
of rare ADR and of ADRs on newly discovered drugs. When compared to similar algorithms, they
report results well above the current state-of-the-art methods. Similar to our work, they used both
SIDER and MedDRA, and computed similarity scores also using the Jaccard index.
Networks have also been recently used for drug repurposing, the identification of novel thera-
peutic effects for existing drugs. In Peyvandipour, Saberian, Shafi, Donato, and Draghici [369], the
authors built drug-disease and drug-genes networks in a systems biology approach. Their network is
integrated with gene-expression measurements to identify drugs with new desired therapeutic effects
based on a system-level analysis method. The authors report being able to recover repurposed drugs
already approved by the FDA on four human diseases: idiopathic pulmonary fibrosis, non-small cell
lung cancer, prostate cancer and breast cancer.
2.4.2 Associative knowledge networks and their backbones 5
The structural (topological connectivity) properties of complex networks are currently well under-
stood, including modularity detection [88]. However, the majority of research on complex networks
treats interactions as binary edges, even though interactions in real networks exhibit a wide range of
intensities or strengths. The varying strength of many real networks, as well the need to understand
and control biochemical and social networks, have lead towards a more recent drive to study com-
plex networks as weighted graphs, and to look at their complexity from the dynamics perspective
[94]. Of particular relevance here is a recent shift in the field to move beyond understanding the
topology of complexity, towards prediction of temporal or dynamical behavior [407].
Here we formalize a generic description of an associative knowledge network, its closure com-
putation, and backbone extraction. Later, in chapter 4, we use associative knowledge networks to
5This section contains excerpts from [RBC7, 117]
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explore drug-drug reactions and interactions from social media data. The notation described below
follows that of Correia, Li, and Rocha [RBC7] and Simas and Rocha [117].
Given a set of items X (nodes), we first compute a symmetric co-occurrence graph R(X). These
graphs are easily represented by adjacency matrices R, where entries ri,j often denote the number of
times where terms xi and xj co-occurred. Naturally ri,i, the diagonal values of the adjacency matrix,
denotes the number of times term xi occurred. To obtain a normalized strength of association among
the set of items X, we compute proximity graphs P (X). Thus, entries of the adjacency matrix P
of a proximity graph are given by:
pi,j =
ri,j
ri,i + rj,j − ri,j , ∀ xi, xj ∈ X (2.24)
where pi,j ∈ [0, 1] and pi,i = 1; pi,j = 0 means that items xi and xj never co-occurred and,
conversely, pi,j = 1 means that items xi and xj always co-occurred. The proximity in eq. (2.24)
is the standard Jaccard index [387, 408], and can be interpreted as the probability that two items
were seen together, given that either of them was individually seen [116, 117]. To ensure enough
support exists in the data for proximity associations between items, we often compute proximity
weights only for items where ri,i + rj,j − ri,j ≥ λ, where λ is generally assigned to 10. This means
that we only consider the proximity between items xi and xj , if jointly they occur at least λ times;
when ri,i + rj,j − ri,j < λ, we set pi,j = 0.
One can think of proximity graphs as associative knowledge networks that represent how often
items co-occur in a large set of observation units such as documents or, as will be seen in chapter 4,
time-windows in social media timelines. As in any other co-occurrence method, the assumption is
that items that frequently co-occur are associated with a common phenomenon. Our group has
used such associative knowledge networks successfully for automated fact-checking [113], protein-
protein interaction extraction [114, 115], and recommender systems [116, 117]. In this dissertation
we use them to reveal strong associations of DDI- and ADR-related terms, which may be useful for
precision public health monitoring and surveillance.
In addition to proximity, many network analysis methods, such as those which depend on
shortest-path calculations, rely on the isomorphic concept of distance [117]. Thus, we can also
compute distance graphs D(X), using the map:
57
di,j = ϕ(pi,j) =
1
pi,j
− 1 (2.25)
Proximity networks are useful to discover associations between items which co-occur. But they
are also useful to infer indirect associations between items. In other words, items that do not directly
co-occur much, but which tend to occur with the same other set of items. In network science we
think of these as semi-metric associations [409]. Items which are very strongly connected via indirect
paths, but not very related directly, thus breaking the triangle inequality (or a generalized measure
of transitivity) [117].
These semi-metric associations (edges) are obtained via the computation of metric closure
DCm(X) of the distance graph, which is isomorphic to a specific transitive closure of the prox-
imity graph [117]. The metric closure is equivalent to computing the shortest paths between every
pair of nodes in the distance graph. Thus, dCmi,j is the length (sum of distance edge weights) of
the shortest path between items xi and xj in the original distance graph D(X). In practice, we
compute DCm(X) using the all pairs shortest paths (APSP) based on the Dijkstra algorithm [410]
or the matrix product [117].
Interestingly, there is an invariant subgraph of Dw(X) when computing the metric closure which
is called the metric backbone [117]. In other words, some edges di,j in D(X) do not change their
distance weight when computing shortest paths, because there is no shorter indirect distance via
other nodes in the graph, therefore di,j = dCmi,j ; these are metric edges because they obey the triangle
inequality. Conversely, semi-metric edges, which break the triangle inequality, whereby there exist
shorter indirect paths than the direct distance: di,j > dCmi,j [116, 117, 409]
There is anecdotal evidence suggesting that semi-metric edges may evolve into metric edges as
systems (networks) grow and become stable. For instance, an early mentioned ADR in social media
initially shows as a semi-metric edge in the distance network. As scientific evidence piles up for the
ADR, co-mentions increase while the ADR edge becomes increasingly metric and eventually part of
the network backbone. Similarly for social context, acquaintances are shown as semi-metric edges,
evolving into an increasingly metric edges as the individual’s friendship—the amount of time spent
together—grows. However, to this date it is unknown whether the claim holds, which we attempt
to untangle in chapter 5. To evaluate such claim, we compute the degree of semi-metricity of edge
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di,j between items xi and xj employing two measures, si,j and bi,j [116]:
si,j =
di,j
dCmi,j
, bi,j =
〈di〉
dCmi,j
∀ xi, xj ∈ X (2.26)
where 〈di〉 is the mean direct distance from xi to all other xk ∈ X such that dik is finite. si,j > 1
for semi-metric edges, and 1 otherwise. bi,j is only computed for edges that do not exist originally
in D(X) (i.e. di,j = ∞), and it measures how much the shortest indirect distance between xi and
xj falls below the average distance of xi to all its directly linked nodes xk. Note that bi,j 6= bj,i and
therefore are often both computed.
Once the proximity network is built, complex network methods can be applied in a purely
bottom-up approach, data-driven form, in an effort to extract macroscopic relational patterns. For
instance, Principal Component Analysis (PCA), described in the section 2.3.3, or a range of different
clustering techniques [88] can be used for such task.
Alternatively, a hypothesis-driven approach can be used, such as querying the proximity network
for specific items most associated with a set of items. This problem of finding which other items
A ⊆ X are near a set of query items Q ⊆ X is common in recommender systems and in the
information retrieval literature [116], from which link prediction is the most fundamental problem.
The answer set A can be computed as:
A ≡
{
xj : ∀xi∈Q Φ
xj∈X−Q
(pi,j) ≥ α
}
(2.27)
where Φ is an operator of choice, pi,j is the proximity weight between terms xi and xj , and α is a
desired threshold. If we are interested in a set of terms A which are strongly related to every term
in query set Q, then we use Φ = min. If we are interested in terms strongly related to at least one
term in Q, then Φ = max. For a compromise between the two, we can use Φ = avg (average).
In the case we present in chapter 4, where nodes in the proximity network are drugs and symptom
terms extracted from social media, these queries can be especially important for scientists and health
professionals interested in a particular phenomena. Providing the ability for specialists to investigate
how a particular drug or symptom is being mentioned may provide additional insights to ongoing
investigations.
We have release a Python package that performs closure computation, backbone extraction and
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calculates aforementioned metrics. The open-source package can be found in github.com/rionbr/
distanceclosure.
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Chapter Three
City-wide analysis of electronic health records reveals gender and age
biases in the administration of known drug-drug interactions 1
“It is a collective constraint on individual elements that
make up the collection”
Howard H. Pattee
American (Theoretical) Biologist
3.1 The DDI Phenomenon
Adverse drug reactions (ADR) from drug-drug interactions (DDI) is a well-known public
health problem worldwide [31, 32, 33]. Most efforts to measure the scale of ADR from DDI focus on
hospitalizations and emergency visits [28, 36, 37, 38, 40, 41, 42] or literature meta-analysis [33, 35,
43]. Very few studies so far have been able to characterize this problem in primary and secondary
care settings. Lack of access to longitudinal data from Electronic Health Records (EHR) of large
populations continues to be the main barrier to measuring the prevalence of DDI and characterizing
1A journal version of this chapter is currently under a second round of reviews. A pre-print can be seen in
Correia, Araújo, Mattos, Wild, and Rocha [RBC6]. This work was also presented in Correia, Mattos, and Rocha
[RBC14] and Correia and Rocha [411].
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the phenomenon in medical care [39, 47, 48]. For instance, Molden et al [44] searched 43,500 patients
in pharmacy databases in southeastern Norway, studying only DDI from CYP inhibitor-substrate
drugs. Pinto et al [45] studied DDI prevalence in a small cohort of forty elderly hypertensive
patients in a primary health care unit in Brazil. Iyer et al [30] mined 50 million clinical notes
from the private EHR database STRIDE [221], to identify signals of unknown potential DDI from
clinical text. While STRIDE contains EHR from multiple care levels, this analysis did not address
the concomitant dispensation of pairs of drugs with known DDI in primary- and secondary-care.
Lastly, Guthrie et al [46] performed a repeated cross-sectional comparison of 84 days in 1995 and
2010, to study the increase in polypharmacy and DDI at the primary- and secondary-care level in
the Tayside region of Scotland (pop. 405,721); DDI was defined according to the British National
Formulary, a private publication. This study estimated that 13% of adults (≥ 20 y.o.) were
prescribed a “potentially serious” known DDI in 2010, and that the number of drugs prescribed
was the characteristic most predictive of DDI. Patients prescribed 15 or more drugs had an almost
27 fold DDI risk increase over those prescribed two to four drugs. However, by using only 84-day
windows, this analysis misses potential co-administrations from separate prescriptions made outside
of the relatively short windows; it also analyzed prescription, rather than dispensation data.
Here we pursue a large-scale longitudinal study of the DDI phenomenon at the primary- and
secondary-care levels in an entire city, using considerably larger time-windows and relying on public
DDI and ADR standards. We obtained 18 months of EHR data for the city of Blumenau in Southern
Brazil (pop. 338,876), a city with a very high Human Development Index (HDI=0.806 [412])—at the
level of the top quartile of countries according to this United Nations Development Programme index
[413]. Brazil has a universal public health-care system, and Blumenau possesses a city-wide Health
Information System (HIS) with prescription and dispensation information for its entire population.
The analysis of Blumenau’s EHR data is thus an opportunity to understand the DDI phenomenon in
a highly developed city in a country where DDI is known to occur similarly to other nations [35, 37].
The study provides a novel understanding of both prevalence and bias in the dispensation of known
DDI outside of hospital settings. Dispensation data is only a surrogate for administration of DDI,
as we are not certain that patients actually take the medications that are dispensed concomitantly.
However, dispensation data can only be a better surrogate of administration than prescription data
that was used in previous studies (e.g.[46]), as a prescription may ultimately not be dispensed.
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From a public-health perspective, the concomitant administration of drugs with adverse inter-
actions is of great concern [35, 36, 37]. Since over 30% of all ADR are thought to be caused by DDI
[30], better identification and prediction of administration of known DDI in primary- and secondary-
care could reduce the number of patients seeking urgent care in hospitals, resulting in substantial
savings for health systems worldwide [33, 38, 39]. A systematic review from 2009 showed that the
proportion of hospital inpatients with ADR (in general, not DDI only) ranged from 1.6 to 41.4%
[35]. Furthermore, an estimated 52% (45%) of ADR in outpatients (inpatients) were preventable
[43]. In the elderly population alone (> 65 y.o.), the yearly financial burden of ADR was estimated
to reach $11.9 million for the province of Ontario (pop. 12M) [28], or about $1 per capita, per year.
As we report below, the yearly cost of major DDI estimated from the Blumenau EHR dispensation
data for the same age group is higher, at least $2 per capita, per year, after adjusting for inflation
and exchange rates—though for less stringent assumptions it can be as high as $7 per capita, per
year. This suggests that the financial burden of DDI is more severe than previously thought. More-
over, the rate of major DDI found to be dispensed in Blumenau is smaller than what was reported
to be prescribed in Scotland [46]. Therefore the financial burden of DDI is likely higher in other
health-care systems, especially those with older populations.
To characterize the significant factors in DDI, we study demographic variables such as gender
and age, as well as the drugs involved in DDI in greater detail, and reveal previously unknown
factors in this phenomenon. We show that women in Blumenau are at a greater risk of being
dispensed known DDI than men, with a 1.6 risk multiplier. This increased risk for females is not
confounded by the larger number of women present in the data nor their age. The analysis also
identifies the drug pairs that most lead to DDI in women which, surprisingly, are not attributable
to female-specific medicines (e.g. hormone therapy). We also demonstrate that there is a significant
increase of DDI risk with age, reaching more than 30% for adults over 65 years of age. Importantly,
using a statistical null model, we show that the age risk growth is not explained simply by the
increase in polypharmacy in older age. This suggests that the specific drugs dispensed to older
populations are more prone to DDI and/or that insufficient attention is paid to this phenomenon
in primary care for this population.
While the number of drugs dispensed and the number of concomitant drug dispensations are
the best predictors of DDI (previously only observed for number of drugs prescribed [46]), we show
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that these quantities by themselves are poor predictors of DDI. We look at demographic variables
such as education and neighborhood aﬄuence and show they do not play a significant role in the
risk for DDI in our data. Other factors, however, play very significant roles, chiefly age, gender,
and the specific drugs dispensed. Indeed, we demonstrate that the automatic prediction of which
patients are dispensed known DDI is quite accurate when those factors are included. This makes
decision-support systems for predicting DDI risk in HIS not only feasible, but necessary to lower
the rates of known DDI being dispensed.
To better understand which drugs are most involved in the DDI phenomenon, we integrate
all DDI information of the Blumenau population into easy-to-visualize DDI networks. Looking at
gender differences, for example, analysis of these networks identifies key drugs and interactions in
the DDI phenomenon, and demonstrates that the higher DDI risk women face is not associated
with any type of hormone therapy. Indeed, drugs that most contribute to the gender-disparity in
DDI risk are not female-specific. This suggests there may be social or biological processes at play in
primary- and secondary-care that lead to increased DDI risk for women. A full listing of the drugs
that most contribute to the DDI observed in our study are presented in our DDI network analysis
and accompanying tables.
Eighteen months of drug dispensing data (Jan 2014-Jun 2015) were gathered from the Pronto HIS
[414, 415]. Drugs reported in this system are available via medical prescription only, free of charge,
and dispensed to citizens of Blumenau (population Ω = 338, 876 [416]) during the observation
period. Doctors prescribe medications by selecting drug and dosage via the HIS. Low-cost drugs
can generally be directly dispensed at the primary-care facilities, whereas specialized and higher-
cost medication is distributed in three central facilities across the city. All drugs are dispensed by
pharmacists who must select in Pronto the drug and quantity to be dispensed, allowing the length
of administration to be estimated. It must be noted that patients are not required to retrieve drugs
from the public system. They can buy prescribed medications from private pharmacies at their
own expense, without such transactions being recorded in Pronto. However, there is no incentive
to pay more at private pharmacies for the same medication. Indeed, our analysis indicates that use
of Pronto is similar across all neighborhoods of Blumenau, irrespective of their average income (see
fig. A.5).
EHR were anonymized at the source and only drug dispensation and demographic variables,
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Figure 3.1: Distribution of patients given gender, age and education level. In total |UM| = 55, 032 (41.46%) were
males and |UF| = 77, 690 (58.54%) were females. On education, a majority |Ue=∅| = 71, 662 (53.99%) did not
report their education level. |Ue−| = 48, 547 (36,58%) declared having at most some high school education whereas
|Ue+| = 12, 513 (9,43%) had completed high school education or above. On age, patients |Uy=[20-24]| = 10, 382
(7,82%) and |Uy=[50-54]| = 10, 650 (8,02%) accounted for the two largest age groups. Labels K-6 and K-12 are
Completed elementary and Completed high school education, respectively. Labels for age y ≥ 80 and education level
above Completed college not shown.
including gender, age, neighborhood, marital status and educational level, were kept. Methods
were performed in accordance with guidelines and regulations. All patient consent was handled at
the source prior to the anonymization and outside of the responsibility of this team. Nonetheless,
this study was approved by Indiana University’s Institutional Review Board (IRB). Drug names
originally in Portuguese were converted to English, disambiguated and matched to their DrugBank
ID (e.g., Cefalexina 500mg Comprimido and Cefalexina 250MG/5ml Suspensão Oral were matched
to Chlorphenamine, DBID DB01114). Medications with multiple drug compounds (e.g., Amoxicillin
500mg & Clavulanate 125mg) were split into their constituent individual drugs. Other dispensed
substances (e.g., infant formula milk or vitamin complexes) unmatched to DrugBank were dis-
carded. In total, 122 unique drugs were keep for analysis. Because we have no means to know
whether patients actually took the dispensed drugs, our analysis assumes that drugs dispensed were
administered.
Throughout the year of 2014 and the first six months of 2015, Blumenau’s Pronto HIS registered
1, 573, 678 distinct drug interval administrations, dispensed to |U | = 132, 722 distinct patients—
39.17% of the city population. The male/female proportions are 41.5/58.5%, respectively. Of the
46% who declared their education level, a large proportion (46.77%) reported having incomplete
elementary school and 20.49% had finished high school or above (see fig. 3.1 and SI for details).
|Uν≥2| = 104, 811 patients, corresponding to 78.97% of the Pronto patient population, were dis-
pensed two or more distinct drugs in the period; only this set could have been dispensed known
DDI.
A drug interaction between a pair of drugs is measured if both drugs were concomitantly admin-
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Figure 3.2: Left. A hypothetical patient-drug dispensing timeline with three drugs (i,j & k). Drug administration
length (a, in days, n) are shown for each dispensation. Right. The three possible pairwise comparisons (i, j), (i, k)
and (j, k) between the dispensed drugs are shown with their co-administration overlap marked with either an orange
(no known DDI) or red (known DDI) background.
istered and the pair is identified as a known DDI in the 2011 version of DrugBank, an open-source
drug database containing DDI information [144]. Figure 3.2 displays a co-administration timeline
example. More formally, let us denote patients by u ∈ U and drugs by i, j ∈ D (|D| = 122); Ui ∈ U
is the subset of users who were dispensed drug i, Du ⊆ D is the subset of drugs administered to
patient u, and νu ≡ |Du| is the number of distinct drugs dispensed to patient u. Patients can be
administered a drug i multiple times in the observation period, therefore Aui ≡ {ai,un } denotes the
set of distinct administration intervals a of drug i to patient u, where a ∈ N is measured in days
(n). αui = |Aui | and λui =
∑
n a
i,u
n denote the number of times and total number of days drug i was
administered to patient u, respectively.
Similarly, αui,j and λ
u
i,j denote the number of times and total number of days (co-administration
length) drugs i and j were co-administered to patient u, respectively. To identify the co- adminis-
tration of drug pair (i, j) to patient u we define a Boolean variable ψui,j ∈ {0, 1} as:
ψui,j =
(
λui,j > 0
)
(3.1)
a logical variable measuring whether patient u was co-administered drug pair (i, j) for at least one
day. Next, we define a symmetrical binary map ∆ : D ×D → {0, 1} to indicate whether drug pair
(i, j) ∈ D × D is (δi,j = 1) a known DDI in DrugBank, or not (δi,j = 0). Thus, to flag the co-
administration of a known drug interaction (i, j) to patient u we similarly define a Boolean variable
ϕui,j ∈ {0, 1} as:
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Table 3.1: Dispensations, co-administration and interaction quantities and subsets used throughout the analysis.
quantity notation number of
νu ≡ |Du| distinct drugs dispensed to patient u.
Ψu =
∑
i,j∈Du
ψui,j co-administrations to patient u.
Ψi,j =
∑
u∈U
ψui,j co-administrations of drug pair (i, j) to all patients.
Φu =
∑
i,j∈Du
ϕui,j co-administrations of known DDI pairs to patient u.
Φi,j =
∑
u∈U
ϕui,j co-administrations of known DDI pair (i, j) to all
patients.
subset notation subset of patients
Uν>x = {u ∈ U : νu > x} who had at least x ∈ N drug administrations.
UΨ = {u ∈ U : Ψu > 0} who had at least 1 co-administration.
UΨi,j = {u ∈ U : ψui,j = 1} who were co-administered pair (i, j).
UΦ = {u ∈ U : Φu > 0} who had at least 1 known DDI.
UΦi,j = {u ∈ U : ϕui,j = 1} who were co-administered known DDI pair (i, j).
Ug = {u ∈ U : gender(u) = g}, g ∈ {M,F} per gender.
U [y1,y2] = {u ∈ U : age(u) ∈ [y1, y2]}, y1, y2 ∈ N per age bracket.
UN = {u ∈ U : neighborhood(u) ∈ N}, N ∈ N per neighborhood.
UE = {u ∈ U : education(u) ≥ E}, E ∈ N per education level. UE=∅ is the subset of patients
who did not report their education level.
From these subsets we also denote their possible intersections by combining the appropriate
sub and superscripts.
ϕui,j =
(
ψui,j = 1 ∧ δi,j = 1
)
. (3.2)
For each DDI pair observed, literature references and a severity score s ∈ {major,moderate,minor, n/a}
were retrieved from Drugs.com [222]. From these values, other quantities and sets are computed
per patient u, drug i or drug pair (i, j) as listed in table 3.1.
The drug pairs (i, j) with the largest “footprint” in the population, are the pairs that maximize
|UΨi,j |. Out of these most co-administered pairs, we are naturally most interested in those that are
known DDI and thus maximize |UΦi,j |. A normalized version of this measure is computed as
γΦi,j =
|UΦi,j |
|Ui| , (3.3)
which conditions the number of users co-administered known DDI pair (i, j) on the number of users
that are administered drug i. This measure is not symmetrical: γΦi,j 6= γΦj,i. Maximizing it yields
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DDI pairs (i, j) that tend to be co-administered to patients who are administered either i or j
independently; see table A.10 for top 20 such DDI pairs.
Another facet of the DDI phenomenon we can observe is related to the co-administration length
of drug pairs (λui,j). A normalized version is computed as: τ
u
i,j = λ
u
i,j/(λ
u
i + λ
u
j − λui,j), where
τ ∈ [0, 1]. This symmetric proximity measure [117] allows us to distinguish drug pairs that tend
to be co-administered to patient u only simultaneously (τui,j → 1), or with small temporal overlap
(τui,j → 0). A normalized measure for the entire patient population is then computed as:
τΨi,j =
∑
u∈UΨi,j
τui,j
|UΨi,j |
(3.4)
This proximity measure defines a weighted graph TΨ [117] on set D; the graph’s edges, τΨi,j ∈ [0, 1],
link drugs that were co-administered in the patient population. τΨi,j is larger when drug pairs (i, j)
tend to be co-administered when either i or j is administered (correlated), and smaller otherwise
(independent). Therefore, τΨi,j is a measure of the strength of drug association in the data for drug
pairs (i, j); high values can pick drug pairs dispensed together for known comorbidities, which
physicians should be aware of, as well as for unknown comobidities (especially involving distinct
specialists prescribing drugs independently). Since we do not know the underlying comorbidities,
we cannot separate the two cases with this dataset. However, to focus on the DDI phenomenon
(for known and unknown comorbidity), we obtain a subgraph TΦ, restricted to known DDI pairs
by computing τΦi,j = τ
Ψ
i,j .δi,j ; thus, T
Φ is a weighted version of ∆.
The relative risk of co-administration (RRC) for women is computed as the ratio of the con-
ditional probabilities of patients being dispensed at least one pair of drugs concomitantly, given
gender:
RRCF =
P (Ψu > 0 |u ∈ UF)
P (Ψu > 0 |u ∈ UM) =
|UΨ,F | /|UF|
|UΨ,M | /|UM| (3.5)
Naturally, the same risk for males is computed as RRCM = 1/RRCF. Similarly, we also computed
the relative risk of interaction (RRI) for women as:
RRIF =
P (Φu > 0 |u ∈ UF)
P (Φu > 0 |u ∈ UM) =
|UΦ,F | /|UF|
|UΦ,M | /|UM| (3.6)
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with RRIM = 1/RRIF.
The DDI Network is a weighted version of graph ∆ (section 3.1) where edge weights between
drugs i, j (nodes in graph) are the values τΦi,j obtained from eq. (3.4)—yielding a proximity between
drug pairs according to their co-occurrence in DDI co-administrations when either drug is admin-
istered (a symmetrical measure of strength of association/correlation [117], see section 3.1). Node
size represents the probability of interaction for drug i:
PI(i) =
∑
j Φi,j∑
j Ψi,j
(3.7)
which denotes the propensity of drug i to be involved in a DDI with all drugs it is co-administered
with in the data (see table A.17 for values); larger nodes thus identify more dangerous drugs in the
sense that they most contribute to potential ADR from DDI in our data.
To better grasp gender differences in the DDI phenomenon, edges are colored according to the
relative risk of drug pair interaction for each gender : RRIgi,j where g ∈ {M,F}. These quantities
are computed for each DDI pair (i, j) via eq. (3.6), but using Φui,j (number of co-administrations of
known DDI pair (i, j) to patient u) instead of Φu. Naturally, RRIFi,j = 1/RRI
M
i,j . If RRI
F
i,j > 1, the
edge is colored in red with intensity proportional to RRIFi,j , otherwise the edge is colored in blue
with intensity proportional to RRIMi,j (see legend). Therefore, increased DDI risk for women (men)
is identified by darker red (blue) edges.
For some results we remove the following contraceptive drugs: Ethinyl Estradiol, Estradiol,
Norethisterone, Levonorgestrel and Estrogens Conjugated.
To investigate the role of age in known DDI co-administration, we aggregated patients into age
groups and computed the risk of specific age groups to be dispensed a known DDI for the amount
of co-administrations observed for that age group. Thus, a risk of interaction for age group [y1-y2]
is calculated as
RI [y1,y2] =
P (Φu > 0 |u ∈ U [y1,y2])
P (Ψu > 0 |u ∈ U [y1,y2]) , (3.8)
which can be interpreted as the probability of being dispensed a known DDI given the expected num-
ber of co-administrations for a patient in a specific age range [y1, y2]. A Risk of Co-administration
for age group [y1-y2], RC [y1,y2], is similarly computed, but using νu ≥ 2—the number of patients
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with at least 2 drug administrations—instead of Ψu. This is interpreted as the probability of be-
ing concomitantly dispensed two or more drugs (co-administration), when a patient of a given age
group is dispensed two or more drugs in the full observation period. Additionally, we also parse age
risk by gender by computing RI [y1,y2],g for each gender g ∈ {M,F} using eq. (3.8), but for users
u ∈ U [y1,y2],g. Similarly, RC [y1,y2],g is computed for the risk of co-administration per age and gender.
The null model, Hrnd0 , aims to capture the expected increase in RIy with age, given the observed
polypharmacy and gender for each specific age group. Thus, the model’s assumption is that all drugs
that were in reality dispensed in a given age group are dispensed at random with the same overall
frequency of co-administration for that age group. Specifically, for each co-administration observed
in the data for an age group [y1, y2], the null model draws random drug pairs (i, j) from the set of
all drugs observed for that age group, D[y1,y2]. The random drug pairs are subsequently checked
for DDI status in DrugBank, just like the original analysis. This way, the null model has exactly
the same number of co-administration occurrences for each age group and gender, but randomly
shuﬄed drug pairs—and only the drugs dispensed for a certain age are randomly shuﬄed for that
age group (additional details in SI section A.7).
We trained linear kernel Support Vector Machine (SVM) [346] and Logistic Regression (LR) [347]
classifiers using stratified 4-fold cross-validation to ensure generalization performance. Age, gender,
number of drugs (νu) and co-administrations (Φu) were used as demographic variables features. In
addition, all |D| = 122 drugs in the data are used as binary features, whereby if patient u was
administered drug i that feature is set to 1 and to 0 otherwise; this allows classifiers to be trained
on which drugs, and drug combinations, are most likely to be involved in DDI.
The trained classifiers are compared to two “coin-toss” null models, one unbiased where each
class has equal probability, and a biased one based on estimated class frequency. A third, more
elaborate null model classifier, finds the best age cutoff for each gender, from which all patients
above the cutoff age are considered as having a DDI. This last “age-gender” null model represents
a baseline comparison of the best we could do if only gender and age were given for each patient.
To assess the performance of all classifiers, in SI section A.11 we report several measures. Here, we
focus on the Matthew’s Correlation Coefficient (MCC) [349], which is regarded as an ideal measure
of the quality of binary classification in unbalanced scenarios such as this [350]. We also report two
other measures widely used in machine learning classifier performance, the area under the receiver
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operating charactistic curve (AUC ROC), and the area under the precision and recall curve (AUC
P/R).
Other classifiers, feature selection and cross-validation techniques can be used to increase per-
formance, but such gains when studying the DDI phenomenon do not typically lead to substantial
performance increases [120], so such optimization is beyond the scope of this article.
3.2 Drugs involved in interactions
Our analysis tallied Ψ = 1, 025, 754 distinct drug pair co-administrations. Almost 3% of these, or
Φ = 26, 524, are known DDI and involve 75 distinct drugs that participate in |∆| = 181 observed
distinct interaction drug pairs. There is very strong linear relationship between volume of drug
dispensation (αN ) and DDI (ΦN ) across neighborhoods (N) which fits a regression line almost
perfectly (R2 = .92, p < 10−6); see fig. A.4-right in Supporting Information (SI). The distribution
of these DDI pairs per severity class is detailed in table 3.2. A majority (69%) are labeled Moderate,
although, worryingly, 22.5% are classified as Major DDI. The observed DDI pairs were dispensed to
|UΦ| = 15, 527 unique patients, which represent 12% of the Pronto patient population (and almost
5% of the entire Blumenau population). Looking only at the adult Pronto population, this number
is raised to 15% (15,336). Almost 4% of all Pronto patients (5.01% of adults) were administered
a major DDI, and 9.58% (12.15% of adults) were administered a moderate DDI; these numbers
represent 1.54% and 3.75% of the entire Blumenau population, respectively. See §Data & Methods
for precise definitions of symbols and formulae used in this section.
We estimate the financial burden of DDI to Blumenau by evaluating how many of the 24,592
hospital admissions billed to this public health system in the same period [417] were due to ADR from
DDI. This estimation relies on conjecturing what proportion (ph) of patients who where dispensed
a major DDI are likely to have an ADR that requires hospitalization (details in SI section A.1). We
focus on the most conservative value from available literature [33] which yields ph = 2.68%, as well
as on a less conservative estimate also previously reported [28] of ph = 8.35%. The most conservative
estimate leads to a cost of DDI-related hospitalization in Blumenau of over $1M in the 18-month
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Table 3.2: Number and proportions of DDI observations and affected patients per DDI severity class. Drugs or
interactions identified in DrugBank but not present in Drugs.com are tallied as n/a, see SI for details. First column:
Φ, number and proportion of observed DDI co-administrations. Second column: |UΦ|, number of patients affected by
at least one DDI. Third and Fourth columns: proportion of patients from the Pronto system and entire Blumenau
populations, respectively. Fifth column: proportion of adult patients (y ≥ 20 y.o) from the pronto system. ∨ denotes
the logical disjunction. Notice that the same patient may have been administered DDI of more than one severity
class.
severity s Φ |UΦ| |UΦ|/|U | |UΦ|/Ω |UΦ,[y>20]|/|U [y>20]|
Major 5,968 (22.50%) 5,224 3.94% 1.54% 5.01%
Moderate 18,335 (69.13%) 12,711 9.58% 3.75% 12.15%
Minor 542 (2.04%) 528 0.4% 0.16% 0.51%
n/a 1,679 (6.33%) 1,493 1.12% 0.44% 1.43%
Major ∨ Moderate 24,303 (91.63%) 15,030 11.32% 4.44% 14.35%
Moderate ∨ Minor 18,877 (71.17%) 12,791 9.64% 3.77% 12.22%
period, or a per capita cost of $2.03. The extrapolated costs to the state and the country are $21M
and $565M, respectively (see tables A.3 and A.4). The less conservative estimate reaches a per
capita cost of $6.33, or $3.2M, $61M, and $1.5B, for the city, state and country levels respectively.
However all of these conjectures are likely to err on the side of under-reporting emergency room
admissions due to DDI or ADR, since this a well-known problem in studies of this phenomenon
[418, 419, 420, 421, 422]. Therefore, in SI we also report cost estimates for various values of ph, so
that readers can judge what is an appropriate value to consider.
Table 3.3 lists the top 20 DDI pairs, ordered by the rank product of their strength of DDI
association, τΦi,j , with the number of patients they were administered to, |UΦi,j |. The complete list
of DDI pairs, including the severity class and other measures, is provided in SI table A.5 ordered
by the number of affected patients. τi,j is largest (smallest) for DDI pairs (i, j) that are more (less)
likely to be co-administered when either one of drugs i or j is administered. Computing the rank
product between τΦi,j and |UΦi,j | identifies DDI pairs that are very prevalent in the population but
which also tend to be co-administered.
Only 2% of the observed DDI administrations are considered ofminor risk, affecting 542 patients.
The highest ranked one (9th) in table 3.3 is (Digoxin, Spironolactone) and it was administered to
|UΦi,j | = 272 patients (for 〈λui,j〉 = 140 days on average); it leads to increased levels of Digoxin while
decreasing the effect of Spironolactone. The vast majority (almost 70% per table 3.2) of observed
DDI administrations fall in the moderate risk class. For instance, (Digoxin, Furosemide) can cause
“possible electrolyte variations and arrhythmia” (4th, |UΦi,j | = 385, 〈λui,j〉 = 155). Others, like the
72
pair (Haloperidol, Biperiden; 2nd, |UΦi,j | = 524, 〈λui,j〉 = 243) give rise to various ADR, such as
central nervous system depression and tardive dyskinesia; despite the known ADR this pair has
been used clinically [222], which explains the large value of τΦi,j = 0.7, meaning that these drugs are
more likely to be co-administered. In hot weather this DDI increases the risk of hyperthermia and
heat stroke, and Blumenau has a humid subtropical climate with temperatures reaching 30◦C with
100% humidity during summer.
(Omeprazole, Clonazepam) is the most frequent DDI pair observed, by a large margin to the
second (5th, |UΦi,j | = 5, 078, 〈λui,j〉 = 102). Omeprazole is used to treat acid reflux and other
gastroesophageal problems, while Clonazepam is a benzodiazepine anti-epileptic. This prevalent
dispensation requires particular attention to dosage since “Omeprazole may increase the pharma-
cological effect and serum levels of certain benzodiazepines via hepatic enzyme inhibition” [222,
423]. Similarly, (Acetylsalicylic Acid (ASA), Glyburide) is the top ranked pair in table 3.3 and
very frequently dispensed (1st, |UΦi,j | = 1, 249, 〈λui,j〉 = 141). This pair is especially problematic for
diabetic patients since “the salicylate increases the effect of sulfonylurea;” It causes hypoglycemia by
enhancing insulin sensitivity, particularly in patients with advanced age and/or renal impairment
[222, 424].
Major DDI pairs represent 22.5% of all observed DDI administrations per table 3.2. The top 20
major DDI pairs are listed in SI table A.9 and include:
• (Diltiazem, Simvastatin), 6th, |UΦi,j | = 470, 〈λui,j〉 = 160, where “Diltiazem increases the effect
and toxicity of simvastatin” possibly causing liver damage as a side effect [425];
• (Fluoxetine, Amitriptyline), 7th, |UΦi,j | = 1, 190, 〈λui,j〉 = 127, where “Fluoxetine increases the
effect and toxicity of tricyclics” [426]. The same ADR affects (Fluoxetine, Imipramine), 23rd,
|UΦi,j | = 257, and (Fluoxetine, Nortriptyline), 33rd, |UΦi,j | = 154.
• (ASA, Ibuprofen), 8th, |UΦi,j | = 2, 117, 〈λui,j〉 = 53, where “Ibuprofen reduces ASA cardio-
protective effects”. In 2015 the European Medicines Agency issued an updated advice that
occasional use of Ibuprofen should not affect the benefits of low-dose ASA [427]. Our analysis
shows that patients were dispensed this pair concomitantly on average for 53 days (±74 s.d.),
conflicting with occasional use. However, since these are common medications we cannot rule
out the possibility they were dispensed to be taken as needed.
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Table 3.3: Top 20 known DDI pairs (i, j) by rank product (1st column; individual rank in parenthesis) of the ranks
of τΦi,j , the strength of DDI association from eq. (3.4), and |UΦi,j |, the number of patients affected by the DDI (2nd
and 3rd columns, respectively). Mean (± s.d.) co-administration length, 〈λui,j〉, is shown in column 4 (in days) for
each DDI pair (i, j) whose English drug names are shown in columns 5 and 6. Relative gender risk of DDI pair co-
administration, RRIFi,j is shown in column 7. DDI severity classification, according to Drugs.com, shown in column
8, with DDIs not found in Drugs.com labeled as None.
rankp(τ, U) τΦi,j |UΦi,j | 〈λui,j〉 i j RRIFi,j class
1 (2,4) 0.60 1249 141 ± 124 ASA Glyburide 0.89 Moderate
2 (1,12) 0.70 524 243 ± 188 Haloperidol Biperiden 0.62 Moderate
3 (4,11) 0.58 535 152 ± 132 Atenolol Glyburide 1.22 Moderate
4 (3,17) 0.60 385 155 ± 125 Digoxin Furosemide 0.61 Moderate
5 (62,1) 0.26 5078 102 ± 95 Omeprazole Clonazepam 2.28 Moderate
6 (8,16) 0.55 470 160 ± 133 Diltiazem Simvastatin 1.27 Major
7 (26,5) 0.45 1190 127 ± 127 Amitriptyline Fluoxetine 3.55 Major
8 (82,2) 0.23 2117 53 ± 74 ASA Ibuprofen 1.42 Major
9 (10,22) 0.55 272 140 ± 114 Digoxin Spironolactone 0.58 Minor
10 (5,46) 0.57 95 140 ± 126 Propranolol Glyburide 1.61 Moderate
11 (15,18) 0.50 377 143 ± 138 Fluoxetine Carbamazepine 0.98 Moderate
12 (91,3) 0.21 1460 54 ± 77 Atenolol Ibuprofen 1.88 Moderate
13 (61,6) 0.27 999 87 ± 86 Omeprazole Diazepam 1.21 Moderate
14 (16,26) 0.49 226 151 ± 145 Amitriptyline Carbamazepine 0.99 Moderate
15 (6,84) 0.56 25 157 ± 136 Diltiazem Amiodarone 1.26 Major
16 (12,47) 0.52 91 154 ± 142 Atenolol Diltiazem 1.19 Major
17 (21,27) 0.47 222 148 ± 139 Fluoxetine Lithium 1.79 Major
18 (40,15) 0.36 496 103 ± 87 ASA Gliclazide 0.78 None
19 (96,7) 0.20 892 56 ± 61 Fluconazole Simvastatin 2.63 Major
19 (14,48) 0.50 90 161 ± 157 Imipramine Carbamazepine 1.35 Moderate
• (Fluoxetine, Lithium), 17th, |UΦi,j | = 222, 〈λui,j〉 = 148), where “the SSRI increases serum
levels of lithium” potentiating the risk of serotonin syndrome, which is rare but serious and
potentially fatal [222, 428];
• (Fluconazole, Simvastatin), 19th, |UΦi,j | = 892, 〈λui,j〉 = 56), which leads to “increased risk
of myopathy/rhabdomyolysis”. Also from the azole class, Ketoconazole and Itraconazole are
considered potent inhibitors generally causing less clinically significant interactions with Sim-
vastatin than Fluconazole [222]. Both substitutes are available free of charge in the public
health care system [429].
In addition, the top 20 DDI pairs ranked by a normalized drug “footprint” in the population are
listed in SI table A.10.
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3.3 Gender Risk and DDI Networks
The set of patients who were co-administered known DDI was comprised of |UΦ,M| = 4, 793 (30.54%)
males and |UΦ,F| = 10, 734 (69.46%) females (see fig. A.1 and SI for additional data). To understand
whether this difference in the proportion of DDI per gender was due to Pronto having more female
patients (59%), or because women tend to be prescribed more drugs in general [430], we computed
two measures of relative risk of for women. The relative risk of co-administration for women is
RRCF = 1.0653 while their relative risk of interaction is RRIF = 1.5864. If the risks were equivalent
for both genders, we would observe RRCM ≈ RRCF ≈ 1 and RRIM ≈ RRIF ≈ 1. While the
relative risk of drug co-administration is only slightly larger (≈ 7%) for females, the relative risk
of drug interaction is much larger (≈ 59%). This risk becomes even higher when we look only at
the most dangerous severity class: RRIFmajor = 1.8739, while RRI
F
minor = .8059. Removing female
anti-contraceptive drugs only slighly lowers RRIF from 1.59 to 1.55.
To understand the DDI phenomenon at large as well as which drugs are most responsible for the
higher risk of DDI women face over men, we also computed DDI networks that characterize drug
pairs according to measures of patient volume (|UΦi,j |) and DDI association strength (τΦi,j). One of
these networks is shown in fig. 3.3 (other shown in SI, fig. A.6). The 75 drug nodes involved in DDI
are colored by their primary action class. Node size represents the probability of interaction of a
drug, PI(i), with larger nodes identifying drugs most contributing to potential ADR from DDI. To
better grasp gender differences in the DDI phenomenon, edges are colored according to the relative
risk of drug pair interaction for each gender, RRIgi,j with g ∈ {F,M}, such that red (blue) edges
denote increased DDI risk for women (men).
Of the |∆| = 181 DDI edges, 133 are associated with an increased risk for women, whereas only 48
denote an increased risk for men—a ratio of 2.8. Removing hormone therapy drugs from the network
changes the number of edges associated with increased risk for women from 133/181 = 73.48% to
116/158 = 73.42%; for men the ratio changes from 48/181 = 26.52% to 42/158 = 26.58%. In other
words, there is virtually no change when hormone therapy drugs are removed from the network.
Looking at the subgraph comprised only of very gender-imbalanced pairs, RRIgi,j > 3, we find 49
drugs in interactions that affected 3,327 women (4.28% of female Pronto population), but only
75
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Figure 3.3: DDI network. A weighted version of network ∆ where weights are defined by τΦi,j . Nodes denote
drugs i involved in at least one co-administration known to be a DDI. Node color represents the highest level of
primary action class, as retrieved from Drugs.com (see legend). Node size represents the probability of interaction
PIi), as defined in text. Edge weights are the values of τΦi,j obtained from eq. (3.4). Edge colors denote RRI
g
i,j ,
where g ∈ {M,F}, to identify DDI edges that are higher risk for females (blue) or males (red). Color intensity for
RRIgi,j varies in [1, 5]; that is, values are clipped at 5.
Table 3.4: Top 10 known major DDI pairs (i, j) with increased risk of co-administration per gender, g ∈ {M,F},
which affected at least 10 patients of each gender. Rows ordered by the rank product of the ranks of RRIgi,j , the
relative gender risk of co-administration, and |UΦ,gi,j |, the number of patients of given gender affected by the DDI.
|UΦ,Fi,j | i j RRIFi,j |UΦ,Mi,j | i j RRIMi,j
13 Carbamazepine Ethinyl Estradiol ∞ 29 Digoxin Amiodarone 1.78
13 Levonorgestrel Carbamazepine ∞ 11 Diclofenac Warfarin 1.19
1,411 ASA Ibuprofen 1.42 -
992 Amitriptyline Fluoxetine 3.55 -
703 Fluconazole Simvastatin 2.63 -
209 Imipramine Fluoxetine 3.08 -
302 Diltiazem Simvastatin 1.27 -
159 Fluoxetine Lithium 1.79 -
122 Fluoxetine Nortriptyline 2.70 -
28 Propranolol Salbutamol 6.61 -
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13 drugs in interactions that affected 64 men (0.01% of male Pronto population). The 65 (9)
such interactions for women (men) contain 16 (3) that are considered major (see also fig. A.6 in SI).
table 3.4 shows the top major DDI pairs per gender which affected at least 10 patients; interestingly,
only two DDI pairs that affect at least 10 patients were observed with a higher relative risk of
interaction for males.
3.4 Age Risk
To investigate the role of age in DDI co-administration we calculated two additional measures, the
risk of co-administration for age group, RC [y1,y2], and the risk of interaction for age group, RI [y1,y2].
If the number of DDI observed were proportional to the number of co-administrations, the latter
quantity would be essentially flat across age groups (see eq. (3.8) in §Data & Methods). As shown in
fig. 3.4, center, RI increases substantially for older age groups, varying from near zero for younger
age groups to 0.35 for groups over 70. While there is some variation, RC varies a lot less than RI—
no more than 6% across all age groups as seen fig. 3.4-left (note the difference in scale). This shows
that risk of co-administration is largely proportional to the number of dispensed drugs, while risk
of interaction seems to grow more than the increase in co-administrations (polypharmacy) observed
with age.
The risk of co-administration is overall quite high for all age groups (RC [y1,y2] ∈ [.92, .98]), with
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Figure 3.4: Left & center. Co-administration (RC [y1,y2]; left) and interaction risk (RI [y1,y2]; center) per age
group, computed via eq. (3.8). Solid orange line is the cubic regression for RC [y1,y2] while solid red line is the cubic
regression for RI [y1,y2] (linear and quadratic regressions in SI). Right. Absolute number of patients with at least
one co-administration known to be a DDI. For all plots, age groups [90,94], [95,99) were aggregated into [90+]. Stars
(?) depict values computed from the null model, Hrnd0 , with background filling denoting the 95% confidence interval
based on 100 runs.
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Figure 3.5: Patients plotted with number of drugs dispensed νu, co-administrations Ψu and interactions Φu.
Bottom row. Each circle depicts a patient, with red (blue) circles denoting females (males). Color intensity
denotes their age, with stronger red (blue) representing older women (men). To reduce circle overlay and enhance
visualization, a uniform noise ∈ [0, 1] was added to both coordinates. Green and orange lines denotes linear and
quadratic regressions, respectively. Inserts with Hexagonal log-bins are included to better depict the density of
patients close to the origin. Top row. Pareto fronts comparing regression results (R2) at increasing regression model
complexity. For example, complexity 1 and 2 denote a linear and quadratic regression, respectively.
increasing values as patients age. Patients dispensed at least two drugs are almost always being
dispensed drugs concomitantly. Conversely, the risk of interaction starts from almost nonexistent
at age [0-14] and reaches more than 25% after the age of 55.
The relationship among the number of drugs dispensed (νu), co-administrations (Ψu), and in-
teractions (Φu) for all users is shown in fig. 3.5. While there is a strong nonlinear (quadratic)
relationship between νu and Ψu (fig. 3.5-left), there is no evidence of a nonlinear relationship be-
tween Ψu and Φu (fig. 3.5-right), which could explain the observed growth of RI with age—which
implies that interactions grow faster than co-administrations with age. In contrast to previous re-
ports [46], co-administrations (Ψu) predict interactions (Φu) better than number of drugs prescribed
(νu), though neither do so particularly well.
To further investigate whether factors other than increase in co-administration cause the increase
of DDI risk with age, we developed a statistical null model; values reported for the null model are
identified with a star (?) and associated 95% confidence intervals (for 100 runs) in fig. 3.4. The
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idea is to explore if the growth of RIy is an expected phenomenon of increased polypharmacy with
age, which necessarily results in a combinatorial increase of possible drug pairs that can interact.
The null model was not able to reproduce the observed behavior of RIy (X2 = 2840.6, p < .01),
especially for older and younger ages (see figs. 3.4 and 3.6 and SI section A.7 for additional details).
We observe that for younger ages, RI [0,29] is much lower than the model’s predicted RI [0,29]?
(fig. 3.4-middle); the same is true for the number of patients affected (fig. 3.4-right). The largest
discrepancies between model and real data occur at this age range, especially [0,4] and [20,24].
However, this expected behavior is inverted for ages [50+], with the transition occurring around age
[40-44] (fig. 3.4-middle). For older ages, the largest discrepancies between model and reality occur
for age groups in [50,70], where the predicted number of patients with DDI (|UΦ?|) for age group
[60-64] is 16% lower than what is observed (see fig. 3.4-right).
We additionally parse age risk by gender by computing RC [y1,y2],g and RI [y1,y2],g, shown in fig. 3.6
(see also tables A.15 and A.16 in SI). Both genders have overall similar risk of co-administration in
all age groups. Even during childbearing age, the co-administration risk is similar for the numbers
of drugs dispensed, even if slightly larger for females (see filling in fig. 3.6-top-left). Interestingly, for
RI [y1,y2],g a clear difference between genders occurs after childbearing age, maximized between 50
and 69 years-old (see filling in fig. 3.6-top-right and absolute number of patients in fig. 3.6-middle).
The gender difference in RI appears after the age of 35, reaching more than a 9% difference for age
group [60-64].
Bottom plots in fig. 3.6 show the null model’s gender risk of interaction RI [y1,y2],g?, in comparison
to observed values, RI [y1,y2],g, for women (left) and men (right), respectively. For both genders, we
still observe that the real RI for children and young adults ([0-34]) is well below the null model.
However, the transition observed for older age is much more pronounced for women. In fact, after
age 40, observed male RI is largely consistent with the null model, while female risk is higher.
79
00
-0
4
05
-0
9
10
-1
4
15
-1
9
20
-2
4
25
-2
9
30
-3
4
35
-3
9
40
-4
4
45
-4
9
50
-5
4
55
-5
9
60
-6
4
65
-6
9
70
-7
4
75
-7
9
80
-8
4
85
-8
9
90
+
0.92
0.93
0.94
0.95
0.96
0.97
0.98
0.99 RC
[y1, y2], g
RC [y1, y2], F
RC [y1, y2],M
00
-0
4
05
-0
9
10
-1
4
15
-1
9
20
-2
4
25
-2
9
30
-3
4
35
-3
9
40
-4
4
45
-4
9
50
-5
4
55
-5
9
60
-6
4
65
-6
9
70
-7
4
75
-7
9
80
-8
4
85
-8
9
90
+
0.0
0.1
0.2
0.3
0.4
9.15%
RI [y1, y2], g
RI [y1, y2], F
RI [y1, y2],M
00
-0
4
05
-0
9
10
-1
4
15
-1
9
20
-2
4
25
-2
9
30
-3
4
35
-3
9
40
-4
4
45
-4
9
50
-5
4
55
-5
9
60
-6
4
65
-6
9
70
-7
4
75
-7
9
80
-8
4
85
-8
9
90
+
0
200
400
600
800
1000
1200
1400
Patients with interactions by gender
UΦ, [y1, y2], F
UΦ, [y1, y2],M
UΦ, [y1, y2], F
UΦ, [y1, y2],M
267 (19%)
00
-0
4
05
-0
9
10
-1
4
15
-1
9
20
-2
4
25
-2
9
30
-3
4
35
-3
9
40
-4
4
45
-4
9
50
-5
4
55
-5
9
60
-6
4
65
-6
9
70
-7
4
75
-7
9
80
-8
4
85
-8
9
90
+
0.0
0.1
0.2
0.3
0.4
6.41%
RI [y1, y2], F
RI [y1, y2], F
RI [y1, y2], F [H rnd0 ]
00
-0
4
05
-0
9
10
-1
4
15
-1
9
20
-2
4
25
-2
9
30
-3
4
35
-3
9
40
-4
4
45
-4
9
50
-5
4
55
-5
9
60
-6
4
65
-6
9
70
-7
4
75
-7
9
80
-8
4
85
-8
9
90
+
0.0
0.1
0.2
0.3
0.4
1.68%
RI [y1, y2],M
RI [y1, y2],M
RI [y1, y2],M [H rnd0 ]
Figure 3.6: Top left. Risk of co-administration per age group and gender, RC [y1,y2],g. Top center Risk of
interaction per age group and gender, RI [y1,y2],g. Top right. Absolute number of patients with at least one known
DDI co-administration, per age and gender UΦ,[y1,y2],g. Bottom. Female and male risk of interaction per age
group and gender, RI [y1,y2],F (left) and RI [y1,y2],M (right). For all plots, age groups [90,94], [95,99], [90, 90+]} were
aggregated into [90+]. Stars (?) depict values computed from the null model, Hrnd0 , with background filling denoting
the 95% confidence interval based on 100 runs. Shaded areas identify specific age groups mentioned in the main
manuscript.
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3.5 Prediction of Patients with DDI
We computed several multiple regression (MR) models. These show that the inclusion of additional
variables does not improve much at all the prediction of the variance of Φu. For instance, a MR with
both νu and Ψu leads only to very marginal increase in the explained variance of Φu: adjusted R2 =
0.492. Adding higher order, nonlinear models also does not improve upon the original regression
between Ψu and Φu. Even the inclusion of demographic variables in MR models does not lead
to improvement of R2 for Φu—we analyzed many neighborhood-level variables such as average
income, robbery, theft, suicide, transit crime, trafficking and rape rates. Restricting the analysis to
the subset of patients who reported education, and using it as an independent categorical variable
also yields no improvement (see SI section A.9 for MR and ANOVA details).
Interestingly, even the inclusion of gender as a categorical variable, does not improve R2 for Φu.
At first glance, this seems a somewhat counter intuitive result, given the observed high risk of DDI
for females in comparison to males. However, the MR analysis revealed that even though women
certainly face a much greater risk of DDI, the number of DDI pairs they are administered (Φu) is
on average similar to that of men, and both have large variance of Φu (see fig. A.2). Thus, while
gender clearly is a very strong factor in the risk of at least one DDI, it is not a good predictor of
the specific number of interactions per patient.
Therefore, we sought to answer the question of how well we can automatically predict patients
with at least one DDI (not the number of interactions per patient)? Using binary classifiers we are
able to achieve very good performance on this task. Classifiers perform well above null models, with
MCC ≈ 0.7 and excellent AUC scores: AUC ROC ≈ 0.97 and AUC P/R ≈ 0.83.
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3.6 Large-scale longitudinal analysis of DDI phenomena reveals biases, higher
costs, and possible counter-measures
Our 18-month longitudinal analysis of EHR data of the entire city of Blumenau allowed us to
study the DDI problem in primary and secondary care in greater detail and for a longer period
of time than what has been hitherto possible. In summary, the DDI phenomenon is stable across
the city, and proportional to population size—demonstrating no major inequalities due to income,
education, crime, or other neighborhood social factors, which suggests a balanced and fair access
to medical care in Blumenau. Our analysis revealed that ≈ 12% of all patients of the Pronto HIS
where administered known DDI, which represents 5% of the entire Blumenau population. If we
consider only the adult population, ≈ 15% were dispensed a known DDI (more than 6% of the
Blumenau adult population). Looking at the type of DDI, we observe that 4% of all patients (5%
of adults) were dispensed a major DDI likely to result in a very serious ADR—almost 2% of the
city’s population.
Given the lack of similar studies, we cannot directly compare the rate of DDI severity observed
in Blumenau to other public health systems. The Tayside study (with a smaller, 84 day observation
window) reported a rate of 13% “potentially serious” DDI for adult patients [46]2. If this severity
is similar to the Drugs.com major DDI class, then Blumenau has a considerably lower rate of this
type of DDI than Tayside—5% to 13%. If, on the other hand, “potentially serious” encompasses
both the major and moderate Drugs.com DDI classes, then the rates observed in Blumenau are
similar to those observed in Tayside—14.35% to 13%.
We uncovered 181 DDI pairs that most likely could have been prevented [43]. These drugs known
to interact were nonetheless dispensed for co-administration to 15,527 people, including more than
five thousand who were administered amajor DDI, likely to require medical attention. In addition to
the human suffering caused, patient hospitalization due to major DDI may lead to a large financial
burden to health-care systems. All our estimates lead to very substantial costs for the various levels
of government, suggesting that the financial burden of DDI is at least double what was previously
2This severity class was derived from the British National Formulary, a private publication we do not have access
to.
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reported—$1 per capita in Ontario [28]—even when considering the most conservative estimate of
the proportion of hospitalizations that derive from co-administration of known major DDIs. Thus,
our large-scale longitudinal analysis suggests that previous estimates based on smaller studies likely
underestimate the cost of the DDI phenomenon.
We provide comprehensive lists of the DDI pairs uncovered in the data, allowing others to look
at specific drugs of interest. The data can be seen from different angles, such as the volume of
people affected or the likelihood that certain drugs are co-administered. These include common
medications such as proton-pump inhibitors (Omeprazole), anti-depressants (Fluoxetine), or com-
mon analgesics (Ibuprofen), as well as not so common drugs (e.g. Erythromycin). It is noteworthy
that the DDI co-administration of CYP(3A4 and 2D6) inhibitors with their respective enzymes sub-
strates was often found in our results. From our dataset CYP[3A4] inhibitors include Omeprazole,
Fluconazole and Erythromycin and their respective substrates include Clonazepam, Simvastatin
and Carbamazepine. Recently, the FDA included a comparison list [431] of in vitro and clinical
inhibitors, inducers and substrates for CYP-mediated metabolisms. In agreement with previous
work [44], our analysis revealed several such DDI, including the most common DDI pair in our
data (Omeprazole, Clonazepam). Many other major interactions, while not ranked at the top, are
nonetheless of concern due to severe ADR. For instance, in 2011 the FDA issued a warning [432]
contraindicating the concomitant use of Simvastatin with Erythromycin, due to increased risk of
myopathy by “possibly increasing the statin toxicity”. Still, our analysis identified 10 patients con-
comitantly administrating this major DDI (117th, |UΦi,j | = 10), also known for its increased risk of
liver damage and a rare but serious condition of rhabdomyolysis that involves the breakdown of
skeletal muscle tissue [222, 433].
Our network representation also allows us to integrate, summarize and visualize the DDI phe-
nomenon. The analysis of the network itself also reveals nodes with largest degree, that is, drugs
that participate in more known DDI. The top ones, participating in over 10 distinct DDI are:
Phenytoin, Carbamazepine, Phenobarbital, Propranolol, Warfarin, Aminophylline, Fluoxetine, Flu-
conazole (see table A.17 in SI for others). Drugs in italic have both high degree and high PI,
meaning they interact with many other drugs and are also more likely to interact with some other
drug when dispensed.
The network also allows us to investigate the roles of individual drugs and DDI pairs, in relation
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to others. For instance, Phenytoin, an anti-seizure medication, is the drug with largest degree
and node size: it interacts with 24 other drugs, granting it the highest total degree strength,∑
j τ
Φ
ij = 6.51; 1 in 5 times that Phenytoin is co-administered with another drug it leads to an
interaction, PI(Phenytoin) = 0.2; and it also has the largest betweeness centrality (0.30) [434],
thus acting as bridge between other drugs with known DDI.
Our characterization of the significant demographic factors in the DDI phenomenon, shows that
women in Blumenau are at a strikingly greater risk of being dispensed known DDI than men, with
a 1.6 risk multiplier. In other words, women in the Blumenau’s Pronto system have an almost 60%
increased risk over men of being dispensed a DDI, but only a 6.5% increased risk of being dispensed
drugs concomitantly. When only major DDI are considered the risk multiplier is even higher: 1.9.
That is, women have almost double the risk of men of being dispensed a major known DDI. It is
noteworthy that we pursued a relative risk analysis for all age groups, showing that females face a
greater or similar risk of DDI than males in all age groups, with substantially higher risk observed
after 50 years of age. For instance, in age group [60-64], 1 in 3 women who are dispensed two or
more drugs concomitantly face a known DDI, whereas that ratio is less than 1 in 4 for men for the
same age group (see fig. 3.6). Therefore increased risk for females is not confounded by the larger
number of women present in the data nor their age.
It is known that age is also a factor in predicting the number of prescribed drugs [430], especially
because of increased co-morbidity in older patients. Our analysis shows that one in every four
patients over 55 is likely to be face a known DDI when co-dispensed two or more drugs. The risk of
interaction for older age groups of both genders is also severe, reaching more than 30% for adults
over 70 years of age in comparison to younger age groups. While a greater risk for older age groups
is expected due to increased polypharmacy with age, a comparison of the observed risk with a null
model accounting for random polypharmacy (and preserving same number of co-administrations
per age) shows that it does not explain the high levels of interactions older age groups face. This
can be contrasted with the almost nonexistent number and risk of interactions in children, which
are considerably lower than what the null model predicts for polypharmacy at that age. It is very
surprising, indeed shocking, that there are more cases (and increased risk) of DDI in older age than
random (age-conditioned) dispensation of drugs would yield. We would expect all age groups to
have fewer cases than a random null model, but this is only observed for younger age groups.
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The null model also revealed an additional gender bias, as older women clearly have a worse-
than-random, while older men have a more similar-to-random risk of DDI in most age groups. In
fact, deviation from the null model in older age is mostly explained by increased risk for females.
In contrast, younger age groups of both genders have much better-than-random risk of DDI. These
observed gender and age risks suggest two possible hypothesis: specific drugs dispensed to women
or older populations are more dangerous; and/or that not as much attention to DDI in primary
care is reserved for these populations. The fact that the specific drugs dispensed greatly improve
the automatic prediction of patients with DDI favors the first hypothesis, but given the age and
gender risks observed, it is also clear that the same DDI-prone drugs are administered differently
between genders and across age groups. This second hypothesis is strengthened by the fact that
removing female-specific hormone therapy from the the DDI network of fig. 3.3 barely reduces the
DDI gender risk (from 59 to 55%). Indeed, the DDI pairs with increased risk for women traverse
all drug classes and are not gender-specific, ranging from cardiovascular to central nervous systems
agents.
While it was already known that drugs withdrawn from the market for ADR presented greater
risks for women [435], our study demonstrates that women (and older populations) in Blumenau
also face a higher risk of being dispensed known DDI. It could be that in older age groups (especially
for women) there are fewer alternative drugs (with fewer adverse reactions) in the Blumenau public
system, either because they are more expensive or simply because they are not available anywhere,
thus forcing the prescription of known DDI. These and other possibilities warrant further study
outside the scope of the present article. For instance, would the introduction of newer and costlier
drugs into the public system, overcome the financial and human burden of current DDI levels?
Nonetheless, since medical care should in principle provide a better-than-random risk of DDI for all
age groups and genders, our results suggest that factors of a social, biological, or medical-care nature
are at play at the primary- and secondary-care levels and should be further studied everywhere.
The performance achieved by our classifiers demonstrates that a useful computational intelli-
gence pipeline can be devised to flag patients for further assessment by a primary care physician,
pharmacist, public official, or even to request a home visit from a community health agent. This
is because drugs may be prescribed by independent physicians, who may not be aware of or check
previous prescriptions, or simply dismiss HIS alerts [436]. To help avoid physician alert fatigue
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[437], personalized alert systems do not necessarily need to be added to prescription systems. They
may in fact be more useful for those involved in integrating and managing the care of individual
patients or the entire public-health system. Those are decisions that each public-health system will
have to weight. Still, our work demonstrates that a personalized alert system for DDI is accurate
and can be used to reduce the DDI phenomenon not only in future versions of the Pronto HIS, but
in other cities that have observed high levels of DDI—e.g. the Tayside region, in Scotland [46]. In
future work we intend to add such a pipeline to Pronto as well as utilize additional sources of data,
such as social media, since Pronto already includes such patient handles. Indeed, such data may
allow early-warning signal detection of adverse events and DDI [RBC7, 438].
Large-scale analyses of EHR to establish the prevalence of known DDI are rare. Most studies
are obtained from small populations in hospital settings, so they vary by a large margin [35, 41, 43,
226]. Our study of the entire city of Blumenau at the primary- and secondary-care level offers an
important new large-scale measurement of the DDI phenomenon in a public health-care system—a
baseline that can be compared to other worldwide locations beyond Brazil, as EHR data becomes
available. For instance, are the gender and age risk levels we observed similar in other primary- and
secondary-care settings? Are there cultural or public/private differences? Will the health systems
of other cities also prove to be unaffected by neighborhood and income levels, etc?
Our large-scale epidemiological analysis demonstrates that an integrated data- and network-
science approach to public health can uncover biases in the DDI phenomenon as well as yield tools
capable of issuing accurate DDI prediction per patient. Both outcomes contribute to preventing
ADR from DDI and thus may lead to a significant positive impact on the quality of life of patients
and finances of public-health systems. Moreover, the gender and age risks of DDI we discovered,
should inform physicians and other health professionals anywhere that such factors are important
in the drug management of their patients. We expect the results to increase awareness of those risks
we uncovered.
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Chapter Four
Monitoring and predicting potential drug interactions and reactions via
network analysis from social media timelines 1
“The cybernetician must apply his competence to himself
lest he will lose all scientific credibility.”
Heinz von Förster
Austrian-American (Bio)Physicist
4.1 Social media for public health
The role of social media in measuring collective human behavior at scale is undeniable. From
social protest [50], to sexual cycles [272] and emotion dynamics [55], social media is helping rewrite
older hypotheses about human nature. In precision public health, the potential for adverse drug
reaction (ADR) extraction from social media data has been recently demonstrated [68, 70], including
or own work [RBC7]. There is still, however, much work to be done in order to fulfill the potential
1Parts of this chapter were published in Correia, Li, and Rocha [RBC7]. This work was also presented in
Correia, Ratkiewicz, Miller, and Rocha [RBC15] and Correia, Wood, Ratkiewicz, Miller, and Rocha [RBC16],
including a keynote presentation [RBC17]. Recent results, derived from this work, were also published in Min, Miller,
Rocha, Börner, Correia, and Shih [RBC18]. An expanded, journal version of this chapter will be submitted as an
independent journal paper [RBC19].
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of social media in the monitoring of public health. For instance, analysis of social media data may
be useful to identify under-reported pathology, particularly in the case of conditions associated
with a perceived social stigma, such as mental disorders [49]. A granular population stratification
particular of precision public health.
Given access to an extremely large population, it is also reasonable to expect that social media
data may provide early warnings about potential drug-drug interaction (DDI) and ADR [68] in
specific, more precise populations. These unprecedented windows into collective human behavior
may also be useful to study the use and potential interactions and effects of natural products—
including cannabis, and illegal or abused drugs, such as heroin and opioids. The pharmacology of
such products constitute an array of DDI and ADR very poorly explored by biomedical research
so far, and thus an arena where social media mining could provide important novel discoveries and
insight.
Most work on social media pertaining to public health monitoring that we are aware of has
relied on data from Twitter or Facebook. However, as we show [RBC7], Instagram is an increas-
ingly important platform, with the availability of posts with geolocation coordinates and images to
supplement textual analysis. Instagram currently has more than 1 billion active users, with 100
million only in the United States, where it has a 52% penetration rate among internet users [75].
It surpasses Twitter (40%) for preferred social network among teens (12-24) in the US, only behind
Facebook (76%) and Snapchat (79%). A majority of its users worldwide, or 61%, are between 18
to 34 years old, and in the US, 64% are adults (18-29) [76]. Although Twitter has a much smaller
footprint, it reaches 262.7 million users worldwide [77], with the strong advantage of having an open
API for public data collection.
In this thesis we show the potential of Instagram for public health monitoring and surveillance of
DDI, ADR and behavioral pathology at large [RBC7]. We expand upon those results by including
additional cohorts of interest, while systematically validating drug-drug and drug-symptom relations
with data from publicly available bioinformatics resources of known DDI, ADR, and drug indication
(DI). Using these resources we analyze depression, epilepsy, and opioid cohorts. Using different
multi-word dictionaries with more than 170,000 terms—including drug and pharmacology, natural
products, allergens, cannabis, epilepsy, and medical terminology—on almost 30.000 user timelines
spanning from late 2006 to mid 2015, we demonstrate that Instagram and Twitter contain substantial
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data of interest to understanding DDI, ADR, and natural product use.
Our analysis relies on treating each social media timeline as a potential patient in the cohort of
interest. We then follow their social media discourse through time, extracting when specific terms of
interest occurred or were mentioned together—including pairs and triplets. We explore this data by
building a monitoring tool to easily observe user-level timelines associated with drug and symptom
terms of interest, which we describe in section 4.2.1. To explore cohort-specific associations derived
from term co-mentions, we also compute knowledge networks that previous work has shown to
be useful for automated fact-checking [113], protein-protein interaction extraction [114, 115], and
recommender systems [116, 117]. A similar approach has already been successfull in uncovering
ADR for Twitter [68], however our cohort-specific network analysis of both Instagram and Twitter
data relies on a novel study of metric redundancy in the topology of complex networks [117]. This
approach allows us to uncover drug and symptom associations and user timelines that preserve
shortest path computations in the knowledge networks. This allows us to obtain important direct
and indirect (latent) associations in the data, as well as remove many redundant associations from
the data.
Below we separate the presented work into two sections, each focusing in a specific set of ques-
tions. The first, asks whether Instagram data and our complex networks methods, can be reliably
used to measure population-level drug-drug and drug-symptom associations. Such measurement,
if accurate, is very useful for drug monitoring and surveillance, which is of particular interest to
public health analysts. To illustrate the potential of such data-driven, population-level associations,
we use spectral methods to reveal network modules of symptoms and drugs. These modules are in
turn associated with the discourse of specific sub-populations, for instance, people suffering from
psoriasis. Thus, demonstrating the potential of social media for an increased precision in public
health. The seconds part drills down into a more refined question: the prediction of known, and
most importantly, the possible uncovering of unknown DDIs, and the ADRs derived from it. We
tackle such question by building networks based on triple co-mentions, where at least two terms are
known drugs and the other is a medical term. Both sections rely on the distance closure of complex
networks [117] but built in different co-mention patterns. Both present a novel development from
related approaches to uncover DDIs and ADRs from social media data. We also provide the commu-
nity with SyMPToM, a web tool for patient-level analysis of users and their social media discourse.
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Our tool enables physicians, scientists, or public health analysis, to inspect and qualitatively vali-
date how terms of interest are mentioned in user timelines. SyMPToM even allows the navigation
of specific term co-mentions, providing supporting evidence of how drug-drug, or drug-symptoms,
are being discussed in our cohorts.
4.2 Monitoring potential drug interaction and reaction via network analysis of
Instagram Timelines 2
We harvested from Instagram all posts containing hashtags that matched 7 drugs known to be
used in the treatment of depression (# posts): fluoxetine (8,143), sertraline (574), paroxetine
(470), citalopram (426), trazodone (227), escitalopram (117), and fluvoxamine (22). Synonyms
were resolved to the same drug name according to DrugBank [144]; for instance, Prozac is resolved
to fluoxetine. see table 4.1 in supporting information (SI) for synonyms used. This resulted in a
total of 9,975 posts from 6,927 users, whose complete timelines, spanning the period from October
2010 to June 2015, were collected. In total, these timelines contain 5, 329, 720 posts, which is the
depression cohort we analyze below.
A subset of a previously developed pharmacokinetics ontology [439] was used to obtain a drug
dictionary. The full ontology contains more than 100k drugs, proteins and pharmacokinetic terms.
Here we used only names of FDA-approved drugs, along with their generic name and synonyms,
resulting in 17,335 drug terms. The natural product (NP) dictionary was built using terms from
the list of herbal medicines and their synonyms provided by MedlinePlus [440]. It contains 179
terms. The Cannabis dictionary was assembled by searching the web for terms known to be used
as synonyms for cannabis, resulting in 26 terms optimized for precision and recall on a subset of
posts (data not shown). The symptom dictionary was extracted from BICEPP [441] by collecting
all entities defined as an Adverse Effect, with a few manual edits to include more synonyms; it is
comprised of 250 terms.
Timeline posts were tagged with all dictionary terms (n-grams) for a total of 299,312 matches.
2This section was published in Correia, Li, and Rocha [RBC7].
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Uppercase characters were converted to lowercase, and hashtag terms were treated like all other
harvested text for the purpose of dictionary matches. We found matches for 414 drugs, 133 of
which with more than 10 matches. These numbers are 148/99 and 74/46 for symptoms and NP,
respectively, for a total of 636 terms. This is a substantial number of dictionary terms, given that
only 7 drugs prescribed for depression were used to harvest the set of timelines. The top 25 matches
for each dictionary are provided in SI. Notice that the term ‘depression’ was removed because of
its expected high appearance. Matches in the cannabis dictionary (e.g. 420, marijuana, hashish)
were aggregated into the term cannabis to be treated as a NP. The top 10 mentions are (counts
shown): cannabis (66,540), anorexia (26,872), anxiety (26,309), pain (15,677), suicide (11,616),
mood (11,532), fluoxetine (9,961), suicidal (8,909), ginger (7,289), insomnia (5,917).
Given the set X of all matched terms (|X| = 636), we first compute a symmetric co-occurrence
graph Rw(X) for time-window resolutions w = 1 month, 1 week and 1 day. These graphs are easily
represented by adjacency matrices Rw, where entries ri,j denote the number of time-windows where
terms xi and xj co-occur, in all user timelines. A matrix Rw is computed for each time-window
resolution independently. To obtain a normalized strength of association among the set of terms X,
we computed proximity graphs [117], Pw(X) for each time-window resolution w. Thus, the entries
of the adjacency matrix Pw of a proximity graph are given by:
pi,j =
ri,j
ri,i + rj,j − ri,j , ∀xi,xj∈X (4.1)
where pi,j ∈ [0, 1] and pi,i = 1; pi,j = 0 for terms xi and xj that never co-occur in the same time-
window in any timeline, and pi,j = 1 when they always co-occur. This measure is the probability
that two terms are mentioned in the same time window, given that one of them was mentioned
[116, 117]. To ensure enough support exists in the data for proximity associations, we computed
proximity weights only when ri,i + rj,j − ri,j ≥ 10; if ri,i + rj,j − ri,j < 10, we set pi,j = 0.
Proximity graphs are associative knowledge networks. As in any other co-occurrence method,
the assumption is that items that frequently co-occur are associated with a common phenomenon.
In this section we use them to reveal strong associations of drug-related terms for public health
monitoring. We also compute distance graphs Dw(X) for the same time-window resolutions, using
the map:
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di,j = ϕ(pi,j) =
1
pi,j
− 1 (4.2)
In some of our analysis below, we compute the metric closure DCw (X) of the distance graphs,
which is isomorphic to a specific transitive closure of the proximity graph[117]. As explained in
the background chapter, the metric closure is equivalent to computing the shortest paths between
every pair of nodes in the distance graph. Thus, dCmi,j is the length (sum of distance edge weights) of
the shortest path between terms xi and xj in the original distance graph Dw(X), and is known to
scale well [113]. Interestingly, there is an invariant subgraph of Dw(X) when computing the metric
closure which is called the metric backbone [117]. In other words, some edges di,j in Dw(X) do not
change their distance weight when computing shortest paths, because there is no shorter indirect
distance via other nodes in the graph, therefore di,j = dCmi,j ; these are metric edges because they
obey the triangle inequality. However, there are also semi-metric edges which break the triangle
inequality, whereby there exist shorter indirect paths than the direct distance: di,j > dCmi,j [RBC7,
116, 117, 409].
To compute the degree of semi-metricity of the edge di,j between nodes/terms xi and xj we
employ two measures, si,j and bi,j [116]:
si,j =
di,j
dCmi,j
, bi,j =
〈di〉
dCmi,j
∀xi,xj∈X (4.3)
where 〈di〉 is the mean direct distance from xi to all other xk ∈ X such that di,k is finite. si,j > 1
for semi-metric edges, and 1 otherwise. bi,j is only computed for edges that do not exist originally
in Dw(X) (i.e. di,j =∞), and it measures how much the shortest indirect distance between xi and
xj falls below the average distance of xi to all its directly linked nodes xk. Note that bi,j 6= bj,i.
4.2.1 SyMPToM: a monitoring tool for user-level behavior
From the analysis of user timelines, it is clear that Instagram is a social media platform with much
data relevant for public-health monitoring. Users often discuss personal health-related information
such as diagnoses and drugs prescribed. Photos posted (see fig. 4.1) often depict pills and packaging,
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Figure 4.1: Sample of Instagram images from collected posts related to all three cohorts: depression, epilepsy, and
opioids.
along with discussions of intake schedules, expectations, and feelings. Some examples are shown
below.
User A on May 25, 2014 “#notmypic .. Say hello to my new friend! Fluoxetina! Side effects by now are a bit
of nausea and inquietude.. Better than zoloft! Yesterday night i started to cry while i was with my 2 friends
because my ex, bulimia’s stress.. I’m sure they thought i’m crazy so i felt like i had to explain my reasons
with one of those friends.. Now i’m terrified of his reaction, he is even a friend of my ex.. Don’t know what to
expect.. It’s so hard telling someone about ED and bulimia. I’m also thinking about a b/p session today after
2 days clean, maybe it’s not the right solution. Idk. #bulimia #bulimic #mia #ed #edfamily #eatingdisorder
#prorecovery #bingepurge #purge #binge #fat #prozac #fluoxetine #depression #meds”
User B on May 13, 2015 “I start fluoxetine tomorrow, the doctor switched me from citalopram to this so let’s
hope it goes better this time #anxietymeds #depressionmeds #citalopram #fluoxetine #anxiety #depression”
User B on May 14, 2015 (one day later) “ok so I don’t know if it’s the tablets that are doing this but I feel
the lowest I’ve ever felt and I’m hoping it’s not the tablets. Hopefully it’s just a bad day, not that there are
many good days I hope tomorrow is a better day for everyone, especially if you are feeling the same way I am.
#fluoxetine #depression #anxiety #depressionmeds #anxietymeds”
User C on Feb 05 2014 “i survived another trip to the clinic, saw a specialist, did a test that explained i’m an
INFJ (introvert) which is apperently only 1% of the population. Added risperidone and upped ritalin as
well as prozac. considering this keeps me ‘sane’ and able to assimilate into the chaos of everyday life i think
this counts as my #100happydays today #findhappinessineachday #bipolar #borderlinepersonalitydisorder
#INFJ #manicdepression #goinggovernment #prozac #lamotragine #ritalin #risperidone”
Given this rich data users post on social media, from the perspective of public-health monitoring
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Figure 4.2: Social Media for Public Health Monitoring (SyMPToM). See text for explanation.
it is useful to be able to quickly navigate and extract posts and user timelines associated with drug
and symptom terms of interest. For that purpose, we developed SyMPToM3, a web application to
facilitate the tagging, navigation, and visualization of term mentions, co-mentions, and knowledge
networks, across different social media platforms and cohorts. This tool also allows downstream
improvement of our dictionaries by observing important discourse features that were left untagged.
Indeed, most of the dictionary match inspection mentioned below, in section 4.2.2, was performed
using SyMPToM. Figure 4.2 shows four screenshots with some of the features: (top left) home
screen; (top right) the definition of multiple cohorts of interest; (bottom left) the possibility of
defining multiple drugs of interest per cohort; (bottom right) a user timeline view that tags class-
specific dictionary matches and displays post frequency in time and where individual posts can be
quickly selected to be visualized separately. Using this tool to inspect and select timelines with high
number of matches, we were able to identify particularly relevant user timelines such as the one
3In previous work [RBC7] referred to as Instagram Drug Explorer. Accessible at http://symptom.soic.indiana.
edu
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Figure 4.3: User timeline showing daily frequency of posts in time; dictionary terms are tagged in time.
depicted in fig. 4.3, which contains matches from all four dictionaries, and varying post frequency.
Furthermore, fig. 4.4 shows the interactive visualization of the (thresholded; pi,j >= 0.01) metric
backbone subnetwork of the depression cohort on Instagram. Left panel displays term (node) names,
proximity value, and whenever available, edge information, showing whether an edge was flagged
as being a known DDI, ADR or DI. Furthermore, the visualization of post co-mention evidence can
be easily accessed, and posts with terms highlighted can be directly inspected (not shown).
Our tool also includes features to visualize mentions in scientific literature extracted from
PubMed abstracts, and clinical reports submitted to FAERS [148]. SyMPToM, therefore, is an
important tool in the formulation of scientific questions, such as the relation between formal (scien-
tific literature) and informal (social media) discourse and the evolution of DDI and ADR discourse
in social media. These two data sources and a temporal analysis of DDIs are discussed in further
detail in chapter 5.
4.2.2 Network analysis of associations in population-level behavior
Using the proximity or the isomorphic distance graphs (see section 4.2), we can explore strong
pairwise term associations that arise from the collection of 5, 329, 720 posts from the population
of 6, 927 users in the Instagram cohort. The assumption is that dictionary terms that tend to
co-occur in a substantial number of user timelines may reveal important interactions among drugs,
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Figure 4.4: Knowledge network of the depression cohort on Instagram shown in SyMPToM.
symptoms, and natural products. Moreover, because we computed these knowledge networks at
different time resolutions, we can explore term associations at different time scales: day, week,
and month. Naturally, a statistical term correlation is not necessarily a causal interaction; also a
drug-symptom association may reveal a condition treated by the drug, rather than an adverse reac-
tion. Nonetheless, large-scale analysis of social media data for relational inference must start with
the identification of multivariate correlations and validations, which can be subsequently refined,
namely with supervised classification and natural-language-processing (NLP) methods, and even
the inclusion of human-in-the-loop annotation methods within SyMPToM. Here, as a first step in
the analysis of Instagram data for public health monitoring, we use unsupervised network science
methods to extract term associations of potential interest.
Consider the proximity networks Pw(X) for time resolution w = 1 week. The full network
contains |X| = 636 terms (see fig. 4.6A for its largest connected component); fig. 4.5 (left) lists the
top 25 Drug/NP vs symptom associations, as well as the adjacency matrix of the distance subgraph
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Figure 4.5: drug/NP vs symptom subnetwork: (left) Top 25 pairs with largest proximity correlation. (right)
adjacency matrix of distance subnetwork; nearest (furthest) term pairs in red (black).
Dw(X) for these drug/NP and symptom pairs (right). The proximity and distance graphs are iso-
morphic (section 4.2), but proximity edge weights (left) are directly interpretable as a co-occurrence
probability (eq. (4.1)), while the isomorphic nonlinear map to distance (eq. (4.2)) provides greater
discrimination in the visualization of the adjacency matrix (right).
Of the top 25 associations listed in fig. 4.5 (left), 12 are known or very likely ADR, 7 do not
have conclusive studies but are deemed possible ADR from patient reports, 4 refer to associations
between drugs/NP and symptoms they are indicated to treat, 1 has been shown to not be ADR, and
1 is unknown. Thus, the strongest edges in the 1 week resolution network are relevant drug/NP-
symptom associations. Furthermore, our methodology allows an analyst to collect (via SyMPToM,
section 4.2.1) all the individual timelines and posts that support every association (edge) in the
proximity networks, supporting a much more detailed study of the affected population—including
for the purpose of fine-tuning dictionaries and mining techniques to better capture the semantics of
specific populations.
The proximity networks Pw(X) also allow us to visualize, explore and search the “conceptual
space” of drugs, symptoms, and NP as they co-occur in the depression cohort. The largest connected
component of the proximity network for w = 1 week is shown in fig. 4.6A. The network representation
allows us to find clusters of associations, beyond term pairs, which may be related via the same
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Figure 4.6: A. Largest connected component of the proximity network for 1 week time resolution; weights shown
only for pi,j ≥ 0.05 with unconnected terms removed. Edges are colored according to correlation with PC 4. B.
Spectrum of the PCA of the proximity network adjacency matrix. C. Biplot of correlation of terms with PC 3 and 4;
red (green) terms are most (anti-) correlated with PC4. D. Subgraph depicting the network of terms most correlated
with PC4, which is related to Psoriasis; blue nodes depict conditions linked to this complex disease (see text for
details); weights shown only for pi,j ≥ 0.05.
underlying phenomenon. Many multivariate and network analysis methods can be used to uncover
modular organization [88]. To exemplify, here we use the Principal Component Analysis (PCA)
[351] of the proximity network adjacency matrix, which reveals potential phenomena of interest.
For instance, fig. 4.6, depicts a set of terms correlated with Principal Component (PC) 4 (red)—
others could be chosen. The subnetwork of these terms is depicted in fig. 4.6D, and it reveals a set of
terms denoting a complex interaction of conditions which are coherent with what is becoming known
about Psoriasis. Several of the edges associate terms related to heart disease, stroke, hypertension,
hypotension, and diabetes which are high risks for Psoriasis patients [442], including potential
drug interactions (Metformin for diabetes, Verapimil for high blood pressure and stroke). This
subnetwork also reveals associations with Psoriasis which are currently receiving some attention,
such as with viral hepatitis [443] and seizure disorder [444]. Naturally, the network also includes
many terms associated with skin infections and immune reactions. The Psoriasis subnetwork is
just an example of a multi-term phenomenon of interest that is represented in the whole network.
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Importantly, we can identify users who may be experiencing this cluster of symptoms by following
the posts and timelines behind the weights in the subnetwork, which is useful for public health
monitoring.
While the Psoriasis subnetwork was discovered purely by data-driven analysis, another way
to use these networks is to to query them for specific terms most associated with a set of drugs or
symptoms of interest. This problem of finding which other items A ⊆ X are near a set of query items
Q ⊆ X (including a subnetwork of interest) is common in recommender systems and information
retrieval [116]. The answer set A can be computed as:
A ≡
{
xj : ∀xi∈Q Φ
xj∈X−Q
(pi,j) ≥ α
}
(4.4)
where Φ is an operator of choice, pi,j is the proximity weight between terms xi and xj (section 4.2),
and α is a desired threshold. If we are interested in a set of terms A which are strongly related to
every term in query set Q, then we use Φ = min. If we are interested in terms strongly related to
at least one term in Q, then Φ = max. For a compromise between the two, we can use Φ = avg
(average). Consider the query Q = {fluoxetine, anorexia} on the network of fig. 4.6A (w = 1
week). Using Φ = min, we obtain an answer set with terms strongly related to both query terms
(ordered by relevance): A = {suicidal, suicide, anxiety, pain, mood, cinnamon, insomnia, soy,
headache, mania, chia, cannabis }. For the query Q = {psoriasis, heart failure, stroke }
using Φ = avg, we obtain (ordered by relevance): A = {infections, diarrhea, hypertension,
seizures, hepatitis, constipation, dermatitis, glaucoma, vomiting }, which relates to the
discussion above.
Proximity Pw(X) networks are useful to discover associations between terms which co-occur
in time windows w of user timelines (section 4.2.2). But they are also useful to infer indirect
associations between terms. In other words, terms that do not co-occur much in user timelines,
but which tend to co-occur with the same other terms. In network science indirect associations are
typically obtained via the computation of shortest path algorithms on the isomorphic distance graphs
Dw(X) [117]. Terms which are very strongly connected via indirect paths, but weakly connected
via direct edges, break transitivity criteria [117]. We have previously shown that such indirect paths
are useful to predict novel trends in recommender systems [117], and are also instrumental to infer
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Figure 4.7: Drug/NP vs symptom subnetwork after shortest path calculation. (left) Top 25 non-transitive term
pairs. (right) adjacency matrix of distance subnetwork after shortest path calculation.
factual associations in knowledge networks [113]. In this context, the hypothesis is that strongly
indirectly associated terms may reveal unknown DDI and ADR.
To find the term pairs that most break transitivity we compute all shortest paths in the net-
works (via Dijkstra’s algorithm): the metric closure DCw (X). Figure 4.7 lists the top 25 Drug/NP vs
symptom associations which most break transitivity. In other words, these are term pairs which are
very strongly associated via indirect paths, but very weakly associated directly. Of the extracted
associations listed in the table of fig. 4.7, 6 are known or likely ADR, 3 are possible ADR from
patient reports but no conclusive study, 2 refer to associations between drugs/NP and symptoms
they are indicated to treat, and all other 14 are unknown. Thus, unlike the case of direct associa-
tions (fig. 4.5), there is less evidence for the indirect associations in the literature. This could be
because they are false associations, or because they have not been discovered yet. Validating these
associations empirically is left for forthcoming work, although he show promising results below (see
section 4.3); here the goal is to show how network analysis methods can be used to select such latent
associations which are highly implied by indirect paths (transitivity) but are not directly observed
in user post co-mentions.
Similarly to what was done with direct associations above, we can also query the proximity net-
work obtained after shortest path computation PCw (X) (the isomorphic proximity graph to DCw (X)
via eq. (4.2)). For instance, if we query the original w = 1 week proximity network PCw (X) (the one
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depicted in fig. 4.6A) with Q = {psoriasis, metformin} (a type 2 diabetes drug), using Φ = min,
we obtain A = {montelukast , hypertension, dermatitis, hypotension, hepatitis} as the top 5
terms—montelukast is a drug used to treat allergies. If we now use the same query Q on the metric
closure network PCw (X) instead, the top 5 answer set becomes AC = {montelukast, hypotension,
naloxone, allopurinol, hypertension}. In other words, after computing shortest paths, naloxone
(a synthetic opiate antagonist used to reverse the effects, including addiction, caused by narcotics)
and allopurinol (a drug used to treat gout, kidney stones, and decrease levels of uric acid in cancer
patients), become more strongly associated with the query terms. These indirect associations do not
occur very strongly in the observed Instagram timeline data, but are strongly implied by indirect
paths in the network of term proximity. In this case, the latent associations may provide additional
evidence supporting recent observations that psoriasis (an autoimmune condition) is linked to heart
disease, cancer, diabetes and depression [442].
4.3 DDI and ADR prediction from multiple cohorts
For this section we build upon the work in section 4.2. Our data includes user timelines from
Twitter, in addition to Instagram. Consistent with section 4.2, social media users met the in-
clusion criteria if their timeline was public and they had mentioned at least one drug known to
treat depression, epilepsy, or drugs associated with the opioid epidemic in the US. Provided we
gathered these populations in two different social media platforms, in total we have six cohorts of
interest. For depression, drug names are the same as in section 4.2: citalopram, escitalopram,
fluoxetine, fluvoxamine, paroxetine, sertraline, and trazodone. For epilepsy, drug names are:
carbamazepine, clobazam, diazepam, lacosamide, lamotrigine, levetiracetam, oxcarbazepine,
and the term seizuremeds, commonly used among epilepsy patients and discovered through textual
analysis of Epilepsy.com discussion forums. Lastly, for the opioid cohort, drug names are limited
to fentanyl and oxycodone, the two opioid-based drugs recently discovered to be abused in the
US. Drug name synonyms were resolved to the same drug name according to DrugBank [144]; for
instance, prozac is resolved to fluoxetine. The full list of synonyms used can be seen in table 4.1.
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Table 4.1: Term and synonyms used as selection criteria to include Twitter and Instagram timelines in the study
for each cohort of interest.
Cohort Term Synonyms
Depression
sertraline sertralina.
fluoxetine fluoxetin, fluoxetina, fluoxetinum, fluoxétine, prozac.
citalopram citadur, nitalapram.
escitalopram escitalopramum, esertia.
paroxetine paroxetina, paroxetinum.
fluvoxamine fluvoxamina, fluvoxaminum.
trazodone trazodona, trazodonum.
Epilepsy
clobazam onfi.
levetiracetam keppra, levetiracetamum.
lamotrigine lamictal, lamotrigina, lamotrigine, lamotriginum.
lacosamide vimpat, SPM927, erlosamide, harkoseride.
carbamazepine carbamazepen, carbamazepin, carbamazepina, carbamazepinum, carba-
mazépine.
diazepam valium, diastat.
oxcarbazepine -
seizuremeds -
Opioids fentanyl -oxycodone -
Twitter timelines came from a previously collected random sample of 665, 081 complete public time-
lines, generously provided by Dr. Bollen [386]. Our Twitter timelines are then extracted from this
set when they mention at least one of the terms in table 4.1. Instagram timelines were collected as
in section 4.2, and include all timelines that mention at least one hashtag (#) that matched a drug
name in table 4.1. At the time of collection the Instagram API allowed us to query all users4.
Table 4.2 shows the total number of timelines and posts for each analyzed cohort. For instance,
the opioid cohort from Twitter is the smallest, n = 525, still much larger than traditional cohort
studies, typically able to survey only a few patients. At the other end the depression cohort from
Instagram contains almost n = 10, 000 timelines. In number of posts analyzed, the epilepsy cohort
on twitter is the largest, containing more than 14M posts from which more than 600, 000 have a
dictionary matched term. These timelines also span several years, from 2007 to 2012 in the case of
Twitter, and from 2011 to early 2016 in the case of Instagram. In Appendix B, fig. B.1 shows the
temporal distribution of dictionary mentions and the number of timelines used for each cohort and
social media platform.
For this analysis we considerably enlarged the set of terms. The dictionaries now include terms
4Since June 2016, and conforming to Facebook policy changes, all data requests to the Instagram API require a
permission review, which severely limited scientific research on the platform.
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Twitter Instagram
timelines posts (with mentions) mentions timelines posts (with mentions) mentions
Epilepsy 5,958 14,152,904 (647,337) 725,885 9,863 8,496,124 (978,266) 1,394,985
Depression 1,966 4,338,778 (228,243) 258,220 6,973 5,402,316 (636,676) 987,595
Opioids 525 1,194,148 (90,857) 105,293 4,335 3,952,457 (507,110) 825,022
Table 4.2: Data description for each cohort and social media platform. Columns denote absolute numbers of:
timelines, posts (post containing at least one mention), and mentions, respectively. Note one post can have several
mentions, and a single- or multi-word token could possibly match one or more terms in the vocabulary.
associated with drugs, allergens, medical terms, symptoms, natural products, epilepsy, and cannabis.
Some of these already included in section 4.2. Terms associated with drugs and allergens were
obtained from DrugBank (v.5.1.0) [159]. These included generic drug names (e.g. Fluoxetine),
brand and product names (e.g., Prozac) and even international drug names (e.g, Fluoxetina). Drug
products with multiple active ingredients were split and matched independently (e.g., Symbyax was
matched to both Fluoxetine and Olanzapine). Medical terms, including symptoms, were obtained
from MedDRA (v.15) [237], a standardized medical terminology dictionary, free for non-commercial
purposes, upon which our ADR and DI validation to SIDER [145] is build upon (see section 4.5).
This dictionary replaced BICEPP from section 4.2. Since MeDRA includes terms not related to
symptoms (e.g., marital status and sexual orientation), we refer to this dictionary as medical terms.
Natural products, beyond those already included in DrugBank, were retrieved from MedlinePlus,
a resource produced by the National Library of Medicine [440], and TCMGeneDIT, a database
for traditional Chinese medicine [445]. Common Cannabis terms, retrieved from internet searches,
were manually added to the Natural Products dictionary (e.g, Mary Jane, 420). Additional epilepsy
terms, both added manually and detected using a C-value [446] tokenizer over discourses on the
Epilepsy.com website, were then validated by an epilepsy specialist, matched to MedDRA codes,
and added to the medical terms dictionary (e.g., Vagus Nerve Stimulator, or VNS for short). Terms
with synonyms are disambiguated to a preferred term as defined by each dictionary. Preferred
terms are used when networks are constructed. Despite our dictionary efforts, it is known that
matching dictionary terms is problematic, as term spelling can be context dependent. We took a
few steps in order to lower the number of false positive matching in our dictionaries. For instance, we
matched terms to the expected occurrence of English words in the Brown Corpus [447] and manually
removed common words (e.g., Nighttime, also commercially known as Benadryl). Also, terms with
fewer than 10 characters, along with posts where they appear, were manually inspected by this
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author. Identical medical and drug terms were manually assigned to a single dictionary, based on
which they related to. In total, our dictionary contains 176, 278 terms, from which 162, 235 are
drugs, 70, 230 are medical terms (including symptoms), 7, 216 are allergens, and 1, 269 are natural
products—including cannabis.
Textual preprocessing included the removal of user mentions and links. Duplicated content
from retweets and regrams—the reposting of a tweet or Instagram post by another individual—
were removed using regular expressions matching and only original text was retained. Common in
Instagram captions, hashtags were separated by a space and the hash symbol (#) was removed prior
to matching. Posts in the timelines were then tagged with all terms (n-grams) in our dictionaries,
ranging from 105, 293 matches in the opioid cohort on Twitter to 1, 4M matches in the epilepsy
cohort on Instagram. In total, close to 4, 3M term matches were found in all the analyzed timelines.
Matches vary across cohorts and also between social media. For instance, the depression cohort
on Instagram has the terms Depression and Decreased appetite as top hits—even though only
timelines mentioning drugs were initially selected. For the depression cohort on Twitter, we found as
top mentions Homosexuality, Death and Neoplasm malignant (cancer). We note that in section 4.2
we removed the word depression due to its high expected appearance. Since this term did not
appear in the top 20 matches of the depression cohort for Twitter, we decided not to remove any
terms as it would help us better understand differences in discourse across platforms. Matches in
the cannabis dictionary (e.g. 420, marijuana, hashish) were aggregated into the term Cannabis and
treated as a natural product.
To focus our analysis solely in the identification of possible DDI and their ADR, and also to
enhance the signal-to-noise ratio for such occurrences, with the larger dictionaries we built graphs
based on specific co-occurrence triads, instead of pairs. The only triads considered were: (Drug,
Drug, Medical term), (Drug, Allergen, Medical Term) and (Drug, Natural product, Medical term).
Our assumption is that medical terms (e.g., symptoms) will be associated with pairs of drugs,
indicating the former is likely due to an ADR from a DDI involving the drug pair, as we expect
these triplets occur in user timelines.
More formally, we repeated the methodology of section 4.2 with larger dictionaries, where entries
to the co-occurrence graph Rw(X) are now denoted by ri,j , ri,k, and rj,k, denoting the number of
time-windows where the triplet (xi, xj , xk) co-occurred, provided that i ∈ XDrugs, j ∈ XDrugs ∪
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Table 4.3: Network statistics per cohort and social media. Individualized tables showns in SI, tables B.1, B.2
and B.4.
Depression Epilepsy Opioids
Twitter Instagram Twitter Instagram Twitter Instagram
Nodes 2,899 3,288 3,662 3,471 2,344 3,544
Edges 150,054 230,799 186,326 199,207 101,624 270,991
Metric edges 19,174 (12.8%) 18,691 (8.1%) 19,770 (10.6%) 14,376 (7.2%) 15,963 (15.7%) 18,919 (6.9%)
no
de
s
Drugs 983 (33.9%) 1,011 (30.8%) 1,247 (34.1%) 1,036 (29.9%) 824 (35.2%) 1,017 (28.7%)
Med. terms 1,632 (56.3%) 1,866 (56.8%) 2,056 (56.1%) 2,023 (58.3%) 1,286 (54.9%) 2,131 (60.1%)
Allergens 184 (6.4%) 208 (6.3%) 200 (5.5%) 217 (6.3%) 167 (7.1%) 224 (6.3%)
Nat. Products 100 (3.5%) 203 (6.2%) 159 (4.3%) 195 (5.6%) 67 (2.9%) 172 (4.9%)
XAllergen ∪XNatural product, and k ∈ XMedical term. Superscripts of X denote subsets of X based on
the term type. We also fix w = 1 week. In section 4.6 we discuss limitations of using a fixed time
window and offer possible expansions for future work.
Once the proximity networks are computed via eq. (4.1) we validate each edge against DrugBank
[159] and SIDER [145]. Edges between drugs are validated for known DDI and edges between a
drug and a medical term are validated against known ADR and DI. Additional interpretability and
scientific evidence on found DDI and ADR are drawn from Drugs.com [222].
Table 4.3 shows descriptive statistics on nodes, edges, and their types, for all analyzed networks.
Similar to results presented for the depression cohort on Instagram (section 4.2), the other
cohorts also contain personal health-related information such as diagnoses, drugs prescribed, side
effects, reasons for changing medication, etc. The photos posted on Instagram also illustrate and
can be used to validate the intent and mood of the user. As already shown in fig. 4.1, these posts
often depict pills, containers and boxes, along with the user’s daily routine. Even naloxone, a drug
used in emergency situations for opioid overdose reversal, was among the posts in the opioids cohort.
Below we show a random sample of user posts, across cohorts and on both social media platforms
not previously mentioned.
Epilepsy cohort user on Instagram “It’s always harder to stay positive and believe that things can get better
when you’re going through a rough patch. Having people you can talk to is key for me. We don’t have to
talk about me, just talk to me so I don’t feel like I’m stuck in a never ending cycle of hospitals, medicines,
and appointments. The past couple of days have been hard, fevers and sickness have kept me down, but
hopefully I’m on the mend. I never seem to get a break, but I just call it an extra long rough patch. If I
can stay positive and make it through this one, maybe the next one will wait a long while before visiting
again. Fingers crossed. Ha #staystrong #keepsmiling #positivity #staypositive #roughpatch #seizures
#seizuressuck #epilepsy #epilepsyawareness #epilepsysucks #sick #meds #tegretol #keppra #grassisgreener
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#dontstopbelieving”
Epilepsy cohort user on Instagram “Grapefruit, anyone? My mood stabilizers have a warning on label that says
DO NOT EAT PINK GRAPEFRUIT. Here they sit, tempting me on the counter. #tegretol #grapefruit #sad
#want #fruit #pharmaceuticals”
Epilepsy cohort user on Twitter “diazapam...valium...tarmazpam...lithiumect...hrt...how long must i stay on this
stuff?please don’t give me more... #moz”
Epilepsy cohort user on Twitter “maybe diazepam can solve my problem though can’t cure my illness #back-
pain”
Epilepsy cohort user on Twitter “i had valium for the first time last week. that was nice. it didn’t help with
pain but it made me not care.”
Opioids cohort user on Instagram “Classic I know but I look at it everytime I feel extra lonely in this addiction
shit hole. #addiction #addictionisreal #xanax #oxycontin”
Opioids cohort user on Instagram “All that #painmeds just for a wisdom tooth extraction #oralsurgery #ibupro-
fen #oxycodone #amoxicillin #hatemeds #nochoice”
Opioids cohort user on Twitter “Ambien is hysterical. [...] Let your Dr know f you’re driving while sleeping to
go to a booty call. #Zoinks!”
Opioids cohort user on Twitter “gums sore, but now passing out thanks to my oxycodone!”
Opioids cohort user on Twitter “i couldn’t be a drugee. oxycodone makes me feel crazy disoriented when it
wears off. go figure, me not liking not being in control lol.”
4.4 DDI and ADR validation
We now explore the question of whether metric edges can be used as a predictive measure for known
DDI, ADR or their DI. Our main assumption is that metric edges will contain a large fraction of
known DDI and ADR, built from direct evidence from the timelines. Conversely, we believe semi-
metric edges, or edges representing indirect evidence, will be indicative of yet unknown DDI and
their ADR. We build this intuition from previous work that showed metric edges of knowledge
graphs are useful for fact-checking and protein-protein interaction prediction [113, 114, 115, 116,
117].
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Table 4.4: Known DDI, ADR, and DI validation on top 25 pairs with largest proximity values on metric and
semi-metric subnetworks. DDI edges calculated from D-D edges; ADR and DI edges calculated from D-MT edges.
Twitter Instagram
DDI ADR DI DDI ADR DI
Depression si,j = 1 1 (4%) 10 (40%) 1 (4%) 2 (8%) 9 (36%) 5 (20%)
si,j > 1 4 (16%) - - 9 (36%) - -
Epilepsy si,j = 1 6 (24%) 2 (8%) - 7 (28%) 4 (16%) 4 (16%)
si,j > 1 4 (16%) - - 2 (8%) 1 (4%) 1 (4%)
Opioid si,j = 1 1 (4%) 1 (4%) 2 (8%) 3 (12%) 4 (16%) 3 (12%)
si,j > 1 5 (20%) - - 7 (28%) - -
We observe that the metric backbone for all networks is much smaller than the original network,
which is compatible with previous results [117]. However across social media, Instagram metric
backbones are smaller when compared to Twitter metric backbones. For instance, for the depression
cohort, the Instagram metric backbone represents 8.1% of the original network, in comparison to
12.8% of the Twitter network. For the epilepsy cohort these numbers are 7.2% and 10.6%; and for
the opioid cohort they are 7% and 15.7%, respectively (see table 4.3). This means that Instagram
knowledge networks have more redundancy—when redundancy is defined as the amount of edges
that are not needed to compute shortest paths—than its Twitter counterpart. When computing
metric backbones of contact networks (see section 2.2.4), we see that social processes that are more
cohesive have smaller backbones [RBC8, RBC11]. For instance, the social process of primary-school
students, where students are organized in classes, is more cohesive then that of visitors to an art
exhibition. By analogy, the discourse process on social media, as analyzed through the lenses of
our dictionaries as we do here, is more coherent on Instagram than on Twitter. This indicates that
Instagram is a better medium for such analysis than Twitter. Our extensive exploration of how
terms were being mentioned in our cohorts via SyMPToM, also strengths this view. The larger
availability of text and richer context in which Instagram users are able to express themselves also
supports this view.
We then focus on the validation of known DDI, ADR and DI from metric and semi-metric edges,
first for top ranked proximity edges and then for all edges in the triplet co-mention networks. We
note that these are heterogeneous knowledge networks, meaning nodes can be of different types.
Therefore analysis of DDI are only performed for possible Drug-Drug (D-D) pairs; similarly for ADR
and DI we only considered possible Drug-Medical Term (D-MT) pairs. In section 4.2 we analyzed
the depression cohort on Instagram, and found that among the top 25 Drug/NP vs symptom
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associations, 12 were known ADR. We repeated the same analysis for the triplet proximity networks
we built with larger dictionaries. According to our gold standards, it contains 9 known ADR in
the top 25 proximity relations—between D-MT pairs only. Table 4.4 shows the number of known
DDI, ADR and DI found on the top 25 proximity edges for each individual cohort. Note that for
some cohorts a larger number of DDI is found among top metric edges, such as the epilepsy cohorts
on both Twitter and Instagram, while in others the inverse is true. For instance, in the depression
cohort from Instagram only 2 edges are known DDI in the top metric edges, versus 9 that are found
in the top semi-metric edges. This indicates that metric edges are not good predictors of known
DDI.
In table 4.5 we show numbers and percentages for all metric and semi-metric edges on the
depression cohorts for both Instagram and Twitter (epilepsy and opioid cohorts are shown in Ap-
pendix B, tables B.3 and B.5). These tables show values for the metric backbone (si,j = 1) and
various degrees of the semi-metric subnetwork (si,j > x, with x ∈ {1, 2, 5, 10}). Metric backbones
across all three cohorts from Instagram contain higher relative percentage of known DDI edges than
their Twitter counterpart. For instance, the depression cohort on Twitter contains 19.6% (557 of
2,839) metric DDI edges, in comparison to 23.4% (4,208 of 18,018) semi-metric DDI edges. For the
depression cohort on Instagram the situation is reversed, it contains 20.9% (404 of 1,933) metric
DDI edges, in comparison to 13.9% (2,429 of 17,485) semi-metric DDI edges. This may point to
underlying differences across social media platforms, that metric edges are not necessarily good
predictors of known DDI, or that our new larger dictionaries have introduced a source of noise in
retrieving known DDI from social media discourse.
To investigate this further we first turn to the distribution of semi-metric edges. Given that
semi-metric edges hold larger number of known DDIs in general, it could be that known DDI are
largely located towards edges that are ‘almost metric’ (si,j ≈ 1). In turn, possible unknown DDIs
would be located on edges that had their distance largely distorted after closure computation (e.g.,
si,j > 10). Again inspecting table 4.5 (and tables B.3 and B.5), we see that the percentage of DDI
at different threshold levels of si,j are not demonstrative of where known DDI are located, since
their percentages are stable across all levels. And this is not due to the distribution of si,j values
(see fig. B.4).
If our larger dictionaries introduced additional noise in retrieving DDI evidence from social
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media data, restricting our validation to edges around drug terms that were used to collect the
cohorts should strengthen the DDI signal. Edges connecting at least one of the drugs used to select
the cohort are shown in table 4.5, denoted as D(si,j = 1) and D(si,j > 1), for metric and semi-
metric subnetworks, respectively. This segmentation provides a unique set of edges that are most
strongly discussed in social media, given how the cohorts were collected. In the depression cohort
on Instagram 86.96% (20/23) and 50.65% (588/1, 161) of metric and semi-metric edges are known
DDIs. For the depression cohort on Twitter, these numbers are 50% (11/22) and 53% (556/1, 040).
The epilepsy cohort on Instagram follows a similar pattern, 58.14% (25/43) and 36.18% (360/995)
of metric and semi-metric edges are known DDI. On Twitter these numbers are 33.85% (22/65)
and 35.97% (364/1, 012), respectively. Lastly, in the opioid cohorts on Instagram 66.67% (4/6)
and 33.48 (231/690) of metric and semi-metric edges are known DDI. On Twitter these are 43.75%
(7/16) and 38.73% (146/377), respectively.
Our results demonstrate major differences in how metric and semi-metric edges relate to known
DDI and ADR across social media platforms. Also, we found no evidence that metric edges are
predictive of known DDI extracted from social media discourse. Furthermore, known DDI are
distributed across a wide range of semi-metric edges. However, further statistical analysis should be
performed to reveal any underlying patterns. Nonetheless, our data science and complex networks
methods were able recover, and validate against gold standards, a large proportion of known DDI
and ADR from social media discourse. Having analyzed overall statistics of our networks, the
natural step is to perform a more qualitative inspection of edges surrounding terms of interest.
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Table 4.5: Depression metric and semi-metric subnetworks for both Twitter and Instagram cohorts. Acronyms D-D
and D-MT denote edges between Drug-Drug and Drug-Medical term nodes, respectively. Percentages for DDI are
calculated from D-D edges. Percentages for ADR and DI are both calculated from D-MT edges.
Twitter Instagram
Total D-D / D-MT DDI/ADR/DI Total D-D / D-MT DDI/ADR/DI
D(si,j = 1) 275 (0.18%)
22 (8%) 11 (50%)
116 (0.05%)
23 (19.83%) 20 (86.96%)
188 (68.36%) 71 (37.77%) 71 (61.21%) 22 (30.99%)11 (5.85%) 5 (7.04%)
D(si,j > 1) 2,952 (1.97%)
1,040 (35.23%) 556 (53.46%)
4,216 (1.83%)
1,161 (27.54%) 588 (50.65%)
1,520 (51.49%) 378 (24.87%) 2,293 (54.39%) 547 (23.86%)79 (5.20%) 136 (5.93%)
si,j = 1 19,174 (12.78%)
2,839 (14.81%) 557 (19.62%)
18,691 (8.10%)
1,933 (10.34%) 404 (20.90%)
11,986 (62.51%) 640 (5.34%) 11,412 (61.06%) 293 (2.57%)333 (2.78%) 275 (2.41%)
si,j > 1 130,878 (87.22%)
18,018 (13.77%) 4,208 (23.35%)
212,106 (91.90%)
17,485 (8.24%) 2,429 (13.89%)
63,432 (48.47%) 3,263 (5.14%) 84,704 (39.93%) 3,405 (4.02%)1,081 (1.70%) 1,254 (1.48%)
si,j > 2 101,698 (67.78%)
13,930 (13.70%) 3,357 (24.10%)
178,551 (77.36%)
15,000 (8.40%) 2,068 (13.79%)
46,360 (45.59%) 2,372 (5.12%) 68,144 (38.17%) 2,958 (4.34%)739 (1.59%) 996 (1.46%)
si,j > 5 61,517 (41.00%)
8,151 (13.25%) 2,011 (24.67%)
120,968 (52.41%)
10,853 (8.97%) 1,136 (14.97%)
26,265 (42.70%) 1,315 (5.01%) 44,616 (36.88%) 1,396 (4.79%)364 (1.39%) 399 (1.37%)
si,j > 10 37,697 (25.12%)
4,999 (13.26%) 1,222 (24.44%)
80,653 (34.95%)
7,588 (9.41%) 1,136 (14.97%)
15,572 (41.31%) 754 (4.84%) 29,161 (36.16%) 1,396 (4.79%)211 (1.35%) 399 (1.37%)
4.5 Network analysis to evaluate ADR from DDI
Using the proximity graphs introduced in section 4.2, but built from co-mention triplets instead of
co-mention pairs, we explore strong term associations that arise from the discourse of the cohorts
of interest. We focus on the discourse surrounding drug terms used to select our cohorts, providing
a more precise characterization of how drug and symptoms are being discussed in social media for
each particular cohort. Given results from the previous section, we assume that triplets connecting
two drugs and a medical term will likely be of a known DDI and its ADR. However, if social media
is indeed a useful medium for DDI monitoring and surveillance, our networks should also discover
a large variety of unknown DDI and their respective ADR, which are difficult to test because by
definition there is no gold standard for them. Still, it is possible that a variety of unknown DDI and
ADR were missed. Either because by definition they have not yet been discovered, because they
are missing from DrugBank or SIDER, or possibly because of language variations. For instance,
users referring to suicidal thoughts, a possible adverse reaction of antidepressant drugs, as “today I
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Figure 4.8: Two-step proximity ego-network seeded from the terms used to select the depression cohort on Instagram.
Edge weight denotes the proximity values, only shown for pi,j ≥ 0.01. Node colors denote term type: drug (red),
medical term (blue), natural product (green), or allergen (yellow; none showed). Edge colors denote: known DDI
(red), ADR (blue), or DI (green); grey nodes denote unknown association. Edges with both ADR and DI are shown
in cyan. Darker (lighter) colors denote metric (semi-metric) edges. Plot generated with Gephi [448]. Drug term
Fluvoxamine, used as inclusion criteria, had no connection in this network and was therefore omitted.
want to cease to exist” would not get be picked up by our dictionary matching. As the statistical
term correlation is not necessarily a causal interaction, in our plots below edges that are known
DDI, ADR and DI—validated from two gold standards (see section 4.3)—are denoted as red, blue
and green edges, respectively; cyan is used for those where the pair is both a DI and ADR—such as
the pair between Fluoxetine and Depression. Metric and semi-metric edges are denoted as darker
and lighter color shades, respectively. We also encourage the reader to navigate the networks on
SyMPToM while following this section, thus enabling a more contextualized view of how terms of
interest are being mentioned in social media for specific cohorts and individuals.
Let us first consider the triplet proximity network Pw(X) for the depression cohort from Insta-
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gram. Figure 4.8 shows the two-step ego-centric network seeded from the terms used as inclusion
criteria, thus of interest to this cohort, for pi,j ≥ 0.01. In this network, several additional drugs, also
known to treat a variety of depressive disorders can be seen, such as Lorazepam, Duloxetine, and
Lamotrigine. In total 167 edges connecting terms denote co-mention triads that appeared in the
timelines (see section 4.3). Most importantly, several co-mentions are either of known DDI (30; red
edges), or of known adverse reactions (18; blue edges), and some of DI (17; green edges). Common
drug-medical terms that are both DI and ADR (26), such as Depression and Fluoxetine (cyan
edges), are also observed in the network.
The strongest, metric connection, denoted by the highest proximity value of pi,j = 0.082, is
between Citalopram and Mirtazapine, a major known DDI [222]. Citalopram is a selective sero-
tonin reuptake inhibitor (SSRI) while Mirtazapine is a tetracyclic with noradrenergic and specific
serotonergic effects (non-SSRI). Their co-administration can increase the risk of ventricular arrhyth-
mias such as torsade de pointes and sudden death [222]—none of which are in our network. In this
network, both are also strongly connected to the medical term of Completed suicide which only
Citalopram is known to cause. According to our gold standard, the increased risk of suicide from
the co-administration of Citalopram and Mirtazapine is still unknown. However, according to
the our proximity network, may require attention. Also, both drugs are strongly connected with
Haemorrhage, from which SSRIs were only recently known to be associated with but no evidence
exists in the validation gold standard [449].
Additional strong connections are found for Duloxetine, connected to Venlafaxine (pi,j =
0.067) and Paroxetine (pi,j = 0.059). Both are major DDI leading to increased risk of serotonin
syndrome, with symptoms that can include confusion, hallucination, seizure, and many others [159,
222]. Duloxetine also has a moderate DDI connection with Promethazine, as the first is a moderate
inhibitor of the CYP[2D6] enzyme, possibly leading to increased drug plasma concentrations [222].
It is noteworthy that in chapter 3, we found DDI co-prescription of CYP inhibitors with their
respective enzymes substrates. Also, the non-existent connection in this network does not mean
they were not co-mentioned at all with a third term, only that these connections were removed by
our strict threshold. This means that the supporting evidence for their co-mention in user timelines
was too few to be considered.
A cluster of DDI connections can also be seen among several drugs, including Omeprazole,
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Lisinopril, Furosemide, Doxycycline, Carvedilol, Warfarin, Digoxin, and Spironolactone.
All of which are strongly connected, 0.057 ≤ pi,j ≤ 0.078, to Cardiomyopathy, but only Carvedilol
is known to be indicated for (green edge). Most of these DDI are listed as moderate with adverse
reactions related to blood pressure and heart rate. However, the co-administration of Lisinopril
and Spironolactone is a major DDI that increases the possasium blood level and may be life-
threatening for patients with renal impairment, diabetes, or severe or worsening heart failure [222].
Of concern is also the widely prescribed (see also chapter 3) proton pump inhibitor Omeprazole,
which combined with these other drugs can increase the risk of bleeding, irregular heart rhythm,
fatigue, upset stomach, dizziness, and several others adverse reactions [222]. Also, these DDI were
captured in our network by semi-metric edges (light red edges) while the metric connection was
with the medical term Cardiomyopathy. This means a strong direct connection exists between
these drugs and cardiovascular issues than between the drugs themselves.
This network also picks up on unintended uses of prescribed drugs. Note Bulimia nervosa is
connected to Sertraline and Citalopram, along with its DI Fluoxetine. A qualitative analysis of
the tweets uncovered posts discussing methods for weight loss which include some of the aforemen-
tioned drugs. Importantly, the uncovering of social media discourse on unintended drug use was
only possible due to a bottom-up data driven approach and our monitoring tool, which allowed for
such inspection.
Finally, in this network Cannabis appears connected with alcohol (Ethanol), Opiates (such as
Oxycodone), Pain, and several others. Studies on the impact of the co-administration of opioids
and smoked cannabis on analgesia and pain treatment are still scarce, but recent results show they
can have synergistic effects without increases in abuse liability [450]. A qualitative understanding
of why users are co-mentioning them these drugs, as well their reported experience in their co-
administration with cannabis is likely to help focus new research on the topic, which we will offer
in future work.
We now inspect results from the Twitter depression cohort. Figure B.2 shows a similar two-
step ego-network built from Twitter co-mention triads. The twitter ego-network is smaller than
its Instagram counterpart, and just by visualizing its content, it is clear that the two cohorts
discuss very different topics of interest. Nonetheless, similar to the Instagram ego-network, the
Twitter ego-network also has several known DDI, ADR, and DI edges. In fact, only a few edges
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have unknown connections. The strongest connection is between Venlafaxine and Alprazolam
(pi,j = 0.037), a known DDI that causes dizziness, drowsiness, confusion, and difficulty concentrating
[222]. Interestingly, some of these side effects are also present in the network, denoted by the medical
terms Feeling abnormal, Migraine, Nausea and Depression, all known ADR from Venlafaxine.
On edges known to treat a specific symptom, both Hydrocodone, an opioid pain medication, and
Alprazolam, a benzodiazepine known to treat chronic pain, are shown strongly connected to Pain,
with pi,j = 0.028 and pi,j = 0.016, respectively. However, Pain is also connected to Venlafaxine
(pi,j = 0.014), from which no DI or ADR is known.
Drugs surrounding the medical term Rash also call for attention. Most connections are known
ADR from these drugs, which include Haloperidol, Quetiapine, Clozapine, Risperidone, and
Paroxetine. However, four other drugs, also connected to Rash at the same proximity strength, are
of unknown type, suggesting a possible unknown ADR. These drugs are Phenelzine, Clomipramine,
Zuclopenthixol, and Fluphenazine. Despite not being matched to SIDER, Drugs.com lists Rash as
possible ADR for both Phenelzine and Clomipramine [222], but not for the two remaining drugs.
Additionally, three other drugs with known DDI—Lamotrigine, Carbamazepine, and Valproic
Acid—are strongly connected to each other and to Rash. The co-administration of Valproic Acid
and Lamotrigine is a major DDI, significantly increasing the plasma concentration of the latter,
while risking serious and life-threatening rash [222].
We now turn to the epilepsy cohort on Instagram (see Figure B.3-top). The strongest edge
is between Hydrocodone and Overdose (pi,j = 0.112), seen with other strongly connected terms,
such as Dependence and Diazepam, Acetaminophen, and Drug abuser. A known DDI connects
Diazepam and Hydrocodone, but these drugs are not known to interact with Acetaminophen. Drugs
commonly prescribed to the epilepsy condition can also be seen in the lower part of the network,
most of which are shown to be known DDI when co-administered. For instance, Lamotrigine,
Gabapentin, Topiramate, and Levetiracetam. We also see most of these drugs connected to
Epilepsy, the reason for administering these drugs in the first place, but in some cases also a
common side-effect of the drug (see cyan edges). There is also an unforeseen relation between
Salvia and REM sleep abnormal (pi,j = 0.096). Salvia divinorum is traditionally known as a
psychoactive herb used as a tranquilizer, but only recently it was shown to diminish rapid eye
movement (REM) sleep and increase the quiet awake stage [451]. Similar to the depression network,
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Figure 4.9: Two-step proximity ego-network seeded at the terms used to select the opioid cohort on Instagram (left)
and Twitter (right). Edge weight denotes the proximity values, only shown for pi,j ≥ 0.01. Node colors denote term
type: drug (red), medical term (blue), natural product (green), or allergen (yellow). Edge colors denote: known DDI
(red), ADR (blue), or DI (green). Edges with both ADR and DI are shown in cyan. Darker (lighter) colors denote
metric (semi-metric) edges. Plot generated with Gephi [448]. Drug terms Fentanyl, used as inclusion criteria, had
no connection in the Twitter network and was therefore omitted.
we also see connection between Cannabis and Alcohol (Ethanol; pi,j = 0.080), but in this network
also well connected to LSD (pi,j = 0.075). We also see Prednisolone, a drug commonly prescribed
to inflammation, strongly connected to Encephalitis, a brain inflammation that can possibly lead
to epileptic conditions. On a population level, epilepsy takes a heavy emotional toll on patients,
who often can also be diagnosed with Depression or Anxiety, both of which are seen in our network
connected to drugs they are known to treat, including Fluoxetine and Quetiapine.
Still from the epilepsy cohort, we now inspect the Twitter ego-network in Figure B.3-bottom.
The strongest edge is the relation between Multiple Sclerosis (MS) and Vitamin D (pi,j = 0.070),
an active area of research. Despite early work dismissing a proposed protective effect of vitamin D
on risk of MS [452], several subsequent studies supported such protective effects, however with still
no clear understanding of its underlying mechanisms [453, 454]. We must also note the connection
between MS and Cannabis (pi,j = 0.031), an active area of research where cannabis, in addition
to symptom management has been shown in mice to slow the neurodegenerative processes of MS
[455]. Interestingly, Rash is a known ADR for several of its associations, except with its connections
to Zuclopenthixol (pi,j = 0.016), Fluphenazine (pi,j = 0.012), Clomipramine (pi,j = 0.013), and
Phenelzine (pi,j = 0.012).
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Lastly, the ego-networks for the opioids cohort on both Instagram and Twitter are shown in
fig. 4.9. This is an important cohort as recent non-medical drug abusers of opioids have been
steadily increasing in the US, particularly among persons 18 to 25 years of age [456], the age window
of our Instagram users. On the Instagram ego-network (fig. 4.9-left), Oxycodone and Fentanyl,
both inclusion criteria terms, are connected to Pain, the prescriptive reason for these opiates in
general. From navigating the posts in this cohort, several photos and their captions depict post-
operative individuals, describing their prescribed opioids for pain management. Hydrocodone (pi,j =
0.031), Acetaminophen (pi,j = 0.025), and Alprazolam (pi,j = 0.014), all known DI for Pain, are
also connected in similar fashion. Interestingly, Depression is strongly connected to four drugs:
Amphetamine (pi,j = 0.072), Dextroamphetamine (pi,j = 0.073) Alprazolam (pi,j = 0.050), and
Oxycodone (pi,j = 0.053). However depression is only known as an ADR from Alprazolam. The
others may be unknown ADR or be related to comorbidities causing depressive states in patients.
If that is the case, patients co-administering both opioids and commonly prescribed SSRI may have
inadequate pain management as the liver enzyme CYP[2D6], required to exert analgesic effects, is
inhibited by SSRIs [457]. Also noteworthy, our network shows a connection between Oxycodone and
Hydrocodone (pi,j = 0.01). These drugs are listed as having a major DDI known to cause serious
side effects including respiratory distress, coma, and even death [222]. Additionally, a discussion
on non-medical drug addiction can also be seen in this network. Note the medical term Opiates
is surrounded by strong connections to Methadone (pi,j = 0.050), Buprenorphine (pi,j = 0.048),
and Naloxone (pi,j = 0.053), all of which are widely used to reduce withdraw symptoms of drug
addiction or in drug detoxification. It is also known that opioids may be entry substance for other
addictions, such as Heroin and Cocaine, both terms can be seen in this ego-network, alongside with
LSD.
Albeit smaller, the twitter ego-network for the opioid cohort contains similar nodes and edges.
For instance, Pain is also connected to the drugs Oxycodone (pi,j = 0.035), Hydrocodone (pi,j =
0.031), Acetaminophen (pi,j = 0.025), and Alprazolam (pi,j = 0.014). Alprazolam and Venlafaxine
are also shown connected to Depression to which they are known ADR. This ego-network also shows
a similar non-medical drug addiction discussion found for the Instagram ego-network. Terms like
Methadone, Buprenorphine, Heroin and Ethanol (alcohol) are all—some strongly—connected to
Naloxone and Dependence, to which the latter is also Cannabis and Cocaine are strongly linked.
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Interestingly, the Twitter ego-network did not contain Fentanyl, one of the inclusion criteria terms.
As much as these ego-networks are illustrative of the population level discussion of possible DDI
and their ADR, some limitations need to be addressed. While navigating timelines, specially the
opioids cohort, we did find profiles devoted to the advertisement of controlled substances. Posts
on these profiles were devoted almost exclusively for the advertisement and the selling of drugs,
with little to no motivation for the disclosure of personal or private experience with symptoms and
medications. While we used SyMPToM to identify and thus limit the amount of such timelines,
few may still be present in our data set, skewing overall results. Future work will be devoted
to automatically remove such spurious profiles, possibly drawing from the social bot literature
[273, 458]. This limitation also draws attention to other social media work that relies on the
collective content of posts with little or no manual curation of profiles and tweets. Not only with bot
versus human differences, but also with human promoted content that is far from being considered
default profile activity on these social media platforms. This limitation encourages the promotion
of laborious human curation and platforms such as those found in SyMPToM. Indeed, this work
would benefit from more careful curation of dictionaries and analytical statistical analysis of the
networks (e.g., null model comparison). Nonetheless, our work contributes to the study of the
DDI phenomema by demonstrating much relevant discourse on DDI and ADR can be found in the
cohorts we analyzed.
4.6 Discussion and Conclusions
Our analysis in this chapter demonstrate that there exists a substantial health-related user commu-
nity both in Instagram and Twitter who posts about their health conditions and medications. This
result is particular important for public health analysts, physicians, and scientists, as it allows them
to follow cohorts of interest and to have a more precise understanding of how these communities
are discussing their health in social media. Moreover, using our tools and methods they are able to
follow this community both on a user-level as well as on a population-level. In the first part of the
chapter, using drug, NP and symptom dictionaries we extracted a large number of posts with such
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data, enough to build knowledge networks of hundreds of terms representing the pharmacology and
symptomatic “conceptual space” of Instagram users posting about depression. Our results and soft-
ware further demonstrate that such space can be navigated for public health monitoring, whereby
analysts can search and visualize user timelines and specific cohorts of interest. Indeed, the network
representation of this space allows us to extract population-level term associations and subnetworks
of terms arising from underlying (modular) phenomena of interest—such as the Psoriasis network
involving various related conditions. Thus, social media in general, and in special Instagram data,
shows great potential for public health monitoring and surveillance for DDI and ADR, as it can add
precision in public health studies.
Direct associations in the knowledge networks are substantiated by actual co-mentions in posts
from user timelines, which can subsequently be retrieved by public health analysts using SyMPToM.
In section 4.2 of this chapter, the top extracted direct associations are shown to be backed by the
literature. Then in section 4.3, we pursue a systematic validation of such associations, demonstrating
that both DDI and ADR mentions are pervasive throughout all three cohorts analyzed. This relied
on a greatly expanded dictionary. Preliminary analysis suggests that metric edges in general are
not very good predictors of DDI or ADR. However, when restricting analysis only to terms used to
extract user timelines, we discovered that a large proportion of metric edges in these subnetwork
are of known DDI or ADR. This suggests that the quality of the knowledge network is higher for
terms used to harvest the timelines. Therefore, edges in this subnetwork should be first explored
as potential unknown DDI with their possible ADR. We exemplify this with two-step ego-networks
seeded at drugs used to collect the cohorts of interest.
We made all extracted networks available to the community interested in public health and
biocomputing, in the hopes that other groups may participate in the validation of this data, and
possibly uncovering unknown DDI and their ADR. Network methods also allow us to uncover
indirect associations among terms. These may reveal latent, yet unknown, associations, and as
such, very relevant for public health monitoring. Studying the network of indirect associations can
be further used to understand community structure as well as redundancy in the data, which we
intend to study next.
In section 4.3 of this chapter we have analyzed posts and user timelines related to different
cohorts: depression, epilepsy, and opioids. In the context of epilepsy, our team is currently working
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on a project, title myAura, to explore knowledge networks and their metric backbones in the context
of helping patients with epilepsy access information relevant to their condition. In this project we
will build networks from heterogeneous data sources, including electronic health records, clinical
trials, and social media. In the future we would like to add additional cohorts (e.g. Alzheimer or
psoriasis), to possibly uncover additional drug-medical term associations.
While the drug dictionary used in the first part of this chapter was already quite well developed,
we extended the dictionaries used in the second part. This increased terminology associated with
symptoms helped in the detection of additional linguistic expressions of symptoms from social media
discourse. Our dictionary expansion also enabled the systematic evaluation of edges known to be
DDI, ADR and DI. However, the smaller number of known ADR found among the top 25 D-MT
edges in section 4.3 is indicative that the new dictionaries have introduced unnecessary noise to our
analysis. In the future we will pursue a citizen-science approach through myAura to increase our
dictionary coverage to specific conditions, starting from and expanding what has already been done
for Twitter [277]. We will also pursue an additional manual curation of dictionary matches, aiming
at better precision in extracting expression of symptoms and their synonyms.
The methodology we describe here allows us to discern drug, medical terms, and natural products
associations derived from user timeline co-mentions at different timescales. All the results displayed
pertain to a one week window, however one could also compute daily and monthly windows, for
example. The comparison of results at different timescales would allow, in principle, the discovery of
more immediate as well as more delayed interactions and adverse reactions. However, since this will
dramatically increase the computational complexity, more focused networks must be constructed.
Such a comparison is something we intend to pursue in the future. Finally, the timeseries analysis
of user timelines can be used to detect discernible changes in behavior for users and groups of users.
One could track, for instance, critical changes in mood associated with the onset of depression [459],
which constitutes yet another exciting avenue to pursue with this line of research.
Overall, our analysis demonstrates that Instagram and Twitter are very powerful source of data
of potential benefit to monitor and uncover DDI and ADR. Moreover, our work shows that complex
network analysis provides an important toolbox to extract health-related associations and their
support from large-scale social media data.
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Chapter Five
Temporal signals of DDI associations from social, clinical, and scientific
sources 1
“Every living organism is essentially an open system. It
maintains itself in a continuous inflow and outflow, a
building up and breaking down of components, never
being, so long as it is alive, in a state of chemical and
thermodynamic equilibrium but maintained in a so-called
steady state which is distinct from the latter.”
Ludvig von Bertalanffy
Austrian (System) Biologist
5.1 Introduction
Several efforts have been made in order to detect drug-drug interaction (DDI) signals from a
variety of biomedical data sources, including the Food and Drug Administration’s (FDA) Adverse
Event Reporting System (FAERS) [232, 234, 235] and the scientific literature [120]. Recent results
1This chapter will be submitted as an independent journal paper [RBC20].
120
show that combining additional data sources into validating signals from FAERS, may advance our
knowledge of unknown DDIs [248]. As we have shown in chapter 4 [RBC7], social media is an in-
creasingly important medium for public health monitoring and pharmacovigilance [59, 70, 72, 278,
288]. Despite previous efforts, it is still unknown whether social media mentions of adverse drug
reactions (ADR) and DDI actually precede reports in FAERS or in the scientific literature. It could
well be that an increase of DDI co-mentions in time, simply follows clinical or scientific discoveries,
thus showing no significant value for uncovering early warning signals for pharmacovigilance. Fur-
thermore, there is currently no study that shows what is the temporal discovery pattern for different
types of scientific evidence of DDI—such as in-vivo, in-vitro, or clinical evidence. Temporal patterns
of DDI discovery may enhance our understanding of the DDI phenomenon, possibly helping driving
research towards filling specific knowledge gaps. In this work we show a preliminary study that
addresses both of these questions, and to the best of our knowledge, is the first to do so. Our overall
assumption is that the complex interactions between patients, physicians and scientists, is a rich
data source for putative ADR and DDI discovery, since each of the aforementioned actors utilize a
diverse set of official and unofficial mediums to communicate their ADR and DDI experience.
In this chapter we inspect relevant signals for DDI discovery. We start with small set of 28
DDIs extracted from triplet co-mentions on two distinct social media, Twitter and Instagram. Only
specific types of triplets are considered, such as those between the mention of two drugs and a
symptom. As shown below, our analysis indicates that most drug pairs known to interact follow a
consistent pattern of scientific discovery. A typical DDI is initially clinically reported in FAERS,
and subsequently reported in the scientific literature. However, we found anecdotal evidence that
some pairs, such as (Diazepam, Hydrocodone), are co-mentioned in social media well before scientific
evidence appears. In fact, this pair was co-mentioned in both Twitter and Instagram well before any
in-vivo or in-vitro evidence of the DDI, specifically 7 years earlier in Twitter and 5 years earlier on
Instagram. In a qualitative analysis of the posts mentioning this pair, however, we were not able to
find direct evidence of ADR from this particular DDI, although the drug pair had to be mentioned
with a third term (i.e. a symptom) to be identified by our methods. We then dismissed social
media data due to little historical data and systematically evaluated all DDI present in DrugBank.
We found that the discovery pattern of different types of DDI is the following: first, co-mention
evidence is seen in clinical reportin (i.e., FAERS), followed by scientific literature evidence of in-vivo,
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clinical, and in-vitro type. We also found that about 90% of all known DDI have supporting evidence
in FAERS, strengthening the importance of clinical reporting for DDI discovery. Conversely, we
found that only 37% have co-mention evidence in the scientific literature. In the specific case of
in-vivo evidence type, scientific publications contain co-mentions for less than 5% of all known DDI,
suggesting that most DDI is yet to be tested scientifically.
Overall, our results show that as newer drugs are developed, or old drugs are repurposed, the
analysis of health-related content from social media discourse will increase its importance for public
health monitoring and pharmacovigilance, as additional longitudinal data is made available. The
availability of this data for a longer time period will further enable the study of longitudinal drug
co-prescription and their possible ADRs. This result also calls for a preemptive role of health
agencies to ensure social media historical data is easily and safely available for future public health
research, similarly to what has been done to clinical reporting in the 1960’s [119]. Additionally, our
results on the discovery patterns of different DDI evidence types point towards effective means of
driving DDI discovery towards filling existent knowledge gaps. Both the importance of social media
for DDI discovery, as well as the elicited evidence gaps, have consequences for health policy and
pharmacovigilance, as well as for drug research in general.
5.2 Data sources
5.2.1 FAERS
Quarterly clinical reports in raw ASCII format were obtained from the FDA Adverse Event Report-
ing System (FAERS) [148]. These were subsequently inserted into a database and de-duplicated
closely following the work of Banda, Evans, Vanguri, Tatonetti, Ryan, and Shah [232], which un-
fortunately could not be used directly due to lack of temporal information in combined tables.
In FAERS, record duplication may occur due to multiple—often mandatory—submissions from a
unique adverse event case; these are often follow ups from an initial case report. Submissions can
come from private practitioners, the pharmaceutical industry or the general public. Importantly,
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FDA mandates that drug adverse events detected during drug development phases must be submit-
ted to FAERS as soon as discovered. After deduplication, the dataset we used contained a total of
8, 569, 693 records with cases from 1968 to 2017 (see fig. C.1).
5.2.2 Medline
Scientific publications—including title, abstracts, MeSH annotation and other accompanying metadata—
were obtained from Medline, a bibliographic database containing more than 25 million references
to journal articles in life sciences, with a concentration on biomedicine, and maintained by the
U.S. National Library of Medicine (NLM) [440]. Medline includes literature published from 1966
to present, with older periods being covered by the OldMedline dataset, also used in this study.
Our complete MedLine dataset was collected mid-2017 and contains a total of 26, 555, 496 papers
published between Jan 1st 1940 to Dec 31st 2016 (see fig. C.1). To limit the number of papers we
match against our term dictionary (see section 5.3.1), we used machine learning methods to clas-
sify papers based on the type of DDI evidence they contained: clinical, in-vitro, and in-vivo. These
abstract-level classifiers were developed as part of a large NIH Grant on predicting evidence gaps for
DDI from the published scientific literature, and were trained to predict these specific types of DDI
evidence. In total we used a subset of 785, 790 Medline papers deemed as positive for containing at
least one type of DDI evidence. A detailed description of such classifiers is upcoming in Parmer,
Wood, Wu, Li, and Rocha [121].
5.2.3 Social Media
Our social media data sets were already introduced in chapter 4. These consists of cohorts of
interest on two different social media platforms, Twitter and Instagram. Complete user time-
lines for these cohorts were collected based on mention of drug names known to treat depression,
epilepsy, and opioid drugs, and their synonyms. For instance, in the depression cohort, drug names
included citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and
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trazodone. For epilepsy, drug names included carbamazepine, clobazam, diazepam, lacosamide,
lamotrigine, levetiracetam, oxcarbazepine, and the term seizuremeds, commonly used among
epilepsy patients and discovered through textual analysis of Epilepsy.com forums. Lastly, for the
opioid cohort, drug names were limited to fentanyl and oxycodone, the two opioid-based drugs
known to be abused in the US. Drug name synonyms were resolved to the same drug name according
to DrugBank [144]; for instance, prozac is resolved to fluoxetine.
Instagram timelines were collected and represent all the timelines that included at least one
hashtag (#) that matched a drug name. Twitter timelines consists in a subset of a random sample
of 665, 081 complete public timelines, established in previous work [386]. For additional details on
the social media datasets, please see chapter 4.
5.3 Methods
5.3.1 Dictionaries and textual matching
The dictionaries we use in this chapter were already introduced in chapter 4. A previously estab-
lished dictionary of Drugs, Allergens, Medical terms, and Natural products (including Cannabis)
were used to match terms in all three data sets. Term associated with drugs and allergens were ob-
tained from DrugBank (v.5.1.0) [159]. Drug products with multiple active ingredients were split and
matched independently. Medical terms, including symptoms, were obtained from MedDRA (v.15)
[237]. Natural products, beyond those already included in DrugBank, were retrieved from Medline-
Plus, a source produced by the National Library of Medicine [440], and TCMGeneDIT, a database
for traditional Chinese medicine [445]. Common Cannabis terms were manually added to the Nat-
ural Products dictionary (e.g, Mary Jane, 420). Additional epilepsy terms from the Epilepsy.com
forums were also added to the medical terms dictionary (e.g., Vagus Nerve Stimulator, or VNS
for short). These terms were manually included or data-driven discovered, as previously described
in section 4.3. Individual dictionary terms are linked to a preferred term. Additional steps were
performed to the dictionary to ensure low false positive matching and are described in section 4.3.
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Overall, our dictionary contains 176, 278 terms, from which 162, 235 are drugs, 70, 230 are medical
terms, 7, 216 are allergens, and 1, 269 are natural products—including cannabis. This dictionary, is
an evolved version of a previously developed pharmacokinetic ontology [439] used in Correia, Li,
and Rocha [RBC7].
5.3.2 Social media putative DDI identification
We extracted known DDI from social media co-mention triplets within a one week time-window.
From these, we built proximity networks and analyzed edges with strong connections to the terms
initially used to collect the social media timelines. We introduced triplet co-mention and proximity
networks from social media data in chapter 4. More formally, given the set X of all matched
terms, for each cohort we compute a symmetric triplet co-occurrence graph Rw(X) for time-window
resolution of w = 1 week. These graphs are represented by adjacency matrices Rw, where entries
ri,j , ri,k, and rj,k denote the number of time-windows where the triplet (xi, xj , xk) co-occurred, in all
user timelines, where i ∈ XDrugs, j ∈ XDrugs∪XAllergen∪XNatural product, and k ∈ XMedical term; see
section 5.3.1 for dictionary details. Superscripts of X denote subsets of X based on the term type.
To obtain a normalized strength of association among the set of terms X, we computed proximity
graphs [117], Pw(X). Thus, the entries of the adjacency matrix Pw of a proximity graph are given
by:
pi,j =
ri,j
ri,i + rj,j − ri,j , ∀xi,xj∈X (5.1)
where pi,j ∈ [0, 1] and pi,i = 1; pi,j = 0 for terms xi and xj that never co-occur in the same time-
window in any timeline, and pi,j = 1 when they always co-occur. This measure is the probability
that two terms are mentioned in the same time window, given that one of them was mentioned
[116, 117]. To ensure enough support exists in the data for proximity associations, we computed
proximity weights only when ri,i + rj,j − ri,j ≥ 10; if ri,i + rj,j − ri,j < 10, we set pi,j = 0.
Next we validate each edge in the proximity network, Pw(X), against DrugBank [159], our gold
standard for DDI. Edges connected to our seeded terms (e.g., Fluoxetine in the depression cohorts),
with strong evidence from social media timelines, such that pi,j ≥ 0.1, and that are known DDI,
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are then selected for temporal co-mention comparison. In total 28 pairs, known to be a DDI and
extracted from social media co-mentions triplets, were compared to clinical reporting and scientific
publications. These pairs can be seen in table C.1.
5.3.3 First seen temporal Distances between drug pair mentions
Temporal distances are calculated based on the first seen evidence of specific DDI in each analyzed
data set. More formally, we define ϕi,j ∈ I ⊆ N as a known DDI between drugs i, j, where again,
i ∈ XDrugs, and j ∈ XDrugs ∪ XAllergen ∪ XNatural product. I denotes all known DDI present in
DrugBank [159]. Each DDI, ϕi,j , has an associated evidence timeline, Tni,j = {t : t ∈ N}ni,j , where
t denotes the day evidence of drug pair (i, j) was co-mentioned, and n ∈ E = {CR, SPclinical ,
SPin-vitro , SPin-vivo , SMtwitter , SMinstagram } are possible evidence types. CR, SP and SM denotes
time-resolved data sets from clinical reporting, scientific publications, and social media, respectively.
First seen evidence of DDI drug pair (i, j) in data set n is defined as tn0,i,j . We then compute the
distance between first seen evidences in different data sets, assuming without loss of generality that
tn0,i,j ≤ tm0,i,j , as:
∆n→mi,j = (t
m
0,i,j − tn0,i,j) ∀ n,m ∈ E . (5.2)
Thus ∆n→mi,j ∈ N, is the difference in days between first seen evidence between different evidence
data sets n and m; n→ m is read n then m. A normalized version of ∆n→mi,j is calculated as
∆˜n→mi,j =
∆n→mi,j∑
k,l∈In→m∆
∆n→mk,l
, (5.3)
where In→m∆ = {i, j : ∃ ∆n→mi,j }, are the interaction pairs (i, j) for which a temporal distance
exists—that is, |Tni,j | > 0 and |Tmi,j | > 0. We also tally the number of times a specific evidence type
was first seen in comparison to others, as
Φn→m =
∑
i,j∈In→m∆
(∆n→mi,j > 0) , (5.4)
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with Φn→m ∈ N.
When computing distribution of temporal distances we limited values to a maximum of 60
years. In total 30 DDI pairs exceeded this threshold: 12 where SPin-vitro → CR; 5 were SPin-vitro
→ SPclinical and SPin-vivo → CR; 3 were SPin-vivo → SPclinical and 1 was SPin-vitro → SPin-vivo .
5.4 Results
We start comparing known DDI uncovered from social media discourse, against clinical reporting
(CR) and scientific publication (SP). We restrict DDI from social media to those connected to
seeded terms used to collect our social media cohorts. These DDIs were extracted from knowledge
networks built from triplet co-mentions—for instance two drugs and a symptom (see section 5.3.2).
In the depression cohort on Instagram, three known DDI co-mentions were identified connected
to our seeded terms (see table C.1). All were first mentioned in CR: (Citalopram, Mirtazapine),
(Trazodone, Gabapentin), and (Duloxetine, Paroxetine). Not surprisingly, after first co-mentions
in FAERS, they were subsequently seen together in SP of clinical type. In the case of (Citalopram,
Mirtazapine), 14 years separated the initial reports to the clinical scientific evidence, but only 1
year to subsequent in-vitro evidence; no in-vivo publication was identified for the first two drug pairs.
Interestingly, (Trazodone, Gabapentin) was not identified for either in-vivo or in-vitro literature
evidence type, but was identified by Instagram posts about 9 years after published literature of
clinical type. On Twitter only one DDI was identified connected to seeded terms. The known DDI
between (Venlafaxine, Trazodone) was co-mentioned and, similarly to the Instagram cohort, it
was first identified in FAERS (in 1989), and then 5 years later in the scientific literature of clinical
(1994) and in-vivo (2007) type.
In the epilepsy cohort on Instagram, 8 known DDIs were found. Of these, 5 were initially iden-
tified in FAERS, while 3 in scientific publications of in-vitro type, from which the pair (Diazepam,
Alprazolam) was also seen as clinical at the same date. Four of them are initially seen in CR (i.e.,
FAERS) and then in SP of clinical, in-vitro, and in-vivo type, respectively in that order. Though
others fail this pattern. The pair (Oxcarbazepine, Phenobarbital) was first seen in the scientific
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Figure 5.1: Relative numbers of known DDI posts in social media (Twitter & Instagram), reports in clinical reporting
(FAERS), and papers in the scientific literature (MedLine) for the term pair (Diazepam, Hydrocodone). Dashed and
dotted vertical lines show when Twitter and Instagram platforms were publicly released, respectively.
literature as in-vitro evidence type, then as in-vivo, and only after was it reported to FAERS (see
timeline in fig. C.3). Another, (Diazepam, Hydrocodone) was initially seen in FAERS, in 1982, and
then subsequently on Twitter and the scientific literature of clinical type in 2009 (see fig. 5.1). In
2011, the pair was co-mentioned on Instagram. But it wasn’t until 2016 that it was seen as scientific
evidence of in-vivo type. It was also in 2016 that the FDA released a safety announcement about the
serious risk of death when combining opioid pain or cough medicines with benzodiazepines [460].
For this case specifically, social media co-mentions predate in-vivo scientific evidence and public
announcement from a regulation agency. However, drug co-mention alone is not sufficient to argue
that this pair was discussed in the context of a DDI, despite our efforts to only select drug pairs
that were co-mentioned with a third medical term—our co-mentions triplets.
Using our previously developed SyPMToM tool (see chapter 4 and Correia, Li, and Rocha
[RBC7]) we can navigate the social media posts in an effort to understand the circumstances in
which this pair was discussed in social media. In May 2009 an Instagram user wrote2:
“anti-depressant and Diazepam. My other 4 tablets are various painkillers [..] Good luck
with your [noun]!”.
The user further continues in a subsequent post:
2Post content has been edited to preserve user privacy and avoid de-anonymization
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“[..] Mine are similar to vicodin, they’re also given to heroin addicts as a substitute.
30mg Dihydrocodeine per tablet [..]”
Vicodin is brand name for Hydrocodone. A different user in March 2011 writes:
“My talent 4 [adjective] & [adjective] humor isn’t working anymore. Vicodin, vodka &
valium have lost their zing - and I’m the "strong" 1 of the bunch.”
Valium is brand name for Diazepam. 3 days later the user complements:
“Head is splitting open. Vicodin isn’t even touching it. I wanna run away from home.”
A third example for June 2011:
“Fighting migraine but I won’t miss [noun]. DVR set just in case my valium/motrin
cocktail actually works. [phone brand] needs a Vicodin app.”
Finally, a forth example from February 2011:
“Thanx [noun]. I’m fought out 4 the day. I think chocolate covered valium w/vicodin
is about as meaningful as about anything out there”
The discussion on social media presents evidence that the drug pair (Diazepam, Hydrocodone)
were being administered together. From the textual content alone, however, we were not able to
find direct evidence of ADR from this particular DDI, although the drug pair had to be mentioned
with a third term (i.e. a symptom) to be identified by our methods.
From the epilepsy cohort on Twitter, 10 DDIs were found. 6 were initially found in clinical reports
on FAERS. The additional 4 were initially seen in the published literature of in-vitro (2) and of
clinical type (2). Three of then, however, (Zolpidem, Diazepam), (Lamotrigine, Risperidone), and
(Zonisamide, Levetiracetam), have not been identified with in-vivo evidence type, but have been
mentioned in both Twitter and Instagram.
In the opioids cohort on Instagram we found 5 known DDIs connected to our seeded terms.
All 5 of them were initially seen in FAERS. However, after CR, 2 of them, namely (Amphetamine,
Oxycodone) and (Oxycodone, Dextroamphetamine), were then seen as social media co-mentions. The
former in both Twitter and Instagram (see fig. C.2), while the latter only on Twitter, but both before
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Table 5.1: Numbers of DDI analyzed per data source and evidence type.
Data set type |Tni,j | (%)
Clinical reporting 107,949 (89.63%)
Scientific publications 44,862 (37.25%)
Scientific publications clinical 34,904 (28.98%)
Scientific publications in-vitro 22,990 (19.09%)
Scientific publications in-vivo 5,629 (4.67%)
their initial appearances in the scientific literature. Furthermore, neither was found as in-vitro
or in-vivo type of evidence to this date. Additionally, the pairs (Amphetamine, Oxycodone) and
(Oxycodone, Hydrocodone) had no match for scientific evidence of in-vivo type. For the opioid
cohort on Twitter, the only known DDI found was the pair (Oxycodone, Hydrocodone), already
described for the Instagram case.
Next, we conduct a systematic temporal co-mention analysis between clinical reports (CR)
and the scientific publications (SP). Unfortunately, we are unable to include social media in this
analysis due to temporal data limited to recent years. In total we compared |I| = 120, 444 known
DDI retrieved from DrugBank against our co-mention timelines. Table 5.1 shows the number of
DDI for which we found co-mention evidence, per type. About 90% of all DDI were co-mentioned
in FAERS and 37% were co-mentioned in the scientific literature. From these, 29% appeared in
literature predicted to contain evidence of clinical type, 19% as in-vitro, and about 5% as in-vivo
evidence type.
Looking at which data set presents first-seen co-mention evidence of DDI, we report that CR
evidence was seen before SP (ΦCR→SP) for 13, 540 DDIs, while SP was seen before CR (ΦSP→CR)
for 17, 644 DDIs (Binomial test, p = 9.29−120); a 4, 104 difference.
We then consider not only which data set precedes the other, but the temporal distance between
first-seen co-mention evidence. Our results shows that about 51% of the time a DDI pair occurs
for the first time in one data set, it takes 1 to 8.4 years for it to occur in another data set. This
rate decay gradually with some 16% of new evidence taking 19 years or more to be seen (see the
temporal distribution in fig. C.4). A temporal distance comparison between CR and SP, however,
shows a different picture. For co-mention evidence of different types that are temporally separated
only by a few years (i.e., 1 to 8.4 years), CR tends to precedes SP. Conversely, as this distance
grows, SP then tends to precede CR. However, when considering the mean first seen distance of all
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Figure 5.2: Normalized temporal distances, ∆˜n→mi,j , between clinical reporting (CR) and scientific publications (SP).
Blue (orange) bars denote the fraction of evidence first seen in clinical reporting (scientific publications).
Table 5.2: Number of first seen co-mention evidence per data source and evidence type. Larger numbers in pairwise
comparison are denoted in bold.
m
Φn→m CR SP clinical SP in-vitro SP in-vivo
n
CR - 12,106 6,270 2,649
SP clinical 13,424 - 6,933 2,601
SP in-vitro 9,515 5,638 - 2,219
SP in-vivo 2,072 1,099 1,147 -
DDIs, CR significantly precedes SP. (see fig. 5.2; KS and t-test therein).
We then further breakdown SP in three different evidence types—SPclinical , SPin-vitro , and
SPin-vivo (see section 5.3.3). Table 5.2 shows the number of DDI that was first seen, per data source
and evidence type. These results show that CR precedes SPin-vivo (Binomial test; p = 4.72−17);
SPclinical precedes CR (p = 1.66−16), SPin-vitro (p = 7.27−31), and SPin-vivo (p = 4.72−17); and
lastly, SPin-vitro precedes CR (p = 4.84−148) and SPin-vivo (p = 2.16−77).
We then again consider the temporal distance between first-seen co-mention evidence, this time
with SP broken down by evidence type. In fig. 5.3 of Appendix C we show the pairwise comparison
of distance distributions as well as a mean distance comparison (KS and t-test therein). When
looking at the distances, again a different picture emerges. In all comparisons, CR precedes all
other types of SP evidence for short distances (i.e., 1 to 12.1 years), but again the inverse is true
for longer distances (i.e., ≥ 15.8 years). The mean distance, however, is shown to be significant
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Figure 5.3: Normalized temporal distance, ∆˜n→mi,j , between clinical reporting (CR) and different evidence types of
scientific publications (SP), such as clinical, in-vitro, and in-vivo.
lower for CR than for any other SP evidence type. Among SP evidence types, ours results show
that the SPin-vivo precedes SPclinical and SPin-vitro evidence for short distances (i.e., 1 to 8.4 year),
but is surpassed at greater distances. The mean distance comparison, however, show that SPin-vivo
is significantly seen before the other two. Lastly, SPclinical is seen for short distances (i.e 4.7 to
12.1 years) before SPin-vitro ; and the inverse is true for greater distances. The mean distance shows,
however, that SPclinical on average is significantly first seen between the two. We must note that the
mean distances when comparing CR to different SP evidence types are larger than when comparing
among the evidence types of SP (see KS and t-test in fig. 5.3). We discuss these results and some
limitations of our work in the next section.
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5.5 Discussion
Drug-drug interaction is a major source of adverse drug interactions, which result in extensive human
suffering and financial burden for private and public systems alike. Despite this fact, polypharmacy
is on the rise—specially in older ages—and thus uncovering new data sources for DDI discovery is
of utmost importance. Towards this goal, several studies have recently shown that social media is
an important source of scientific knowledge for both DDI and ADR [59, 72, 277, 278, 279, 280, 288],
including our own work [RBC7]. However, none of these studies have questioned whether evidence
of DDI on social media is new, and therefore precedes that of official sources, such as FAERS and
the scientific literature. In this work we show a preliminary study that addresses this question, and
to the best of our knowledge, is the first to do so.
Despite the small amount of longitudinal data that is available from social media in comparison
to clinical reporting and the scientific literature (see fig. C.1), we found anecdotal evidence that co-
mention of DDI may precede that of other official sources. The DDI pair (Diazepam, Hydrocodone)
was uncovered by our triplet co-mention networks as then identified as being first co-mentioned in
both Twitter and Instagram well before it was seen as in-vivo or in-vitro evidence in the scientific
literature. Specifically, it was first seen in 2010 and 2011 in Twitter and Instagram, respectively.
And even though we found evidence for this pair in FAERS long before any other type of evidence,
it was only in 2016 that the FDA released an official safety announcement about the serious risk of
death it poses. We also found that the pair (Amphetamine, Oxycodone) was also first co-mentioned
in social media but at a smaller scale. However, we must stress that we only found two cases—one
with little evidence—where social media preceded other data sources, among the 28 DDI inspected.
Furthermore, a qualitative analysis of the context in which the drug pair (Diazepam, Hydrocodone)
was discussed in social media did not help elucidate possible early warning signals. An added dif-
ficulty is that the potential risk of death from this DDI is difficult to validate from social media
discourse alone. Nonetheless, this result may prove specially important for newer, or even recently
repurposed, drugs. As longer historical social media becomes available, additional temporal valida-
tions, such the one we present here, will be enabled. The fact that older generations are increasingly
utilizing social media also may prove of future importance, despite the fact that current social media
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users are mostly younger people, and thus little prone to discuss drugs in general prescribed to older
patients. The inclusion of social media data also enables discovery of drugs that are not officially
being co-prescribed—and thus not present in either FAERS or PubMed—possibly shining light into
unknown DDI affecting individuals that are administering drugs for recreational purposes.
The results we present also raises an issue to public health agencies and regulators. Scientific
access to social media data is increasingly difficult (e.g., Facebook & Instagram), and content holders
have little to no incentives to perform such studies. Our results show that social media data needs to
be made safely available to public health analysis and pharmaco-epidemiologists. In similar fashion,
we argue, to what was done to clinical reporting [119].
The relatively small time interval of social media data that is available prevents a systematic
temporal validation of DDI co-mention. We therefore used only FAERS and MedLine as data
sources to investigate their general temporal pattern. Our intuition was that most—if not all—DDI
were initially seen through clinical reporting. Once physicians, and the general public reported
them in large enough numbers, public health analysis and scientists would then pick up on this
signals to investigate the case further. We expected only then, to see any evidence of scientific
publication of the DDI. There is also the case of which type of DDI evidence was first seen in the
scientific literature. We expect that early DDI communication could be a clinical case or note,
published in a medical journal. Only after we would expect to see any evidence of in-vitro and
in-vivo communication. Also, between the latter two, we also would expect to first see in-vitro
studies, as these are much cheaper to conduct than clinical trials. We must also note that this
evidence type differentiation has never been done for scientific publications. For instance, there is
currently no MeSH term in PubMed that identifies DDI papers specifically of in-vivo, or in-vitro
type. Therefore to the best of our knowledge, our work is the first such attempt to identify DDI
per evidence type.
Our results show that a large proportion of known DDI were seen as co-mentions in FAERS
(90%). Conversely, only a small proportion of DDI pairs appear in PubMed, specially for in-vitro
(19%) and in-vivo (4.7%) evidence types. This result demonstrates the difficulty in gathering in-
vivo evidence for DDI, while at the same time strengthening the importance of FAERS for DDI
discovery. Importantly, it suggests that most DDI is yet to be tested scientifically. However, we
must note other potential reasons for such difference. It could be that some papers may not mention
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the drugname, but a general drug class (e.g., Selective Serotonin Reuptake Inhibitor (SSRI) instead
of Fluoxetine) thus failing to be picked up by our automatic methods. The same would be true
for older FAERS data, for which no disambiguation identifier is available and inputs may contain
misspellings. Furthermore, even though our machine learning pipeline achieves great performance
in classifying DDI papers per evidence type, it might still contain false positives. That is, the subset
of papers we analyze may not encompass all DDI papers published. Nonetheless, that should not
preclude nor hamper the systematic analysis we conducted. As our classifiers are further refined in
future work, we expect additional results to further help identify gaps in the DDI literature.
On the temporal patterns, surprisingly, we found that in general scientific publications of DDI
precede clinical reporting. We actually expected the inverse, but perhaps this could represent the
differences among drug interactions or the modern advances in high-throughput screening that only
recently enabled large scale investigation of drugs and targets. A qualitative analysis of which DDI
pertain to each group is forthcoming, but outside the scope of the present work.
Give this result, we then conjectured that the temporal distance from first seen in one data
source to another would vary across the DDI spectrum. And this in turn could be a representation
of the complexity in the study and development of drugs for different diseases and drug targets.
Analyzing the temporal distance between first seen evidences across data sources we found that, in
general, about 51% of all first seen distances happen between 1 and 8.4 years; 24% between 8.4 and
15.8 years; 15% between 15.8 and 23 years; and then some 10% of new evidence takes 23 years or
more to be seen. This result reflects the complexity in DDI discovery and the long time it takes for
them to be discovered. In fact, most DDI are only discovered well after drugs have been approved
and are in widespread use.
Our computed distance also allowed us to investigate whether there were temporal differences
between first seen evidence across different data sources and evidence types. Interestingly, we found
that DDI with small temporal distances were in general first seen in clinical reporting. Conversely,
those with larger temporal distance were first seen in scientific publishing. This result may be
linked to DDI that were easier to be uncovered, such as those commonly reported or that have large
pathway overlap; in contrast to those that are rare in the population due to genetic mutation, or
that have small pathway overlap, thus requiring additional, and perhaps multiple, laboratory and
clinical testing.
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When comparing temporal distances among all evidence types, clinical reporting was seen first—
most for shorter distances, then being overtaken in longer distances by their scientific publication
counterparts of clinical, in-vitro, and in-vivo type; and thus consistent with previous result above.
Surprisingly, when comparing among scientific evidence types, in-vivo was first seen, followed by
clinical, and then by in-vitro evidence type. This was somehow unexpected and may well represent
different types of DDI, or perhaps different discovery methods, characterizing the temporal evolution
of DDI investigation by the scientific method. It may well represent different types of DDI that
could only be discovered after the invention of new techniques or machinery to process then, such
as high-throughput screening. We must also note that, even though our results are significant,
the observed differences among scientific publications of different type are relatively small. When
comparing between clinical reporting and scientific evidence, the differences are notably larger. Also,
all types have a large number of outliers, which may represent the peculiarities of overlapping drug
pathways or rare DDI. As noted above, a more qualitative analysis of this result to disentangle
possible underlying mechanics for such temporal system will be forthcoming and thus outside of the
scope of the present work. In future work we will attempt to predict specific knowledge gaps in the
literature, pointing towards an effective means of predicting and possibly driving DDI discovery.
In this work we analyzed the temporal discovery of DDI in different data sources, including
social media. Our results shine light onto the role of social media platforms for public health
monitoring and pharmacovigilance, specially as new drugs are developed or repurposed. Towards
that end, we argue for a preemptive role of health agencies to ensure social media historical data is
made easily and safely available for public health research. Our results on the discovery patterns
of different evidence types also points towards an effective means of predicting and possibly driving
DDI discovery towards filling existent knowledge gaps.
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Chapter Six
Putting it all together: an integrative, systems approach to DDI
monitoring and discovery
“How could a device made of silicon be conscious?
How could it feel pain, joy, fear, pleasure and
forebonding? (...) A moment’s reflection should
convince you that it is equality amazing that such
capacities should show up in, of all things, meat.”
Andy Clark
Professor of Philosophy
6.1 Reconciling problems and results
In this thesis we studied the prevalence and prediction of known DDI and ADR in a variety of
heterogeneous data sources—from electronic health records, to social media, clinical reporting, and
the scientific literature. We also attempted to uncover possible unknown DDIs that were left for
future work to prove their real existence or not. The results we achieve in this thesis were also
possible due to the interdisciplinary approach we pursued, using methods from complexity science
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and its sub-fields of data and network science. This allowed us to study the DDI phenomena in
novel ways and to uncover results not previously known by the public or the scientific community in
general. Below we summarize our findings and contributions while matching our proposed questions
and hypothesis to the results of our work.
In chapter 3 we studied the extent to which primary and secondary care patients were co-
administering drugs that are known to interact (Problem 1). To answer this question we measured
risk, computed statistical analysis and built machine learning classifiers on drug administration data
from the the public health care system of Blumenau, southern Brazil. We found that the prevalence
of DDI in the Blumenau is widespread, demonstrated by the long list of known DDI prescribed to
almost 5% of the entire population (Question 1). We were also able to characterize patients being
prescribed such DDI (Question 2). In fact, we showed that women are at increased risk of DDI
when compared to their male counterparts (Hypothesis 1 was confirmed). However we found that
education level, or any other neighborhood-level variables, such as average income or crime rates,
not to play a role in the prevalence of DDI (Hypothesis 2 and 4 to 6 were disproved). This result,
along with prescription and DDI rates across Blumenau neighborhoods indicated an equitable and
fair access to public health care services. Moreover, we found that the increased risk of DDI for
older populations, specially women of older age, are worst-than-random. This result was based
on computed null models. Lastly, overall the increased risk of DDI does grows linearly with age
(Hypothesis 3 was disproved). We were also successful in predicting patients likely have at least one
DDI (Question 4) using machine learning classifiers. However, we found that only age and gender
alone were not sufficient to achieve acceptable performance measures (Hypothesis 7 was disproved),
which were only increased with the inclusion of the dispensed drugs the patient had administered
(Hypothesis 8 was confirmed).
Then, in chapter 4, we studied whether social media discourse contained known DDI and ADR
co-mentions in three different relevant populations. We also investigated whether complex networks
methods could help in the prediction of unknown DDI and ADR (Problem 2). To address this
problem we used social media data from Twitter and Instagram along with text-mining, proximity
and distance closure graphs. Our analysis showed that both Twitter and Instagram contained DDI
and ADR evidence in user timelines that could be extracted as co-mentioned terms (Questions 5
and 6 were positive). From a complex networks perspective we then asked whether the knowledge
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networks, and the semi-metric topology of these co-mention networks, could help predict DDI and
ADR associations (Question 7). In these knowledge networks, terms associated with specific health
conditions or co-morbidities tended to cluster, and could be investigates using spectral methods
(Hypothesis 9 was confirmed). When using a dictionary of symptoms to build our networks, we
found that high ranked proximity edges were indeed associated with known ADR in the scientific
literature. A manual inspection of the top 25 terms found 12 such known ADR. When looking at
the high ranked semi-metric edges, we also found evidence that could point to possible still unknown
ADRs, from an anecdotal case and clinical reporting (at this point Hypothesis 10 and 11 seemed
confirmed for ADR). We then enlarged our dictionaries and built triplet co-mention networks—e.g.
from the triplet (drug, drug & symptom)—to focus specifically on possible DDIs. Edges in these
networks were also systematically validated for DDI and ADR from two gold standards. In our triplet
co-mention networks, however, we found metric and semi-metric edges not to be directly associated
with known DDIs: they were found throughout the range of proximities and not increasingly in
metric edges. We conjecture that the increase in dictionary terms unbalanced the signal-to-noise
ratio in our networks, or that the process of DDI and ADR in social media discourse is not related
to shortest paths (Hypothesis 10 and 11 were then disproved for DDI and ADR). To enhance the
DDI signal from social media discourse, we the focused on two-step ego-networks seeded from terms
used to collect our cohorts. In these ego-networks we found several known DDI and ADR (up
to 50% of edges in some cases). We believe these ego-networks are a better representation of the
macro level behavior of our cohorts of interest when specifically attempting to uncover DDIs. Also,
in these ego-networks we found several edges between drugs and symptoms that could in fact be
yet unknown DDI and ADR. The confirmation of such edges is left for future work as it requires
biomedical testing.
After confirming that social media contained evidence of both DDI and ADR, in chapter 5 we
asked whether this evidence could precede official means of DDI research, such as clinical reporting
and scientific literature (Problem 3 and Question 8). We limited the analysis to known DDI found
connected to the seeded terms used to collect our cohorts of interest. We used text-mining, time
series, and statistical analysis to address the problem. Of all 28 known DDI extracted from social
media discourse, we only found two cases where their co-mention preceded other evidence types.
In a majority of cases evidence was first seen in clinical reporting, from FAERS. The known DDI
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pair (Diazepam, Hydrocodone) was seen co-mentioned in social media up to 7 years before any in
vivo or in vitro evidence, and 5 years before the FDA released a safety announcement of the DDI
(anecdotal evidence for the confirmation of Hypothesis 12). However, a qualitative analysis of the
context in this drug pair was discussed in social media did not find evidence for a possible early
warning signal of DDI. An added difficulty is the fact that the potential risk of death from this DDI
is difficult to validate from social media discourse alone. Overall, we believe this result is in part due
to limited temporal social media data. In the future, as more data is made available and new DDIs
are discovered, a stronger confirmation of this hypothesis may be possible. We also conducted a
systematic temporal evaluation of when DDIs were first seen between clinical reporting and scientific
publications, including different evidence types. We discovered the significant temporal order to
be: first in clinical reporting to FAERS (Hypothesis 13 is confirmed), then in scientific literature
evidence of in vivo, then clinical, and finally of in vitro type (Hypothesis 14 is disproved). However,
we discuss some limitation of our work in the comparison among different scientific publications
evidence types (see section 5.5). For instance, although differences were significant, the were rather
slim. A more qualitative analysis is warranted in future work. Another surprising result was that a
large proportion of known DDIs could not be located as co-mentions in scientific publications. For
instance, only 19% of all known DDI had in-vitro evidence. For in-vivo we only found 4.7%. In
contrast, about 90% of all known DDI had co-mention evidence in FAERS. This result demonstrates
the difficulty in gathering in-vivo evidence for DDI, while at the same time strengthening the
importance of FAERS for DDI discovery. Our results on the discovery patterns of different evidence
types points towards an effective means of predicting and possibly driving DDI discovery towards
filling existent knowledge gaps.
To summarize, in this thesis we learned about the widespread co-administration of DDI, and its
increased risk for women and older patients. The worst-than-random chance of being prescribed a
DDI in older age, specially for women, was indeed disheartening. We also learned of a potential
much higher cost of hospitalizations caused by major DDI than previously thought, which can reach
$2-7 US dollars per capita, per year. Soothing, we learned that computation intelligence pipelines
can helps us identify patients at increased risk of DDI, thus possibly helping decrease overall DDI
levels in a population. While investigating social media for its potential for ADR and DDI discovery,
we learned it contains abundant mentions of drugs, symptoms, and natural products. And most
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importantly, these mentions can be leveraged using complex networks methods for precision public
health, both at the individual and population levels. We also learned that social media may play an
increasingly important role in the investigation of ADR, specifically from DDI, specially as longer
historical social media data becomes available. We found anecdotal evidence that mentions of DDI
in social media may actually precede that of official means, such as scientific publications. Finally,
we also learned about the large knowledge gap that exists in the study of different evidence types
of DDI. Less than 5% of all known DDI are have any scientific evidence of in-vivo type. Overall, we
learned that methods from complexity science, such as data and network science, can be effectively
used to address 21th century problems, such as the DDI phenomena.
Beyond the results we presented, this thesis also made available python packages that are freely
available to the community. On network closure computation, backbone extraction and metrics
mentioned in chapter 4, we released DistanceClosure (github.com/rionbr/distanceclosure).
For the computation of redundancy and control in biologically inspired Boolean network models,
we released CANA (github.com/rionbr/CANA). Even though it did not pertain to the DDI phe-
nomena, we discussed Boolean network models in section 2.2.1. Lastly, we have also released the
implementation of VTT (github.com/rionbr/VTT), a machine learning classifier previously devel-
oped by our group and used in literature mining tasks [308, 314].
6.2 Future perspectives
One of the most important recognition in science is whether ideas and methods put forwards by
scientists are endorsed by their colleagues and funding agencies. The work we presented in this
thesis, or methods we described therein, have provided the opportunity to foster collaborations
with a diverse range of researchers and laboratories, in the United States, Europe and Brazil. These
collaborations are specially important in the context of the transdisciplinary research agenda, put
forward by this thesis. The work we presented also contributed to secure a grant award.
Our social media analysis for public health, presented in chapter 4 and published in Correia, Li,
and Rocha [RBC7], contributed to a collaboration with Professors Katy Börner and Wendy Miller
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on an National Institutes of Health (NIH) and National Library of Medicine (NLM) grant award.
The work we presented in chapter 3 was the first analysis of electronic health records our group
ever conducted. This data came from Pronto, the city-wide health information system I helped
develop prior to my doctoral studies. This work has contributed to foster a collaboration with
Alfonso Valencia and his laboratory in Barcelona, Spain; and a continuing collaboration with the
Technology Development and Transfer Laboratory (LDTT), in Blumenau, Brazil. In the context of
heterogeneous health data, we are also fostering a collaboration with Joana Gonçalves Sá, from the
Instituto Gulbenkian de Ciência (IGC) and the Nova School of Business and Economics, in Oeiras,
Portugal. Also from IGC, we are currently working with Paulo Navarro-Costa, on redundancy
reduction and controlability of biologically relevant Boolean network models, briefly detailed in
section 2.2.1. Lastly, our metric backbone computation are also being used in collaboration with
Alain Barrat, in Marseilles, France. These network backbones are helping in the prediction of
epidemic spreads using data from physical proximity (contact) networks, described in section 2.2.4.
As it may be apparent from these collaborations, there is plenty of work to be done in the
future. Opportunities for several other doctoral students to continue the research agenda this thesis
initiates. In chapter order, I will now list some of them.
The electronic health records data from Blumenau enables countless scientific questions to be
pursued, with ramifications that can enhance the quality of life of citizens in Blumenau and else-
where. Results from our data-driven approach, presented in chapter 3, directly require further
interdisciplinary work to be elucidated. For instance, it is still unclear whether physicians in Blu-
menau prescribed DDIs out of lack of information, habit, or necessity. It is also unclear whether
the inclusion of new drugs to the public health care system can lower the amount of DDIs we dis-
covered. Further research should also uncover actual hospitalization cost from DDI prescribed at
primary- and secondary-care, which in this thesis were estimated. A direct collaboration with re-
searchers from the new interdisciplinary program in Collective Health at the Universidade Regional
de Blumenau (FURB) can help elucidate these questions. Furthermore, general health questions
about disease trajectories—the odds of patients developing additional health complications given
their current disease—can result in better health care and treatments for complex conditions, such
as epilepsy and Alzheimer’s disease. Few large-scale studies so far have been able to characterize
this phenomena and discover new disease trajectories [216, 217]. The EHR data from Blumenau
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are a perfect match to compare and uncover novel evidence of disease trajectories. Additionally,
the inclusion of EHR from other locations—through our network of collaborators, like Joana Sá, in
Portugal, or Alfonso Valencia, in Barcelona—can spark multi-country comparison of DDI prevalence
and other public health issues.
The DDI work based on social media data also has additional potential for further development.
The inclusion of additional cohorts of interest into SyMPToM, through collaborations with domain
experts in different conditions, can also help solidify the importance of social media to public
health monitoring and surveillance. Naturally, for conditions with high social stigma [23], other
social media platforms could be investigated. These can include specialized discussion forums and
chatroom data, for example. In fact, we have additional data sets that could be readily analyzed by
new students within the same methodology we applied in this thesis. Examples include “ChaCha”,
a short messaging system data set, and the Epilepsy Foundation forums and chatrooms data sets.
Also, further methodological work can be done to enhance the dictionaries we used. As social media
discourse is far from standardized language used in books, the translation of idiomatic expressions
into standardized medical terminology is an arduous tasks. Recent advances in Deep Learning
methods may provide an avenue towards achieving better results with this task. We are currently
building an interdisciplinary team of scientists to tackle such questions in multiple health related
data sources.
The preliminary temporal analysis we conducted using clinical reports, scientific literature and
social media data also has potential for future research. Specifically, the release of a drug timeline
database, where individual drugs could be inspected temporally of when facts were discovered about
them, could greatly enhance our understanding of the dynamics of DDI research, including lobbying
from the industry and changes in public health policy. For instance, this database would contain
dates and references of when certain interactions and adverse reactions were found, but also when
it became available or was retracted from countries, with a detail evolution of the textual content
of their labels. Most importantly, it could be made open-source and free of charge. The temporal
dynamics in the scientific literature alone, with different DDI evidence types, can prove useful to
drive DDI research and grant funding. Detecting possible knowledge gaps in specific drugs, or even
drug classes, can also help elucidate and discover possible new ADRs from DDIs.
Finally, our work on Boolean models, which were not included as a complete chapter in the
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thesis, enables a myriad of new and important research opportunities. Boolean models can be used
as computationally efficient and simplified models of biochemical and gene regulatory networks in
systems biology. In these networks nodes are genes, proteins, drugs compounds, or even qualitative
states, such as cell death (apoptosis). Constructing new biologically relevant models, using CANA
to test and predict their dynamical behavior, can help accelerate costly and strenuous biological
research. These models can help us better understand the complex machinery of human biology
on a mechanistic level. This, of course, requires a transdisciplinary approach with collaborations in
diverse fields of biology.
It is my intent to become a bridge scientist, among collaborators from diverse fields and back-
grounds, to help advance our understanding of the multi-level complexity of human health. In this
thesis we laid the groundwork for this future career path.

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Appendix A
Supplemental material for chapter 3: City-wide analysis of electronic
health records reveals gender and age biases in the administration of
known drug-drug interactions
A.1 Projected Cost of DDI in hospitalizations
Estimating the financial burden of DDI prescribed in primary and secondary care is difficult, since
outcomes vary by a large margin and only few result in short-term symptoms requires hospital-
ization. Measuring hospitalizations due to DDI are also strenuous, since underestimation of true
risk can be masked in practitioners and pharmacists failing to recognize adverse patient outcomes
caused by DDI as such. However, drug- and cohort-focused studies have shown that the number of
DDI is associated with a significantly increased risk of hospitalization [461, 462]. A review paper
in 2007 [33] estimated that DDI were held responsible for 0.054% of emergency room (ER) visits,
0.57% of hospital admissions (4.8% in the elderly population) and 0.12% of re-hospitalizations. The
most common outcomes were gastrointestinal bleeding (32.8%), hypertension/hypotension (18%)
and cardiac rhythm disturbances (18%).
In this section a study of the financial burden of possible DDI-related hospitalizations is pre-
sented. It considers various rates of hospitalization expected for major DDI co-administrations, and
is based on a cost estimate of ADR hospitalizations in Canada [28], and average hospitalization
costs for Brazil at city, state and national levels. As average hospitalization costs were not found
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Table A.1: Population, number of hospitalizations, and average cost per hospitalization in the analyzed period shown
for city, state and national levels. Population follows the official projections for 2015. Hospitalization numbers and
cost shown by type. Urgent hospitalization values in parenthesis shown for patients over 64 years old. Note Blumenau
has a much higher average cost per hospitalization than state and national levels. Brazil data from Hospitalization
Information System (Sistema de Informações Hospitalares do SUS; SIH/SUS) [417]. Ontario data from Wu, Bell,
and Wodchis [28], adjusted for inflation.
Blumenau Santa Catarina Brazil Ontario
city state national province
Population 338,876 6,819,190 204,450,649 13,680,425
Hospitalization
Elective 9,761 146,395 3,391,088 -
Urgent 24,592 (5,808) 507,189 (110,748) 13,440,043 (2,711,527) -
Work Accident 87 2,106 64,485 -
External Causes 786 902 110,922 -
Total 35,226 656,592 17,006,538 -
Avg. Cost
Elective R$ 3,764.62 R$ 1,533.10 R$ 1,583.45 -
Urgent R$ 2,606.03 R$ 1,379.13 R$ 1,083.23 C$ 8,443.14
Work Accident R$ 1,663.27 R$ 2,595.45 R$ 1,541.38 -
External Causes R$ 2,321.31 R$ 2,203.50 R$ 1,256.36 -
for the United States, results in Canadian dollars were also converted to US dollars. Our estimation
then relies on guessing what proportion patients with major DDI co-administrations are likely to
cause ADR that require hospitalization.
To compute costs we gathered number of public health care hospitalizations and average costs
for each level (see table A.1) from the national Hospitalization Information System (Sistema de
Informações Hospitalares do SUS ; SIH/SUS), a data source managed by the Informatics Department
under the Executive Secretary of Brazil’s Ministry of Health [417].
As reported, the number of patients prescribed a major DDI in Blumenau (city level) was
|UΦ,s=major| = 5, 224. For state and national levels, we estimated this number from the percentage
of hospitalizations it represents at city level, a reasonable assumption due the lack of data that
generalizes medical practice in Blumenau for the state and country. For example, say 261 (or 5%)
Pronto patients prescribed a major DDI had to be hospitalized. In hospitalization terms, that
accounts for 1.06% of all hospitalizations in the same period. At the state and national level,
the same 1.06% accounts for 5,376 and 142,564 patients, respectively. Cost are then estimated by
multiplying the number of assumed patients hospitalized by the average hospitalization cost, per
level.
Wu, Bell, and Wodchis [28] argued in 2007 that the average cost of ADR-related hospitalization
for all adults over 65 in the province of Ontario (pop. 12M in 2006; 13.6M in 2014) was C$ 7,528
(C$ 8,443.14 or $7,380.78 in 2014 when adjusted for inflation and exchange rate) for a total annual
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cost of C$ 13.6 million (C$ 15.2M or $13.3M after adjusting), or estimated C$ 35.7 million (C$
40M or $35M after adjusting) in Canada. In an attempt to compare results, we also multiplied
the number of patients assumed to have been hospitalized to their average cost of ADR-relation
hospitalization (see columns 6 and 7 of table A.2). Moreover, tables A.2 to A.4 show the estimated
costs at different percentages of hospitalizations at city, state and national levels, respectively. Costs
in Brazilian Reais (columns 4 and 5) are computed based on the average cost of hospitalization in
Brazil. Costs in C$ use Wu, Bell, and Wodchis [28] as reference (columns 6 and 7), and then
converted to US$ with the average exchange rate between the two currencies for the whole period
of our data (columns 8 and 9).
The average exchange rate in the period was C$1.00 Canadian dollar equals to $0.8742 US dollar,
and maximum and minimum rates were .9418 in January 4th 2014 and .7821 in March 14th 2015,
respectively.
Despite the numbers presented above, we still need to guess a reasonable number of DDI-related
hospitalizations upon which our cost predictions should be based. We can provide two educated
guesses that rely on previous work, which uncovered a fraction of hospitalizations found to be due
to DDI or ADR. Following ML, M, PW, LE, HG, and BH [33], we could assume that 0.57% of
all hospital admissions were due to DDI, which in our data would correspond to 2.68% (140) of
all patients prescribed a major DDI (see last two rows in table A.2). Alternatively, we can follow
Wu, Bell, and Wodchis [28] and assume that 0.75% of all hospitalizations of patients over 65 years
old were due to ADR—but not necessarily from DDI—, which brings the percentage of affected
patients to 8.35% (436). Costs are then calculated based on the number of patients presumably
affected—either 140, 436 or any other proportion of patients, as shown in tables A.2 to A.4—over
the average cost of hospitalization at each level: city, state, or country. This means that if we
consider 140 patients hospitalized due to DDI-related ADR, Blumenau had $1M in direct cost from
such hospitalizations, extrapolated to $21M and $565M when state and country levels as considered,
respectively. A comparable per citizen cost can also be calculated as the total cost, divided by the
respective population, at each level. Using the same 140 patients as our guess, the per capita cost
for Blumenau is $688, 873/338, 876 = $2.03 (see values in tables A.1 and A.2). The cost for the
state of Santa Catarina and Brazil are $2.09 and $1.84, respectively. Similarly, the cost for Ontario
is $13, 334, 044.31/13, 680, 425 = $C0.97. Note the $13,3M is the C$13,6M from [28] adjusted for
188
inflation and exchange rate, and 13,6M is the population of Ontario in 2014. Furthermore, if we
consider 436 (8.35%) or 522 (10%) patients were hospitalized, the per capita cost for Blumenau is
$6.33 and $7.58, respectively. This suggests that the financial burden of DDI is at least twice more
severe than previously thought.
To put these numbers in context we can compute per capita costs using Brazilian average
hospitalization costs (see table A.1). The per capita cost of DDI are then R$0.72, R$0.39, and
R$0.27, for city, state and national level, respectively. Brazil’s minimum monthly wage was R$724
(R$9,412/year1) in 2014, and workers in Blumenau received on average 2.9 wages a month [416].
This constitutes an average gross income of R$2,099.60 a month (R$27,294.80/year). If we assume
the same 140 patients were hospitalized due to ADR caused by DDI, the direct cost of such hospi-
talizations is equal to 3,707 lost productive worker/days (considering an 8 hour working day), with
possible much higher indirect costs.
Some limitations should be noted. When comparing to ML, M, PW, LE, HG, and BH [33],
data from IBGE [416] includes patients over 64, while in their work the authors included patients
over 65 years old. Our analysis then possibly contains additional patients exactly age 65, although
we do not believe this affects the results presented given their large difference. In general, other
studies [33] divide hospital admissions only between two categories, emergency room (ER) visits and
hospitalizations. It is not possible to conclude whether electives or external causes are included in
their hospitalization numbers. SIH/SUS data are only available for patients that were hospitalized
in the public system, meaning the cost of hospitalization was billed to the public system. Therefore,
if a patient was hospitalized and his/her private insurance covered the costs, the SIH/SUS would
have no record of it. Furthermore, SIH/SUS provides the number of hospitalizations broken down
by type. These consist of “electives” (e.g., schedules cesareans), “urgencies”, “work accidents”, and
“other external causes” (codes V01 to Y98 of ICD-102; e.g., car accident, poisoning, and drowning).
To better approximate reality, we have calculated the cost of DDI-related hospitalizations only using
the number of urgent hospitalizations.
1Brazilians receive a 13th salary in December. Thus, yearly gross income is calculated by a 13, and not by a 12,
multiplier.
2http://www.datasus.gov.br/cid10/V2008/WebHelp/v01_y98.htm
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Table A.2: Projected cost of DDI for the city of Blumenau in Reais (R$), Canadian Dollars (C$) and US dollars
(US$) for the analysis period (18 months) and yearly (12 months). Each row calculates the associated cost based on
different proportion of patients who had at least one major DDI and required hospitalization. Last row shows the
projected cost when only 0.75% of all hospitalizations of patients over 64 years old are considered, based on results of
Wu, Bell, and Wodchis [28]. Similarly, second-to-last row shows projected cost when only 0.57% of all hospitalization
are considered, based on results of ML, M, PW, LE, HG, and BH [33]. In the 18 month period, Blumenau had a
total of 24,592 public health care emergency hospitalizations, from which 5,808 were of patients age over 64 years
old. Average cost per hospitalization in the city is R$ 2,606.03. US$ costs were calculated based on C$ exchange rate
of .8742, the average rate in the study period.
Cost R$ Cost CA$ Cost US$
ph |UΦmajor| % of hosp. 18 months 12 months 18 months 12 months 18 months 12 months
100% 5,224 21.24% 13,613,909 9,075,940 44,106,963 29,404,642 38,557,213 25,704,809
50% 2,612 10.62% 6,806,955 4,537,970 22,053,482 14,702,321 19,278,606 12,852,404
30% 1,567 6.37% 4,083,652 2,722,434 13,230,400 8,820,267 11,565,688 7,710,458
25% 1,306 5.31% 3,403,477 2,268,985 11,026,741 7,351,161 9,639,303 6,426,202
20% 1,044 4.25% 2,720,697 1,813,798 8,814,638 5,876,425 7,705,538 5,137,025
10% 522 2.12% 1,360,349 906,899 4,407,319 2,938,213 3,852,769 2,568,513
5% 261 1.06% 680,174 453,450 2,203,660 1,469,106 1,926,384 1,284,256
2.68% 140 0.57% 364,844 243,230 1,182,040 788,026 1,033,310 688,873
8.35% 436 0.75% 1,136,230 757,487 3,681,209 2,454,139 3,218,022 2,145,348
Table A.3: Projected cost of DDI for the state of Santa Catarina in Reais (R$), Canadian Dollars (C$) and US
dollars (US$) for the analysis period (18 months) and yearly (12 months). Each row calculates the associated cost
based on different proportion of patients who had at least one major DDI and required hospitalization. Last row
shows the projected cost when only 0.75% of all hospitalizations of patients over 64 years old are considered, based
on results of Wu, Bell, and Wodchis [28]. Similarly, second-to-last row shows projected cost when only 0.57% of all
hospitalization are considered, based on results of ML, M, PW, LE, HG, and BH [33]. In the 18 month period, Santa
Catarina had a total of 507,189 public health care emergency hospitalizations. Average cost per hospitalization in
the state is R$ 1,379.13. US$ costs were calculated based on C$ exchange rate of .8742, the average rate in the study
period.
Cost in R$ Cost in CA$ Cost in US$
ph |UΦmajor| % of hosp. 18 months 12 months 18 months 12 months 18 months 12 months
100% 107,726 21.24% 148,567,620 99,045,080 909,545,700 606,363,800 795,102,280 530,068,187
50% 53,863 10.62% 74,283,810 49,522,540 454,772,850 303,181,900 397,551,140 265,034,093
30% 32,307 6.37% 44,555,391 29,703,594 272,772,524 181,848,349 238,450,972 158,967,314
25% 26,931 5.31% 37,141,215 24,760,810 227,382,203 151,588,136 198,771,880 132,514,586
20% 21,555 4.25% 29,727,039 19,818,026 181,991,883 121,327,922 159,092,788 106,061,859
10% 10,752 2.12% 14,828,352 9,885,568 90,780,641 60,520,428 79,358,184 52,905,456
5% 5,376 1.06% 7,414,176 4,942,784 45,390,321 30,260,214 39,679,092 26,452,728
2.68% 2,890 0.57% 3,985,671 2,657,114 24,400,675 16,267,116 21,330,464 14,220,309
7.71% 8,306 0.75% 21,645,699 14,430,466 70,128,721 46,752,481 61,304,788 40,869,858
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Table A.4: Projected cost of DDI for Brazil in Reais (R$), Canadian Dollars (C$) and US dollars (US$) for the
analysis period (18 months) and yearly (12 months). Each row calculates the associated cost based on different
proportion of patients who had at least one major DDI and required hospitalization. Last row shows the projected
cost when only 0.75% of all hospitalizations of patients over 64 years old are considered, based on results of Wu,
Bell, and Wodchis [28]. Similarly, second-to-last row shows projected cost when only 0.57% of all hospitalization
are considered, based on results of ML, M, PW, LE, HG, and BH [33]. In the 18 month period, Brazil had a total
of 13,440,043 public health care emergency hospitalizations. Average cost per hospitalization in the country is R$
1,083.23. US$ costs were calculated based on C$ exchange rate of .8742, the average rate in the study period.
Cost in R$ Cost in CA$ Cost in US$
ph |UΦmajor| % of hosp. 18 months 12 months 18 months 12 months 18 months 12 months
100% 2,854,665 21.24% 3,092M 2,061M 24,102M 16,068M 21,070M 14,046M
50% 1,427,332 10.62% 1,546M 1,031M 12,051M 8,034M 10,535M 7,023M
30% 856,130 6.37% 927M 618M 7,228M 4,819M 6,319M 4,213M
25% 713,666 5.31% 773M 515M 6,026M 4,017M 5,267M 3,512M
20% 571,201 4.25% 619M 412M 4,823M 3,215M 4,216M 2,811M
10% 284,928 2.12% 309M 206M 2,406M 1,604M 2,103M 1,402M
5% 142,464 1.06% 154M 103M 1,203M 802M 1,051M 701M
2.68% 76,608 0.57% 83M 55M 647M 431M 565M 377M
7.12% 203,365 0.75% 530M 353M 1,717M 1,145M 1,501M 1,001M
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A.2 Drug Interactions
This section lists DDI found in the analysis. Data source for these interactions were retrieved
from http://wifo5-04.informatik.uni-mannheim.de/drugbank/. This dataset was last updated
in 2011 and it contains the DrugBank ID for each pair of drugs and a textual description of the
interaction. The latest (version 5.0) version of the DrugBank database includes a much larger
number of interaction although much of the interaction at the top of the list could not be validated
from a second source, namely Drugs.com [222]. Thus we opted for a more conservative approach
with fewer number of overall unique interaction that we could attribute a severity score from a
second data source.
From Drugs.com [222], the description of each severity score is as follow:
• Major : Highly clinically significant. Avoid combinations; the risk of the interaction outweighs
the benefit.
• Moderate: Moderately clinically significant. Usually avoid combinations; use it only under
special circumstances.
• Minor : Minimally clinically significant. Minimize risk; assess risk and consider an alternative
drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Note that some interactions present in DrugBrank were not found in Drugs.com. These are
marked as None.
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Table A.9: Top 20 major DDI pairs (i, j) by rank of |UΦi,j |, the number of patients affects by the DDI (1st and
2nd columns, respectively). The normalized drug pair footprint in the population (γΦi,j) as well as the normalized
co-administration length (τΦi,j), are shown in columns 3 and 4, respectively. Mean (± s.d.) co-administration length,
〈λui,j〉, is shown in column 5 (in days) for each DDI pair (i, j) whose English drug names are shown in columns 6 and
7. The relative gender risk of DDI pair co-administration, RRIFi,j , is shown in column 8. DDI severity classification,
according to Drugs.com, shown in column 9.
rankΦ |UΦi,j | γΦi,j τΦi,j 〈λui,j〉 i j RRIFi,j severity
2 2117 0.18 0.23 53 ± 74 ASA Ibuprofen 1.42 Major
5 1190 0.19 0.45 127 ± 127 Amitriptyline Fluoxetine 3.55 Major
7 892 0.14 0.20 56 ± 61 Fluconazole Simvastatin 2.63 Major
16 470 0.63 0.55 160 ± 133 Diltiazem Simvastatin 1.27 Major
23 257 0.16 0.42 123 ± 130 Imipramine Fluoxetine 3.08 Major
27 222 0.02 0.47 148 ± 139 Fluoxetine Lithium 1.79 Major
33 154 0.01 0.33 94 ± 92 Fluoxetine Nortriptyline 2.70 Major
36 148 0.14 0.49 168 ± 160 Haloperidol Lithium 1.31 Major
47 91 0.01 0.52 154 ± 142 Atenolol Diltiazem 1.19 Major
62 52 0.08 0.49 118 ± 114 Digoxin Amiodarone 0.56 Major
63 51 0.00 0.23 93 ± 90 Hydrochlorothiazide Lithium 2.90 Major
73 31 0.01 0.20 48 ± 66 Propranolol Salbutamol 6.61 Major
84 25 0.03 0.56 157 ± 136 Diltiazem Amiodarone 1.26 Major
85 24 0.00 0.05 3 ± 2 Diclofenac Warfarin 0.84 Major
89 23 0.03 0.47 152 ± 143 Diltiazem Propranolol 2.01 Major
89 23 0.00 0.16 36 ± 44 Fluconazole Haloperidol 1.33 Major
91 22 0.00 0.07 9 ± 4 Ciprofloxacin Warfarin 1.02 Major
93 21 0.01 0.08 10 ± 6 Tobramycin Furosemide 3.01 Major
95 19 0.00 0.07 10 ± 7 Ciprofloxacin Aminophylline 1.21 Major
97 18 0.00 0.13 33 ± 44 Fluconazole Warfarin 0.89 Major
Table A.10: Top 20 known DDI pairs (i, j) by rank product (1st column) of the ranks of γΦi,j and γΦj,i, the normalized
drug pair footprint in the population (1st, 2nd and 3rd columns, respectively). The number of patients affected by
the drug pair, |UΦi,j |, is shown in column 4. Mean (± s.d.) co-administration length, 〈λui,j〉, is shown in column 5
(in days) for each DDI pair (i, j) whose English drug names are shown in columns 6 and 7. The relative gender risk
of DDI pair co-administration, RRIFi,j , is shown in column 8. DDI severity classification, according to Drugs.com,
shown in column 9; DDIs or drugs not found in Drugs.com are labeled as None or *, respectively.
rankp(γ) γΦi,j γ
Φ
j,i |UΦi,j | 〈λui,j〉 i j RRIFi,j severity
1 0.50 0.61 524 243 ± 188 Haloperidol Biperiden 0.62 Moderate
2 0.59 0.12 385 155 ± 125 Digoxin Furosemide 0.61 Moderate
3 0.19 0.36 5078 102 ± 95 Omeprazole Clonazepam 2.28 Moderate
4 0.10 0.50 1249 141 ± 124 ASA Glyburide 0.89 Moderate
5 0.42 0.14 272 140 ± 114 Digoxin Spironolactone 0.58 Minor
6 0.63 0.02 470 160 ± 133 Diltiazem Simvastatin 1.27 Major
7 0.27 0.15 173 109 ± 96 Digoxin Carvedilol 0.53 Moderate
8 0.04 0.44 496 103 ± 87 ASA Gliclazide 0.78 None
9 0.04 0.31 999 87 ± 86 Omeprazole Diazepam 1.21 Moderate
9 0.19 0.09 1190 127 ± 127 Amitriptyline Fluoxetine 3.55 Major
11 0.14 0.16 148 168 ± 160 Haloperidol Lithium 1.31 Major
12 0.07 0.22 535 152 ± 132 Atenolol Glyburide 1.22 Moderate
13 0.18 0.08 186 142 ± 156 Haloperidol Carbamazepine 0.62 Moderate
14 0.18 0.06 2117 53 ± 74 ASA Ibuprofen 1.42 Major
14 0.20 0.04 1460 54 ± 77 Atenolol Ibuprofen 1.88 Moderate
16 0.02 0.24 222 148 ± 139 Fluoxetine Lithium 1.79 Major
17 0.03 0.18 201 107 ± 95 Atenolol Gliclazide 1.09 None
18 0.01 0.26 154 94 ± 92 Fluoxetine Nortriptyline 2.70 Major
19 0.28 0.00 149 115 ± 109 Phenytoin Omeprazole 0.80 Moderate
20 0.03 0.17 377 143 ± 138 Fluoxetine Carbamazepine 0.98 Moderate
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Table A.11: Top 20 known DDI pairs (i, j) by rank of τΦi,j , the normalized co-administration length (1st and 2nd
columns, respectively). The number of patients affected by the drug pair, |UΦi,j |, is shown in column 3. Mean (± s.d.)
co-administration length, 〈λui,j〉, is shown in column 4 (in days) for each DDI pair (i, j) whose English drug names
are shown in columns 5 and 6. The relative gender risk of DDI pair co-administration, RRIFi,j , shown in column 7.
DDI severity classification, according to Drugs.com, shown in column 8; DDIs or drugs not found in Drugs.com are
labeled as None or *, respectively.
rankτ τΦi,j |UΦi,j | 〈λui,j〉 i j RRIFi,j severity
1 0.70 524 243 ± 188 Haloperidol Biperiden 0.62 Moderate
2 0.60 1249 141 ± 124 ASA Glyburide 0.89 Moderate
3 0.60 385 155 ± 125 Digoxin Furosemide 0.61 Moderate
4 0.58 535 152 ± 132 Atenolol Glyburide 1.22 Moderate
5 0.57 95 140 ± 126 Propranolol Glyburide 1.61 Moderate
6 0.56 25 157 ± 136 Diltiazem Amiodarone 1.26 Major
7 0.56 13 122 ± 113 Propranolol Methyldopa 8.50 Major
8 0.55 470 160 ± 133 Diltiazem Simvastatin 1.27 Major
9 0.55 5 82 ± 86 Propranolol Aminophylline 1.06 Major
10 0.55 272 140 ± 114 Digoxin Spironolactone 0.58 Minor
11 0.53 2 288 ± 213 Phenytoin Medroxyproges. Ac. inf Moderate
12 0.52 91 154 ± 142 Atenolol Diltiazem 1.19 Major
13 0.51 1 31 ± 0 Phenytoin Sulfadiazine 0.00 Moderate
14 0.50 90 161 ± 157 Imipramine Carbamazepine 1.35 Moderate
15 0.50 377 143 ± 138 Fluoxetine Carbamazepine 0.98 Moderate
16 0.49 226 151 ± 145 Amitriptyline Carbamazepine 0.99 Moderate
17 0.49 52 118 ± 114 Digoxin Amiodarone 0.56 Major
18 0.49 1 179 ± 0 Phenytoin Levonorgestrel inf Major
18 0.49 1 179 ± 0 Phenytoin Ethinyl Estradiol inf Major
20 0.49 148 168 ± 160 Haloperidol Lithium 1.31 Major
0.000.010.020.030.040.05
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Figure A.1: The joint probability a patient was dispensed at least one drug P (Uν>0,y,g), had co-administrations
P (UΨ,y,g), or had a DDI P (UΦ,y,g), given age range ([y1, y2]) and gender (g), are shown in blue, orange and red
lines, respectively. Values for age group y ≥ 90 were aggregated for plotting. Population distribution for Blumenau
P (Ωy,g) is shown as a green fill. A Kolmogorov-Smirnov test cannot reject the hypothesis that both the female and
male distribution of patients with at least one co-administration known to be DDI (UΦ,y,g) are drawn from the same
underlying continuous distribution (KS = .3810, p-value = .0706).
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Figure A.2: Left. Mean number of drugs dispensed (νu) to patients in each age group. Middle. Mean number
of drug pairs co-administered (Ψu) by patients in each age group. Right. Mean number of drug pairs known to be
a DDI (Φu) co-administered by patients in each age group. Numbers for male and female patients shown in lighter
and darker colors, respectively. In all plots vertical bars denote the standard deviation.
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Figure A.3: Left. Absolute number of patients with at least one co-administration per age group, |UΨ,[y1,y2]|.
Right. Absolute number of patients with at least one co-administration per age group and gender, |UΨ,[y1,y2],g|.
Table A.12: The 2nd column lists the numbers of interactions, Φs, per DDI severity class (1st column); percentages
of interactions per class are shown in parenthesis. Drugs or interactions identified in DrugBank but not present in
Drugs.com are tallied as None. Interactions for Berotec tallied as *. The 3rd column lists the number of patients
affected by at least one interaction |UΦs |, per DDI severity. Fourth and fifth columns lists the proportion of patients
in each DDI severity class for the Pronto system and the entire Blumenau populations, respectively. Notice that the
same patient may have been administered DDI of more than one severity type.
severity s Φs |UΦs | |UΦs |/|U | |UΦs |/|Ω|
Major 5,968 (22.50%) 5,224 3.94% 1.54%
Moderate 18,335 (69.13%) 12,711 9.58% 3.75%
Minor 542 (02.04%) 528 0.40% 0.16%
None 1,489 (05.61%) 1,314 0.99% 0.39%
* 190 (00.72%) 179 0.13% 0.05%
Total 26,524 (100%) 19,956 -% -%
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A.3 Relative Risk per gender
Table A.13: Absolute number of patients and relative risk measures per gender (g, 1st column). Columns 2 through
5 lists, per gender, absolute numbers of: patients (|Ug|), patients with at least 2 administrations (|Uν≥2|), patients
with at least one co-administration (|UΨ,g|), and patients with at least one known DDI co-administration (|UΦ,g|).
Relative Risk for women for both co-administration (RRCF ) and known DDI co-administration (RRIF ) are listed
in columns 6 and 7, respectively.
g |Ug | |Uν≥2| |UΨ,g | |UΦ,g | RRCF RRIF
Male 55,032 41,922 39,723 4,793 1.0000 1.0000
Female 77,690 62,889 59,738 10,734 1.0653 1.5864
A.4 Risk Measures per age
Table A.14: Absolute number of patients and risk measures per age range ([y1, y2], 1st column). Columns 2
through 5 lists, per age range, absolute numbers of: patients (|U [y1,y2]|), patients with at least 2 drug administrations
(|Uν≥2,[y1,y2]|), patients with at least one co-administration (|UΨ,[y1,y2]|), and patients with at least one known
DDI co-administration (|UΦ,[y1,y2]|). Per age range risk for both co-administration (RC [y1,y2]) and known DDI
co-administration (RI [y1,y2]) are listed in columns 6 and 7, respectively.
[y1, y2] |U [y1,y2]| |Uν≥2,[y1,y2]| |UΨ,[y1,y2]| |UΦ,[y1,y2]| RC[y1,y2] RI[y1,y2]
00-04 8,946 7,195 6,810 20 0.9465 0.0029
05-09 6,390 4,688 4,362 7 0.9305 0.0016
10-14 5,631 3,794 3,507 25 0.9244 0.0071
15-19 8,305 6,094 5,705 139 0.9362 0.0244
20-24 10,382 7,819 7,334 237 0.9380 0.0323
25-29 9,725 7,305 6,835 301 0.9357 0.0440
30-34 9,100 6,787 6,386 525 0.9409 0.0822
35-39 8,844 6,696 6,259 687 0.9347 0.1098
40-44 9,184 7,043 6,615 1,023 0.9392 0.1546
45-49 10,085 8,039 7,610 1,426 0.9466 0.1874
50-54 10,650 8,617 8,200 1,868 0.9516 0.2278
55-59 9,236 7,686 7,386 1,956 0.9610 0.2648
60-64 8,179 7,049 6,801 2,006 0.9648 0.2950
65-69 6,315 5,572 5,444 1,794 0.9770 0.3295
70-74 4,412 3,916 3,843 1,311 0.9814 0.3411
75-79 3,398 3,042 2,968 1,057 0.9757 0.3561
80-84 2,129 1,909 1,874 638 0.9817 0.3404
85-89 1,174 1,029 1,007 349 0.9786 0.3466
90+ 637 531 515 158 0.9699 0.3068
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Table A.15: Absolute number of male patients and risk measures per age range ([y1, y2], 1st column). Columns
2 through 5 lists, per age range, absolute numbers of: male patients (|Uy|), male patients with at least 2 drug
administrations (|Uν≥2,M,[y1,y2]|), male patients with at least one co-administration (|UΨ,M,[y1,y2]|), and male patients
with at least one known DDI co-administration (|UΦ,M,[y1,y2]|). Per age range women risk for both co-administration
(RCM,[y1,y2]) and known DDI co-administration (RIM,[y1,y2]) are listed in columns 6 and 7, respectively.
[y1, y2] |UM,[y1,y2]| |Uν≥2,M,[y1,y2]| |UΨ,M,[y1,y2]| |UΦ,M,[y1,y2]| RCM,[y1,y2] RIM,[y1,y2]
00-04 4,537 3,664 3,473 8 0.9479 0.0023
05-09 3,319 2,416 2,239 3 0.9267 0.0013
10-14 2,932 1,926 1,776 14 0.9221 0.0079
15-19 3,518 2,390 2,247 33 0.9402 0.0147
20-24 4,204 3,020 2,838 76 0.9397 0.0268
25-29 4,066 2,890 2,708 99 0.9370 0.0366
30-34 3,692 2,641 2,500 1,68 0.9466 0.0672
35-39 3,428 2,488 2,317 1,90 0.9313 0.0820
40-44 3,504 2,559 2,394 2,79 0.9355 0.1165
45-49 3,945 3,043 2,892 4,17 0.9504 0.1442
50-54 4,142 3,219 3,048 5,25 0.9469 0.1722
55-59 3,638 2,953 2,829 6,06 0.9580 0.2142
60-64 3,257 2,731 2,622 6,26 0.9601 0.2387
65-69 2,525 2,197 2,148 6,45 0.9777 0.3003
70-74 1,729 1,494 1,461 4,27 0.9779 0.2923
75-79 1,303 1,162 1,127 3,44 0.9699 0.3052
80-84 718 649 637 1,86 0.9815 0.2920
85-89 361 312 304 98 0.9744 0.3224
90+ 214 168 163 49 0.9702 0.3006
Table A.16: Absolute number of female patients and risk measures per age range ([y1, y2], 1st column). Columns
2 through 5 lists, per age range, absolute numbers of: female patients (|Uy|), female patients with at least 2 drug
administrations (|Uν≥2,F,[y1,y2]|), female patients with at least one co-administration (|UΨ,F,[y1,y2]|), and female
patients with at least one known DDI co-administration (|UΦ,F,[y1,y2]|). Per age range women risk for both co-
administration (RCF,[y1,y2]) and known DDI co-administration (RIF,[y1,y2]) are listed in columns 6 and 7, respectively.
[y1, y2] |UF,[y1,y2]| |Uν≥2,F,[y1,y2]| |UΨ,F,[y1,y2]| |UΦ,F,[y1,y2]| RCF,[y1,y2] RIF,[y1,y2]
00-04 4,409 3,531 3,337 12 0.9451 0.0036
05-09 3,071 2,272 2,123 4 0.9344 0.0019
10-14 2,699 1,868 1,731 11 0.9267 0.0064
15-19 4,787 3,704 3,458 106 0.9336 0.0307
20-24 6,178 4,799 4,496 161 0.9369 0.0358
25-29 5,659 4,415 4,127 202 0.9348 0.0489
30-34 5,408 4,146 3,886 357 0.9373 0.0919
35-39 5,416 4,208 3,942 497 0.9368 0.1261
40-44 5,680 4,484 4,221 744 0.9413 0.1763
45-49 6,140 4,996 4,718 1,009 0.9444 0.2139
50-54 6,508 5,398 5,152 1,343 0.9544 0.2607
55-59 5,598 4,733 4,557 1,350 0.9628 0.2962
60-64 4,922 4,318 4,179 1,380 0.9678 0.3302
65-69 3,790 3,375 3,296 1,149 0.9766 0.3486
70-74 2,683 2,422 2,382 884 0.9835 0.3711
75-79 2,095 1,880 1,841 713 0.9793 0.3873
80-84 1,411 1,260 1,237 452 0.9817 0.3654
85-89 813 717 703 251 0.9805 0.3570
90+ 423 363 352 109 0.9697 0.3097
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A.5 Neighborhood Analysis
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Figure A.4: Left. Number of drugs intervals dispensed αN against population ΩN in each neighborhood N . Right.
Number of drug intervals dispensed (αN ) versus number of interactions (ΦN ), per neighborhood (N), normalized by
population (ΩN ). Color denotes the average per capita income of neighborhood, in Brazilian Reais (R$). Regression
line shown in green. Patients who reported living in neighborhood Other were discarded from computation.
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Figure A.5: Top. Neighborhood average income in Brazilian Reais (R$) [416]. Middle & bottom. Age-
neighborhood bins of male (middle; UN,y,g=M/ΩN,y,g=M ) and female (bottom; UN,y,g=F /ΩN,y,g=F ) patients regis-
tered in Pronto with at least one drug dispensed and matched to DrugBank. Each bin is a probability-like value
of patients normalized by official census population data collected and defined by IBGE [416]. Green bins represent
values above 1, meaning our data has more patients than IBGE[416] census data. Conversely, cyan bins represent
values where our data contains no patient.
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A.6 DDI Networks
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Figure A.6: DDI network. A weighted version of network ∆ where weights are defined by |UΦi,j |. Nodes denote
drugs i involved in at least one co-administration known to be a DDI. Node color represents the highest level of
primary action class, as retrieved from Drugs.com (see legend). Node size represents the probability of interaction
PIi), as defined in text. Edge weights are the values of τΦi,j obtained from eq. (3.4). Edge colors denote RRI
g
i,j ,
where g ∈ {M,F}, to identify DDI edges that are higher risk for females (blue) or males (red). Color intensity for
RRIgi,j varies in [1, 5]; that is, values are clipped at 5.
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Table A.17: Louvain modules of weighted version of network ∆ where weights are defined by τΦi,j . Each Louvain
module is shown separated by a horizontal line. Drugs nodes (i; 1nd column) and their respective degree, degree
strength, and betweenness centrality measure, shown in columns 2, 3, and 4, respectively Column 5 shows the drug
probability of interaction, PI(i). Drug class is shown in column 6. Continues on Table A.18.
i deg(i) degstr(i) betweenness(i) PI(i) class
Phenytoin 24 6.51 0.30 0.20 CNS agents
Phenobarbital 15 2.17 0.28 0.05 CNS agents
Ethinyl Estradiol 9 1.78 0.03 0.04 Hormones
Doxycycline 8 1.39 0.02 0.04 Anti-infectives
Prednisone 7 0.96 0.02 0.03 Hormones
Prednisolone 6 0.54 0.03 0.00 Hormones
Diazepam 5 1.12 0.05 0.09 CNS agents
Erythromycin 5 0.20 0.18 0.01 Anti-infectives
Estradiol 4 0.57 0.00 0.01 Hormones
Estrogens Conj. 4 0.58 0.00 0.01 Hormones
Norethisterone 3 0.73 0.00 0.00 Hormones
Levonorgestrel 3 0.79 0.00 0.00 Hormones
Medroxyproges. Ac. 3 1.06 0.00 0.00 Hormones
Omeprazole 3 0.85 0.00 0.05 Gastrointestinal agents
Folic acid 2 0.50 0.00 0.00 Nutritional Products
Clonazepam 2 0.42 0.00 0.09 CNS agents
Amoxicillin 2 0.30 0.00 0.00 Anti-infectives
Clavulanate 2 0.23 0.00 0.00 Anti-infectives
Sulfadiazine 1 0.51 0.00 0.01 Anti-infectives
Trimethoprim 1 0.16 0.00 0.00 Anti-infectives
Carbamazepine 18 4.84 0.20 0.18 CNS agents
Fluoxetine 10 3.41 0.02 0.06 Psychotherapeutic agents
Haloperidol 6 2.32 0.03 0.20 Psychotherapeutic agents
Lithium 9 2.05 0.13 0.17 Psychotherapeutic agents
Fluconazole 10 1.74 0.09 0.11 Anti-infectives
Salbutamol 7 1.53 0.00 0.03 Respiratory agents
Amitriptyline 5 1.47 0.00 0.08 Psychotherapeutic agents
Imipramine 5 1.31 0.01 0.07 Psychotherapeutic agents
Nortriptyline 5 1.30 0.00 0.09 Psychotherapeutic agents
Fenoterol 8 0.81 0.13 0.01 Respiratory agents
Biperiden 1 0.70 0.00 0.13 CNS agents
Methylphenidate 1 0.24 0.00 0.02 CNS agents
Losartan 1 0.21 0.00 0.00 Cardiovascular agents
Captopril 1 0.18 0.00 0.00 Cardiovascular agents
Metronidazole 3 0.17 0.16 0.00 Anti-infectives
Enalapril 1 0.16 0.00 0.00 Cardiovascular agents
Methyldopa 7 2.30 0.01 0.06 Cardiovascular agents
Iron (II) Sulfate 5 1.12 0.02 0.04 Nutritional Products
Levodopa 3 0.97 0.03 0.01 CNS agents
Ciprofloxacin 4 0.35 0.21 0.01 Anti-infectives
Norfloxacin 2 0.29 0.00 0.01 Anti-infectives
Metoclopramide 1 0.11 0.00 0.00 Gastrointestinal agents
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Table A.18: Continuation. See Table A.17 for column description.
i deg(i) degstr(i) betweenness(i) PI(i) class
Digoxin 9 3.70 0.03 0.24 Cardiovascular agents
Warfarin 14 3.31 0.17 0.13 Coagulation modifiers
Diltiazem 6 2.66 0.03 0.13 Cardiovascular agents
Amiodarone 3 1.40 0.00 0.02 Cardiovascular agents
Furosemide 5 1.31 0.05 0.04 Cardiovascular agents
Levothyroxine 3 1.15 0.00 0.01 Hormones
Simvastatin 4 1.07 0.00 0.02 Metabolic agents
Propylthiouracil 2 0.87 0.00 0.01 Hormones
Hydrochlorothiazide 2 0.69 0.00 0.00 Cardiovascular agents
Spironolactone 1 0.55 0.00 0.02 Cardiovascular agents
Allopurinol 1 0.46 0.00 0.01 Metabolic agents
Amlodipine 1 0.34 0.00 0.00 Cardiovascular agents
Acetaminophen 1 0.22 0.00 0.00 CNS agents
Gentamicin 1 0.12 0.00 0.02 Anti-infectives
Diclofenac 2 0.09 0.03 0.01 CNS agents
Tobramycin 1 0.08 0.00 0.00 Topical Agents
Azithromycin 1 0.07 0.00 0.00 Anti-infectives
Alendronate 1 0.04 0.00 0.01 Metabolic agents
Aminophylline 10 1.93 0.23 0.01 Respiratory agents
Hydrocortisone 3 0.06 0.20 0.01 Hormones
Timolol 7 1.11 0.16 0.06 Cardiovascular agents
Ibuprofen 7 1.28 0.06 0.05 CNS agents
Atenolol 8 2.22 0.05 0.06 Cardiovascular agents
Propranolol 14 4.81 0.06 0.10 Cardiovascular agents
ASA 7 1.57 0.01 0.07 CNS agents
Verapamil 4 1.11 0.01 0.04 Cardiovascular agents
Glyburide 5 2.29 0.00 0.12 Metabolic agents
Carvedilol 6 1.70 0.00 0.07 Cardiovascular agents
Gliclazide 5 1.64 0.00 0.12 Metabolic agents
Chlorpromazine 1 0.33 0.00 0.00 CNS agents
Dexamethasone 3 0.24 0.00 0.03 Hormones
Maprotiline 1 0.23 0.00 0.01 Psychotherapeutic agents
Epinephrine 1 0.0 0.0 0.02 Respiratory agents
206
A.7 Null Model for RIy
To test if sheer combinatorics explains the increased risk of DDI in older age, we compared the
observed risk of interactions RIy with a random null model, Hrnd0 . We separated all patients u in
our dataset per age range y. From these subset of patients U [y1,y2] we also separated which drugs d
were prescribed in their age range as D[y1−y2]. For clarity, we will refer to all measures previously
reported with an added star (?) in the notation to indicate that these values are calculated for the
null model (e.g., RIy? is the null model value of the risk of interaction per age range, RIy).
The null model is then computed by proportionally sampling patients for each age range, u ∈
U [y1−y2]. For each drawn patient u we sampled |Du| drugs available to patients in the patient’s age
range D[y1,y2], and then randomly drew Ψu co-administrations from the patient’s possible pairwise
combinations
(|Du|
2
)
of drugs, thus yielding random drug pairs ψu?i,j that matched the observed
number of co-administrations, Ψu ≡ Ψu?. To decide if a co-administration is an interaction in the
null model, we compare the randomly drawn pair of drugs against DrugBank to decide if ϕu?i,j is an
interaction or not.
This null model allow us to measure what is the expected number of interactions given the
increase of co-administrations observed with age, assuming drugs are prescribed completely at ran-
dom. In other words, it measures the risk of DDI if only age, and the drugs available to patients in
these ages, were given to them at random with the same number of co-administrations.
To compute confidence intervals for the number of patients in the null model, we proportionally
sampled the same number of patients observed in each age range, 100 times. Confidence intervals
can be seen as background fills in figs. 3.4 and 3.6. To measure the significance of our null models,
table A.19 shows the chi-square tests against the expected number of patients in each age bin,
|U [y1,y2]|, from our data. The null model rejects the hypothesis it was sampled from the same
distribution as our data. This means the observed increase in DDI with age, seen in our data,
cannot be explained alone by the increased combinatorics of drug co-administrations alone.
Table A.19: Chi-square statistic when the number of patients in the null model, |Uy?|, is compared to the observed
values, |Uy|.
model chi-square p-value
1 Hrnd0 22378.5912 0.0
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A.8 Simple Regression (SR) models
In fig. 3.5 of the main manuscript we show single regression models predicting the number of
interactions. Specifically, νu predicts Ψu best with a quadratic regression (R2 = .857) as shown
in fig. 3.5-left. When it comes to predicting number of interactions (fig. 3.5, center and right), on
the other hand, there is much more dispersion of the data, which leads to a relatively small linear
correlation between Ψu and Φu (R2 = .487)—though better than the linear correlation between
νu and Φu (R2 = .304). However, higher order regressions do not improve the prediction of the
variance of Φu, as demonstrated by the Pareto front in fig. 3.5-top-right (see also section 3.5)—
thus discarding the hypothesis of a clear nonlinear relationship between co-administrations and
interactions, which could explain the growth of RI with age.
Tables below contain additional information on these and additional regression models.
Listing A.1: Ψu from νu linear model
===================================================
Ψu
νu 3.891*** (0.007)
Constant -8.818*** (0.037)
---------------------------------------------------
Observations 132 ,722
R2 0.712
Adjusted R2 0.712
Residual Std. Error 8.650 (df = 132720)
F Statistic 328 ,478.000*** (df = 1; 132720)
===================================================
Note: *p<0.1; **p <0.05; ***p<0.01
Listing A.2: Ψu from νu quadratic model
===================================================
Ψu
νu -0.121*** (0.012)
(νu)2 0.273*** (0.001)
Constant -0.023 (0.036)
---------------------------------------------------
Observations 132 ,722
R2 0.857
Adjusted R2 0.857
Residual Std. Error 6.088 (df = 132719)
F Statistic 399 ,075.300*** (df = 2; 132719)
===================================================
Note: *p<0.1; **p <0.05; ***p<0.01
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Listing A.3: Φu from νu linear model
==================================================
Φu
νu 0.110*** (0.0005)
Constant -0.267*** (0.003)
--------------------------------------------------
Observations 132 ,722
R2 0.304
Adjusted R2 0.304
Residual Std. Error 0.580 (df = 132720)
F Statistic 58 ,011.640*** (df = 1; 132720)
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
Listing A.4: Φu from νu quadratic model
==================================================
Φu
νu -0.009*** (0.001)
(νu)2 0.008*** (0.0001)
Constant -0.007** (0.003)
--------------------------------------------------
Observations 132 ,722
R2 0.372
Adjusted R2 0.372
Residual Std. Error 0.551 (df = 132719)
F Statistic 39 ,357.930*** (df = 2; 132719)
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
Listing A.5: Φu from Ψu linear model
===================================================
Φu
Ψu 0.030*** (0.0001)
Constant -0.033*** (0.002)
---------------------------------------------------
Observations 132 ,722
R2 0.487
Adjusted R2 0.487
Residual Std. Error 0.498 (df = 132720)
F Statistic 126 ,232.900*** (df = 1; 132720)
===================================================
Note: *p<0.1; **p <0.05; ***p<0.01
A.8.1 RCy models
In fig. 3.4 of the main manuscript two regressions were calculated to predict the growth of RCy and
RIy based on age range (y = [y1− y2]). Both RCy and RIy can be best approximated by a cubic
polynomial regression (see fig. 3.4 for R2) The regression lines show different growth processes for
co-administration and interaction risks. RCy first decreases in children age range [5-14], followed
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by an almost flat level between ages [15,44] before a steeper growth is observed for older age groups
(see shaded area in fig. 3.4-left). In contrast, RIy is initially quite flat and only starts to increase
after the age of 15, after which it has a much steeper growth curve than RC [y] (note the difference
in scale).
In addition, Tables below contain other regression models that were computed along with their
respective ANOVA comparison, when appropriate.
A linear model is the simplest model one could fit to the increased risk of co-administration.
Listing A.6: RCy linear model
===============================================
RCy
-----------------------------------------------
y 0.003*** (0.0004)
Constant 0.926*** (0.004)
-----------------------------------------------
Observations 19
R2 0.798
Adjusted R2 0.787
Residual Std. Error 0.009 (df = 17)
F Statistic 67.336*** (df = 1; 17)
===============================================
Note: *p <0.1; **p <0.05; ***p <0.01
A quadratic model fits slightly better but the increased model complexity is not significant.
Listing A.7: RCy quadratic model
===============================================
RCy
-----------------------------------------------
(y)2 0.0001 (0.0001)
y 0.001 (0.001)
Constant 0.931*** (0.005)
-----------------------------------------------
Observations 19
R2 0.820
Adjusted R2 0.798
Residual Std. Error 0.009 (df = 16)
F Statistic 36.493*** (df = 2; 16)
-----------------------------------------------
Model 1: RCy ~ y
Model 2: RCy ~ (y)2 + y
Res.Df RSS Df Sum of Sq F Pr(>F)
1 17 0.0013609
2 16 0.0012139 1 0.00014698 1.9374 0.183
===============================================
Note: *p <0.1; **p <0.05; ***p <0.01
A cubic model gives almost perfect fit while being significant for the more complex model.
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Listing A.8: RCy cubic model
===============================================
RCy
-----------------------------------------------
(y)3 -0.0001*** (0.00001)
(y)2 0.001*** (0.0003)
y -0.008*** (0.002)
Constant 0.943*** (0.004)
-----------------------------------------------
Observations 19
R2 0.936
Adjusted R2 0.923
Residual Std. Error 0.005 (df = 15)
F Statistic 72.789*** (df = 3; 15)
-----------------------------------------------
Model 1: RCy ~ y
Model 2: RCy ~ (y)2 + y
Model 3: RCy ~ (y)3 + (y)2 + y
Res.Df RSS Df Sum of Sq F Pr(>F)
1 17 0.00136086
2 16 0.00121387 1 0.00014698 5.0807 0.0395787 *
3 15 0.00043394 1 0.00077993 26.9599 0.0001094 ***
===============================================
Note: *p <0.1; **p <0.05; ***p <0.01
A.8.2 RIy models
Similarly to how we modeled RIy, with the risk of known DDI co-administration (RIy) we start
with the simplest linear model possible.
Listing A.9: RIy linear model
===============================================
RIy
-----------------------------------------------
y 0.024*** (0.002)
Constant -0.032* (0.016)
-----------------------------------------------
Observations 19
R2 0.932
Adjusted R2 0.928
Residual Std. Error 0.037 (df = 17)
F Statistic 233.631*** (df = 1; 17)
===============================================
Note: *p <0.1; **p <0.05; ***p <0.01
A quadratic model fits slightly better but the increased model complexity is not significant.
Listing A.10: RIy quadratic model
===============================================
RIy
-----------------------------------------------
(y)2 -0.0004 (0.0003)
y 0.030*** (0.006)
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Constant -0.050** (0.023)
-----------------------------------------------
Observations 19
R2 0.937
Adjusted R2 0.930
Residual Std. Error 0.037 (df = 16)
F Statistic 119.823*** (df = 2; 16)
-----------------------------------------------
Model 1: RCy ~ y
Model 2: RCy ~ (y)2 + y
Res.Df RSS Df Sum of Sq F Pr(>F)
1 17 0.023355
2 16 0.021550 1 0.001805 1.3401 0.264
===============================================
Note: *p <0.1; **p <0.05; ***p <0.01
Finally, a cubic model gives us almost perfect fit while being significant for the more complex
model.
Listing A.11: RIy Cubic model
===============================================
RIy
-----------------------------------------------
(y)3 -0.0003*** (0.00001)
(y)2 0.007*** (0.0004)
y -0.019*** (0.003)
Constant 0.013** (0.006)
-----------------------------------------------
Observations 19
R2 0.997
Adjusted R2 0.997
Residual Std. Error 0.008 (df = 15)
F Statistic 1 ,927.479*** (df = 3; 15)
-----------------------------------------------
Model 1: RIy ~ y
Model 2: RIy ~ (y)2 + y
Model 3: RIy ~ (y)3 + (y)2 + y
Res.Df RSS Df Sum of Sq F Pr(>F)
1 17 0.0233550
2 16 0.0215500 1 0.001805 30.391 5.96e-05 ***
3 15 0.0008909 1 0.020659 347.842 8.66e-12 ***
===============================================
Note: *p <0.1; **p <0.05; ***p <0.01
A.9 Multiple Regression (MR) models
This section displays several MR models that were generated in order to analyze the possible
prediction of drug interaction based on patient demographics. Tables below contain the model
results and also their respective ANOVA comparison when appropriate.
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A.9.1 Baseline (no transformation)
This is the baseline MR model with no transformation.
Listing A.12: Baseline linear regression model
==================================================
Φu
--------------------------------------------------
νu -0.026*** (0.001)
Ψu 0.035*** (0.0002)
Constant 0.041*** (0.003)
--------------------------------------------------
Observations 132 ,722
R2 0.492
Adjusted R2 0.492
Residual Std. Error 0.496 (df = 132719)
F Statistic 64 ,377.810*** (df = 2; 132719)
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
A.9.2 Baseline (transformed)
These are other baseline MR model with transformed variables
Listing A.13: Transformed baseline MR model
==================================================
Φu
--------------------------------------------------
νu -0.004*** (0.001)
Ψu 0.040*** (0.0002)
(νu)2 -0.003*** (0.0001)
Constant -0.006** (0.003)
--------------------------------------------------
Observations 132 ,722
R2 0.497
Adjusted R2 0.497
Residual Std. Error 0.493 (df = 132718)
F Statistic 43 ,696.240*** (df = 3; 132718)
--------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + (νu)2
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132718 32304 1 288.37 1184.7 < 2.2e-16 ***
==================================================
Φu
--------------------------------------------------
νu -0.033*** (0.001)
Ψu 0.038*** (0.0002)
(Ψu)2 -0.00002*** (0.00000)
Constant 0.053*** (0.003)
--------------------------------------------------
Observations 132 ,722
R2 0.494
Adjusted R2 0.494
Residual Std. Error 0.495 (df = 132718)
F Statistic 43 ,145.430*** (df = 3; 132718)
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--------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + (Ψu)2
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132718 32508 1 84.745 345.99 < 2.2e-16 ***
==================================================
Φu
--------------------------------------------------
νu -0.008*** (0.001)
Ψu 0.041*** (0.0003)
(νu)2 -0.003*** (0.0001)
(Ψu)2 -0.00000*** (0.00000)
Constant 0.001 (0.003)
--------------------------------------------------
Observations 132 ,722
R2 0.497
Adjusted R2 0.497
Residual Std. Error 0.493 (df = 132717)
F Statistic 32 ,786.680*** (df = 4; 132717)
--------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + (νu)2 + (Ψu)2
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132717 32297 2 295.59 607.33 < 2.2e-16 ***
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
A.9.3 Baseline + age + gender
This section shows the MR results when age and gender are included as dependent variables in the
baseline model.
Listing A.14: Baseline MR model added variables age and gender.
==================================================
Φu
--------------------------------------------------
νu -0.027*** (0.001)
Ψu 0.034*** (0.0002)
age 0.002*** (0.0001)
C(gender)Male -0.010*** (0.003)
Constant -0.021*** (0.004)
--------------------------------------------------
Observations 132 ,722
R2 0.496
Adjusted R2 0.496
Residual Std. Error 0.494 (df = 132717)
F Statistic 32 ,639.900*** (df = 4; 132717)
--------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + age + C(gender)
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132717 32369 2 223.56 458.33 < 2.2e-16 ***
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
214
A.9.4 Baseline (replacing Ψu with y)
Interestingly, number of co-administrations (Ψu) and age (y) are virtually exchangeable.
Listing A.15: Baseline MR model exchanging variables Ψu and y.
==================================================
Φu
--------------------------------------------------
Ψu 0.029*** (0.0001)
age 0.002*** (0.0001)
Constant -0.100*** (0.003)
--------------------------------------------------
Observations 132 ,722
R2 0.491
Adjusted R2 0.491
Residual Std. Error 0.496 (df = 132719)
F Statistic 63 ,937.920*** (df = 2; 132719)
--------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ Ψu + age
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132719 32702 0 -110.03
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
A.9.5 Baseline + education level
This section shows the OMR results when education level is included as one of the dependent
variables in the model.
Note that this model fits a smaller dataset because the number of patients that have given their
education level is smaller than the full dataset.
Listing A.16: Baseline MR model added education level variable.
================================================================
Φu
----------------------------------------------------------------
νu -0.015*** (0.001)
Ψu 0.033*** (0.0002)
C(education)Cant read/write -0.027** (0.014)
C(education)Complete college -0.007 (0.018)
C(education)Complete elementary 0.037*** (0.013)
C(education)Complete high school 0.003 (0.013)
C(education)Doctoral -0.106 (0.132)
C(education)Espec./ Residency 0.009 (0.045)
C(education)Incomplete college 0.004 (0.018)
C(education)Incomplete elementary 0.024** (0.011)
C(education)Incomplete high school -0.006 (0.014)
C(education)Masters -0.050 (0.119)
Constant 0.018 (0.011)
----------------------------------------------------------------
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Observations 61,060
R2 0.511
Adjusted R2 0.511
Residual Std. Error 0.602 (df = 61047)
F Statistic 5 ,312.884*** (df = 12; 61047)
----------------------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + C(education)
Res.Df RSS Df Sum of Sq F Pr(>F)
1 61057 22127
2 61047 22107 10 19.845 5.4801 3.472e-08 ***
================================================================
Note: *p <0.1; **p <0.05; ***p <0.01
A.9.6 Baseline + marital status
This section shows the OMR results when marital status is included as one of the dependent variables
in the model.
Listing A.17: Baseline MR model added marital status variable.
=====================================================
Φu
-----------------------------------------------------
νu -0.027*** (0.001)
Ψu 0.035*** (0.0002)
C(marital)Divorced 0.105*** (0.025)
C(marital)Ignored -0.029*** (0.008)
C(marital)Married -0.005 (0.008)
C(marital)Not informed -0.072*** (0.008)
C(marital)Separated 0.080*** (0.011)
C(marital)Single -0.014* (0.008)
C(marital)Widower 0.019* (0.011)
Constant 0.077*** (0.008)
-----------------------------------------------------
Observations 132 ,722
R2 0.494
Adjusted R2 0.494
Residual Std. Error 0.495 (df = 132712)
F Statistic 14 ,420.090*** (df = 9; 132712)
-----------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + C(marital)
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132712 32464 7 128.13 74.829 < 2.2e-16 ***
=====================================================
Note: *p <0.1; **p <0.05; ***p <0.01
A.9.7 Baseline + average neighborhood income assigned to patients
Listing A.18: Baseline MR model added average neighborhood income variable.
==================================================
Φu
--------------------------------------------------
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νu -0.026*** (0.001)
Ψu 0.035*** (0.0002)
avg_income 0.00003*** (0.00000)
Constant 0.016*** (0.005)
--------------------------------------------------
Observations 132 ,722
R2 0.493
Adjusted R2 0.493
Residual Std. Error 0.495 (df = 132718)
F Statistic 42 ,944.890*** (df = 3; 132718)
--------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + avg_income
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132718 32582 1 9.9727 40.622 1.853e-10 ***
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
A.9.8 Baseline + neighborhood safety variables assigned to patients
Listing A.19: Baseline MR model added neighborhood safety variables.
==================================================
Φu
--------------------------------------------------
νu -0.026*** (0.001)
Ψu 0.035*** (0.0002)
theft_pc -0.737*** (0.283)
robbery_p1000 -0.004 (0.003)
suicide_p1000 0.006 (0.009)
transitcrime_p1000 0.022*** (0.002)
traffic_p1000 0.008*** (0.002)
rape_p1000 -0.002 (0.004)
Constant 0.024*** (0.004)
--------------------------------------------------
Observations 132 ,722
R2 0.493
Adjusted R2 0.493
Residual Std. Error 0.495 (df = 132713)
F Statistic 16 ,148.060*** (df = 8; 132713)
--------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + theft_pc +
robbery_p1000 + suicide_p1000 +
transitcrime_p1000 + traffic_p1000 +
rape_p1000
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132713 32538 6 54.096 36.773 < 2.2e-16 ***
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
A.9.9 Baseline + neighborhood
Listing A.20: Baseline MR model added neighborhood as categorical variables.
======================================================
Φu
------------------------------------------------------
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νu -0.026*** (0.001)
Ψu 0.035*** (0.0002)
C(hood)BADENFURT -0.021 (0.014)
C(hood)BOA VISTA 0.009 (0.024)
C(hood)BOM RETIRO 0.150*** (0.036)
C(hood)CENTRO 0.012 (0.013)
C(hood)DA GLORIA -0.009 (0.013)
C(hood)DO SALTO -0.005 (0.016)
C(hood)ESCOLA AGRICOLA -0.041*** (0.012)
C(hood)FIDELIS 0.005 (0.013)
C(hood)FORTALEZA -0.030*** (0.011)
C(hood)FORTALEZA ALTA -0.029** (0.014)
C(hood)GARCIA -0.009 (0.011)
C(hood)ITOUPAVA CENTRAL 0.005 (0.011)
C(hood)ITOUPAVA NORTE -0.023** (0.011)
C(hood)ITOUPAVA SECA -0.037** (0.019)
C(hood)ITOUPAVAZINHA 0.012 (0.012)
C(hood)JARDIM BLUMENAU -0.053 (0.047)
C(hood)NOVA ESPERANCA -0.055*** (0.014)
C(hood)OTHER -0.067*** (0.010)
C(hood)PASSO MANSO 0.025* (0.015)
C(hood)PONTA AGUDA -0.009 (0.013)
C(hood)PROGRESSO -0.006 (0.011)
C(hood)RIBEIRAO FRESCO 0.010 (0.021)
C(hood)SALTO DO NORTE 0.019 (0.015)
C(hood)SALTO WEISSBACH 0.018 (0.018)
C(hood)TESTO SALTO -0.009 (0.015)
C(hood)TRIBESS -0.041*** (0.012)
C(hood)VALPARAISO -0.015 (0.014)
C(hood)VELHA -0.015 (0.011)
C(hood)VELHA CENTRAL -0.009 (0.013)
C(hood)VELHA GRANDE -0.031* (0.017)
C(hood)VICTOR KONDER 0.026 (0.024)
C(hood)VILA FORMOSA -0.225*** (0.053)
C(hood)VILA ITOUPAVA 0.015 (0.017)
C(hood)VILA NOVA -0.041*** (0.015)
C(hood)VORSTADT -0.028** (0.014)
Constant 0.067*** (0.010)
------------------------------------------------------
Observations 132 ,722
R2 0.494
Adjusted R2 0.494
Residual Std. Error 0.495 (df = 132684)
F Statistic 3 ,502.150*** (df = 37; 132684)
------------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + C(hood)
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132684 32486 35 106.61 12.441 < 2.2e-16 ***
======================================================
Note: *p<0.1; **p <0.05; ***p<0.01
A.10 Linear Mixed-Effect (LMM) models
To be sure there were not nested effects between variables gender and age, we ran a linear mixed-
model (LMM) where variable gender is nested within age. The results indicate that is not the
case.
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Listing A.21: Linear Mixed Model with age nested within gender.
Linear mixed model fit by maximum likelihood [’lmerMod ’]
ForFormula: Φu ~ νu + Ψu + (1 | age/gender)
Data: data
AIC BIC logLik deviance df.resid
189314.1 189372.9 -94651.1 189302.1 132716
Scaled residuals:
Min 1Q Median 3Q Max
-13.1102 -0.2048 -0.0734 0.0394 19.2402
Random effects:
Groups Name Variance Std.Dev.
gender:age (Intercept) 0.0001645 0.01282
age (Intercept) 0.0021678 0.04656
Residual 0.2432636 0.49322
Number of obs: 132722 , groups: gender:age , 213; age , 109
Fixed effects:
Estimate Std. Error t value
(Intercept) 0.0483215 0.0055929 8.64
νu -0.0262493 0.0007287 -36.02
Ψu 0.0343219 0.0001590 215.87
Correlation of Fixed Effects:
(Intr) νu
νu -0.367
Ψu 0.224 -0.831
To be sure that neighborhood did not differ in their DDI observations, we ran a linear mixed-
model (LMM) with neighborhood as a random effect. Our results indicate that is also not the
case.
Listing A.22: Linear Mixed Model with neighborhood as random effect.
Linear mixed model fit by maximum likelihood [’lmerMod ’]
Formula: Φu ~ νu + Ψu + (1 | hood)
Data: data
AIC BIC logLik deviance df.resid
189980.7 190029.6 -94985.3 189970.7 132717
Scaled residuals:
Min 1Q Median 3Q Max
-13.1462 -0.1846 -0.0678 0.0180 19.1046
Random effects:
Groups Name Variance Std.Dev.
hood (Intercept) 0.0005935 0.02436
Residual 0.2448642 0.49484
Number of obs: 132722 , groups: hood , 36
Fixed effects:
Estimate Std. Error t value
(Intercept) 0.0544948 0.0050850 10.72
νu -0.0264618 0.0007270 -36.40
Ψu 0.0348255 0.0001572 221.58
Correlation of Fixed Effects:
(Intr) νu
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νu -0.411
Ψu 0.268 -0.841
A.11 Patient classification
We applied machine learning classifiers in order to predict if a specific patient had at least one DDI in
the whole 18 month period. A binary classification task. Support Vector Machine (SVM)[346] and
Logistic Regression (LR)[347] are considered both standard and reliable machine learning algorithm
for binary classification problems. We built models for each classifier considering different sets of
features, including demographic (i.e., age & gender) and drugs the patient was prescribed in the
period. For baseline comparison we also ran against three null model classifiers. One with a “coin-
toss” probability of classification (Uniform), another with a bias with respect to class probability
(Biased), and a custom made (AgeGender) which finds the best age cutoff for each gender from
which it consider all patients older than the cutoff as having a DDI. Regression and classification
models were computed using R and Python [463].
A.11.1 Simple model
Patients: 132,722
DDI (positive): 15,527 (11.70%)
no DDI (negative): 117,195 (88.30%)
Features: 127
Demographic: gender† (g), age (y), number of drugs (νu), number of co-administrations
(Ψu).
Neighborhood: average income, number of thefts per capita, number of robberies per capita,
number of suicides per capita, number of transit crimes per capita, number of traffic
accidents per capita, number of rapes per capita.
Drug: all drugs D.
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Table A.20: Individual fold and mean performance of Support Vector Machine (SVM) classifier on stratified 4-
fold cross-validation, using demographic and drug features. Measures of performance shown are: Precision, Recall,
F1 (balanced Precision and Recall), Matthew’s Correlation Coefficient, the Area Under the Receiver Operating
Characteristic Curve, and the Area Under the Precision and Recall Curve.
Fold Precision Recall F1 MCC AUC ROC AUC P/R
1 0.8196 0.6309 0.7130 0.6877 0.9676 0.8269
2 0.8241 0.6494 0.7264 0.7011 0.9702 0.8365
3 0.8127 0.6504 0.7226 0.6957 0.9697 0.8315
4 0.8187 0.6436 0.7207 0.6949 0.9690 0.8311
Mean 0.8188 0.6436 0.7207 0.6948 0.9691 0.8315
Table A.21: Individual fold and mean performance of Logistic Regression (LR) classifier on stratified 4-fold cross-
validation, using demographic and drug features. Measures of performance shown are: Precision, Recall, F1 (balanced
Precision and Recall), Matthew’s Correlation Coefficient, the Area Under the Receiver Operating Characteristic
Curve, and the Area Under the Precision and Recall Curve.
Fold Precision Recall F1 MCC AUC ROC AUC P/R
1 0.8085 0.6535 0.7228 0.6953 0.9675 0.8249
2 0.8096 0.6669 0.7314 0.7037 0.9700 0.8337
3 0.7991 0.6662 0.7266 0.6977 0.9697 0.8299
4 0.8092 0.6612 0.7277 0.7002 0.9691 0.8304
Mean 0.8066 0.6619 0.7271 0.6992 0.9691 0.8297
Classifier Precision Recall F1 MCC AUC ROC AUC P/R
Uniform 0.1181 0.5075 0.1916 0.0035 0.5 0.5585
Biased 0.1147 0.1153 0.1150 -0.0026 0.4987 0.1668
GenderAge 0.2044 0.8834 0.3320 0.2751 0.7139 0.5507
Table A.22: Mean performance of Uniform (coin-toss), Biased (biased coin-toss on class distribution) and Gender-
Age (hard cutoff for gender and gender) classifiers on stratified 4-fold cross-validation, using demographic and drug
features. Measures of performance shown are: Precision, Recall, F1 (balanced Precision and Recall), Matthew’s Cor-
relation Coefficient, the Area Under the Receiver Operating Characteristic Curve, and the Area Under the Precision
and Recall Curve.
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Table A.23: Mean performance of classifiers on stratified 4-fold cross-validation, using all possible features, including
demographic, neighborhood and drugs dispensed. Measures of performance shown are: Precision, Recall, F1 (balanced
Precision and Recall), Matthew’s Correlation Coefficient, the Area Under the Receiver Operating Characteristic
Curve, and the Area Under the Precision and Recall Curve.
Classifier Precision Recall F1 MCC AUC ROC AUC P/R
SVM 0.8186 0.6442 0.7210 0.6951 0.9690 0.8312
LR 0.8070 0.6619 0.7273 0.6994 0.9690 0.8295
A.11.2 Complete model
Patients: 132,722
DDI (positive): 15,527 (11.70%)
no DDI (negative): 117,195 (88.30%)
Features: 154
Demographic: gender† (g), age (y), number of drugs (νu), number of co-administrations
(Ψu), education levels‡.
Neighborhood: average income, number of thefts per capita, number of robberies per capita,
number of suicides per capita, number of transit crimes per capita, number of traffic
accidents per capita, number of rapes per capita.
Drug: all drugs D.
A.11.3 No Drugs model
This model is similar to the “simple” model, except no drug features are used.
Patients: 132,722
DDI (positive): 15,527 (11.70%)
no DDI (negative): 117,195 (88.30%)
Features: 5
Demographic: gender† (g), age (y), number of drugs (νu), number of co-administrations
(Ψu).
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Table A.24: Mean performance of classifiers on stratified 4-fold cross-validation, using only demographic features.
Measures of performance shown are: Precision, Recall, F1 (balanced Precision and Recall), Matthew’s Correlation
Coefficient, the Area Under the Receiver Operating Characteristic Curve, and the Area Under the Precision and
Recall Curve.
Classifier Precision Recall F1 MCC AUC ROC AUC P/R
SVM 0.7578 0.3791 0.5053 0.4971 0.9185 0.6539
LR 0.7172 0.4170 0.5273 0.5044 0.9130 0.6391
Neighborhood: None.
Drug: None.
A.11.4 Feature loadings
Tables A.25 and A.26 shows the feature loading for both SVM and LR classifiers on model “simple”.
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Table A.25: Feature weights for Support Vector Machine (SVM) classifier on model “simple”.
feature coef feature coef
d=Digoxin 1.1677 d=Acetaminophen -0.1169
d=Diltiazem 0.8718 d=Tobramycin -0.1185
d=Warfarin 0.6938 d=Hydrochlorothiazide -0.1203
d=Haloperidol 0.6879 d=Norethisterone -0.1225
d=Glyburide 0.6681 d=Propylthiouracil -0.1242
d=Pyrimethamine 0.6549 d=Phenylephrine -0.1309
d=Phenytoin 0.6015 d=Estrogens Conjugated -0.1312
d=Biperiden 0.5807 d=Trimethoprim -0.1325
d=Carbamazepine 0.5752 d=Sulfamethoxazole -0.1325
d=Gliclazide 0.4735 d=Colchicine -0.1333
d=Clonazepam 0.4717 d=Diclofenac -0.1347
d=Methyldopa 0.4617 d=Ranitidine -0.1374
d=Propranolol 0.4487 d=Neomycin -0.1383
d=Lithium 0.3887 d=Bacitracin -0.1383
d=Fluconazole 0.3716 d=Nimesulide -0.1413
νi 0.3169 d=Fenoterol -0.1446
d=Acetylsalicylic Acid 0.3119 d=Nystatin -0.1508
Ψi,j 0.3080 d=Albendazole -0.1514
d=Diazepam 0.3038 d=Nitrofurantoin -0.1514
d=Omeprazole 0.2822 d=Loratadine -0.1611
d=Amitriptyline 0.2810 d=Metamizole -0.1624
d=Iron (II) Sulfate 0.2584 d=Spironolactone -0.1634
d=Ethinyl Estradiol 0.2571 d=Tramadol -0.1643
d=Ibuprofen 0.2170 d=Dexchlorpheniramine maleate -0.1664
d=Imipramine 0.1825 d=Enalapril -0.1671
d=Fluoxetine 0.1639 d=Azithromycin -0.1672
d=Verapamil 0.1455 d=Miconazole -0.169
d=Timolol 0.1452 d=Scopolamine butylbromide -0.171
d=Atenolol 0.1432 d=Metronidazole -0.1747
d=Nortriptyline 0.1159 d=Cephalexin -0.1767
d=Doxycycline 0.1046 d=Ipratropium Bromide -0.1779
d=Nifedipine 0.0973 d=Hydrocortisone -0.1812
d=Methylphenidate 0.0638 d=Metoclopramide -0.1832
d=Vaseline 0.0596 d=Levodopa -0.1872
y 0.0518 d=Medroxyprogesterone Acetate -0.1877
d=Phenobarbital 0.0274 d=Doxazosin -0.1909
d=Prednisone 0.0232 d=Amlodipine -0.1936
d=Estradiol 0.0181 d=Losartan -0.1937
d=Atropine 0.0000 d=Metformin -0.1943
d=Thiocolchicoside 0.0000 d=Mebendazole -0.1945
d=Salbutamol -0.0071 d=Fluphenazine -0.204
d=Dexamethasone -0.0102 d=Captopril -0.2041
d=Penicillin G procaine -0.0115 d=Amiodarone -0.2042
d=Simvastatin -0.0191 d=Bromazepam -0.2063
d=Gentamicin -0.0229 d=Codeine -0.2064
d=Epinephrine -0.0347 d=Valproic acid -0.2083
d=Furosemide -0.0395 d=Penicillin G Benzathine -0.2123
d=Carvedilol -0.0544 d=Aminophylline -0.2133
d=Erythromycin -0.0588 d=Clavulanate -0.2141
d=Chlorpromazine -0.0605 d=Clopidogrel -0.2162
d=Methotrimeprazine -0.0683 d=Carbidopa -0.2269
d=Morphine -0.0759 d=Insulin -0.246
d=Levothyroxine -0.0776 d=Isosorbide Mononitrate -0.269
d=Alendronate -0.0820 d=Nicotine -0.3003
d=Amoxicillin -0.0908 d=Glucose -0.305
d=Ciprofloxacin -0.0937 g = M -0.3193
d=Prednisolone -0.0944 g = F -0.3213
d=Permethrin -0.0978 d=Sodium chloride -0.3474
d=Levonorgestrel -0.0982 d=Isosorbide Dinitrate -0.351
d=Folic acid -0.0983 d=Oseltamivir -0.3643
d=Promethazine -0.1059 d=Betamethasone -0.4765
d=Maprotiline -0.1073 d=Spiramycin -0.521
d=Norfloxacin -0.1100 d=Sulfadiazine -0.5259
d=Allopurinol -0.1148 - -
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Table A.26: Feature weights on Logistic Regression (LR) classifier on model “simple”.
feature coef feature coef
d=Digoxin 3.6826 d=Norethisterone -0.4217
d=Diltiazem 2.7678 d=Amoxicillin -0.4283
d=Haloperidol 2.3874 d=Promethazine -0.4327
d=Warfarin 2.3423 d=Colchicine -0.434
d=Glyburide 2.2139 d=Hydrochlorothiazide -0.4526
d=Phenytoin 2.1363 d=Norfloxacin -0.4545
d=Carbamazepine 2.1098 d=Estrogens Conjugated -0.4683
d=Biperiden 1.9247 d=Tobramycin -0.4763
d=Clonazepam 1.6984 d=Propylthiouracil -0.4767
d=Methyldopa 1.6363 d=Trimethoprim -0.4888
d=Propranolol 1.5735 d=Sulfamethoxazole -0.4888
d=Gliclazide 1.5618 d=Acetaminophen -0.502
νi 1.4941 d=Spiramycin -0.506
d=Fluconazole 1.3668 d=Ranitidine -0.5178
d=Lithium 1.3303 d=Diclofenac -0.5242
d=Acetylsalicylic Acid 1.0479 d=Betamethasone -0.5301
d=Diazepam 1.0178 d=Nimesulide -0.5316
d=Omeprazole 1.0114 d=Neomycin -0.5318
d=Amitriptyline 0.9684 d=Bacitracin -0.5318
d=Iron (II) Sulfate 0.8905 d=Nystatin -0.5508
Ψi,j 0.7721 d=Prednisolone -0.5531
d=Ibuprofen 0.7282 d=Fenoterol -0.5542
d=Pyrimethamine 0.6518 d=Spironolactone -0.564
d=Fluoxetine 0.6245 d=Hydrocortisone -0.5778
d=Imipramine 0.6188 d=Mebendazole -0.5857
d=Atenolol 0.5100 d=Enalapril -0.5955
d=Ethinyl Estradiol 0.4965 d=Albendazole -0.5991
d=Verapamil 0.3885 d=Nitrofurantoin -0.6128
d=Doxycycline 0.3681 d=Miconazole -0.6173
y 0.3547 d=Ipratropium Bromide -0.619
d=Timolol 0.3492 d=Loratadine -0.6196
d=Nortriptyline 0.3217 d=Metamizole -0.6206
d=Nifedipine 0.2797 d=Scopolamine butylbromide -0.6347
d=Levonorgestrel 0.2220 d=Tramadol -0.6364
d=Phenobarbital 0.1465 d=Metronidazole -0.6476
d=Vaseline 0.1118 d=Dexchlorpheniramine maleate -0.6534
d=Estradiol 0.0873 d=Medroxyprogesterone Acetate -0.6733
d=Prednisone 0.0824 d=Metformin -0.6762
d=Epinephrine 0.0357 d=Azithromycin -0.6796
d=Erythromycin 0.0242 d=Captopril -0.6855
d=Thiocolchicoside -0.0044 d=Losartan -0.6882
d=Atropine -0.0128 d=Amlodipine -0.6899
d=Sulfadiazine -0.0250 d=Cephalexin -0.6901
d=Penicillin G procaine -0.0593 d=Doxazosin -0.6929
d=Salbutamol -0.0845 d=Metoclopramide -0.7212
d=Phenylephrine -0.0869 d=Aminophylline -0.7297
d=Simvastatin -0.0914 d=Codeine -0.7311
d=Dexamethasone -0.0917 d=Clopidogrel -0.7375
d=Gentamicin -0.1000 d=Amiodarone -0.7402
d=Methylphenidate -0.1019 d=Clavulanate -0.7449
d=Sodium chloride -0.1856 d=Valproic acid -0.7461
d=Fluphenazine -0.2091 d=Carbidopa -0.7552
d=Furosemide -0.2152 d=Bromazepam -0.7571
d=Methotrimeprazine -0.2171 d=Levodopa -0.7619
d=Carvedilol -0.2223 d=Penicillin G Benzathine -0.8072
d=Chlorpromazine -0.2356 d=Insulin -0.8443
d=Maprotiline -0.2791 d=Isosorbide Mononitrate -0.9186
d=Morphine -0.2889 d=Nicotine -0.9342
d=Levothyroxine -0.2929 d=Glucose -0.9742
d=Folic acid -0.3650 g = M -1.116
d=Alendronate -0.3683 g = F -1.132
d=Allopurinol -0.3954 d=Isosorbide Dinitrate -1.178
d=Permethrin -0.4101 d=Oseltamivir -1.3
d=Ciprofloxacin -0.4119 - -
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Appendix B
Supplemental material for chapter 4: Monitoring and predicting
potential drug interactions and reactions via network analysis from
social media timelines
Table B.1: Depression networks.
Twitter Instagram
Nodes 2,899 3,288
Drugs 983 (33.91%) 1,011 (30.75%)
Medical Terms 1,632 (56.30%) 1,866 (56.75%)
Allergens 184 (6.35%) 208 (6.33%)
Natural Products 100 (3.45%) 203 (6.17%)
Edges 150,054 230,797
Metric (si,j = 1) 19,174 (12.78%) 18,691 (8.10%)
Semi-metric (si, > 1) 130,878 (87.22%) 212,106 (91.90%)
Drug-Drug 20,857 (13.90%) 19,418 (8.41%)
Drug-Medical term 75,418 (50.26%) 96,116 (41.64%)
Drug-Medical term (¬DI) 74,004 (49.32%) 94,587 (40.98%)
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Figure B.1: Mention distribution for cohorts (rows) and social media platforms (columns). Absolute number of
mentions shown with circles while the cumulative number of timelines is shown as a magenta line, both per month.
The social media platform launch date is shown as a dotted line.
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Table B.2: Epilepsy social networks.
Twitter Instagram
Nodes 3,662 3,471
Drugs 1,247 (34.05%) 1,036 (29.85%)
Medical Terms 2,056 (56.14%) 2,023 (58.28%)
Allergens 200 (5.46%) 217 (6.25%)
Natural Products 159 (4.34%) 195 (5.62%)
Edges 186,322 199,204
Metric (si,j = 1) 19,770 (10.61%) 14,376 (7.22%)
Semi-metric (si,j > 1) 166,552 (89.39%) 184,828 (92.78%)
Drug-Drug 23,925 (12.84%) 16,315 (8.19%)
Drug-Medical term 84,394 (45.29%) 79,793 (40.06%)
Drug-Medical term (¬DI) 82,839 (44.46%) 78,350 (39.33%)
Table B.3: Epilepsy metric and semi-metric subnetworks for both Twitter and Instagram cohorts. Acronyms D-D
and D-MT denote edges between Drug-Drug and Drug-Medical term nodes, respectively. Percentages for DDI are
calculated from D-D edges. Percentages for ADR and DI are both calculated from D-MT edges.
Twitter Instagram
Total D-D / D-MT DDI/ADR/DI Total D-D / D-MT DDI/ADR/DI
D(si,j = 1) 206 (0.11%)
65 (31.55%) 22 (33.85%)
159 (0.08%)
43 (27.04%) 25 (58.14%)
125 (60.68%) 11 (8.80%) 93 (58.49%) 15 (16.13%)4 (3.20%) 10 (10.75%)
D(si,j > 1) 3,094 (1.66%)
1,012 (32.71%) 364 (35.97%)
3,685 (1.85%)
995 (27.00%) 360 (36.18%)
1,689 (54.59%) 149 (8.82%) 2,075 (56.31%) 267 (12.87%)19 (1.12%) 24 (1.16%)
si,j = 1 19,770 (10.61%)
3,128 (15.82%) 528 (16.88%)
14,376 (7.22%)
1,618 (11.25%) 360 (22.25%)
12,022 (60.81%) 535 (4.45%) 8,506 (59.17%) 331 (3.89%)337 (2.80%) 226 (2.66%)
si,j > 1 166,552 (89.39%)
20,797 (12.49%) 4,829 (23.22%)
184,828 (92.78%)
14,697 (7.95%) 2,856 (19.43%)
72,372 (43.45%) 4,054 (5.60%) 71,287 (38.57%) 3,658 (5.13%)1,218 (1.68%) 1,217 (1.71%)
si,j > 2 137,138 (73.60%)
16,895 (12.32%) 3,957 (23.42%)
160,448 (80.54%)
12,676 (7.90%) 2,471 (19.49%)
56,455 (41.17%) 3,158 (5.59%) 59,804 (37.27%) 3,106 (5.19%)877 (1.55%) 969 (1.62%)
si,j > 5 92,012 (49.38%)
11,147 (12.11%) 2,505 (22.47%)
114,451 (57.45%)
9,229 (8.06%) 1,823 (19.75%)
35,223 (38.28%) 1,965 (5.58%) 40,969 (35.80%) 2,094 (5.11%)470 (1.33%) 574 (1.40%)
si,j > 10 61,320 (32.91%)
7,621 (12.43%) 1,670 (21.91%)
80,183 (40.25%)
6,775 (8.45%) 1,365 (20.15%)
22,499 (36.69%) 1,244 (5.53%) 27,940 (34.85%) 1,400 (5.01%)293 (1.30%) 369 (1.32%)
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Table B.4: Opioids social networks.
Twitter Instagram
Nodes 2,344 3,544
Drugs 824 (35.15%) 1,017 (28.70%)
Medical Terms 1,286 (54.86%) 2,131 (60.13%)
Allergens 167 (7.12%) 224 (6.32%)
Natural Products 67 (2.86%) 172 (4.85%)
Edges 101,622 270,990
Metric (si,j = 1) 15,963 (15.71%) 18,919 (6.98%)
Semi-metric (si,j > 1) 85,659 (84.29%) 252,071 (93.02%)
Drug-Drug 14,602 (14.37%) 24,044 (8.87%)
Drug-Medical term 55,026 (54.15%) 118,578 (43.76%)
Drug-Medical term (¬DI) 53,941 (53.08%) 117,080 (43.20%)
Table B.5: Opioids metric and semi-metric subnetworks for both Twitter and Instagram cohorts. Acronyms D-D
and D-MT denote edges between Drug-Drug and Drug-Medical term nodes, respectively. Percentages for DDI are
calculated from D-D edges. Percentages for ADR and DI are both calculated from D-MT edges.
Twitter Instagram
Total D-D / D-MT DDI/ADR/DI Total D-D / D-MT DDI/ADR/DI
D(si,j = 1) 80 (0.08%)
16 (20.00%) 7 (43.75%)
52 (0.02%)
6 (11.54%) 4 (66.67%)
44 (55.00%) 5 (11.36%) 39 (75.00%) 5 (12.82%)2 (4.55%) 3 (7.69%)
D(si,j > 1) 1,477 (1.45%)
377 (25.52%) 146 (38.73%)
2,689 (0.99%)
690 (25.66%) 231 (33.48%)
911 (61.68%) 78 (8.56%) 1,623 (60.36%) 98 (6.04%)26 (2.85%) 27 (1.66%)
si,j = 1 15,963 (15.71%)
2,814 (17.63%) 530 (18.83%)
18,919 (6.98%)
1,703 (9.00%) 263 (15.44%)
9,930 (62.21%) 456 (4.59%) 11,058 (58.45%) 322 (2.91%)260 (2.62%) 217 (1.96%)
si,j > 1 85,659 (84.29%)
11,788 (13.76%) 2,456 (20.83%)
252,071 (93.02%)
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Figure B.2: Two-step proximity ego-network seeded from the terms used to select the depression cohort on Twitter.
Edge weight denotes the proximity values, only shown for pi,j ≥ 0.01. Node colors denote term type: drug (red),
medical term (blue), natural product (green), or allergen (yellow). Edge colors denote: known DDI (red), ADR
(blue), or DI (green); grey nodes denote unknown association. Edges with both ADR and DI are shown in cyan.
Darker (lighter) colors denote metric (semi-metric) edges. Plot generated with Gephi [448]. Drug terms Setraline,
Citalopram, and Fluvoxamine, used as inclusion criteria, had no connection in this network and were therefore
omitted.
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Figure B.3: Two-step proximity ego-network seeded from the terms used to select the epilepsy cohort on Instagram
(top) & Twitter (bottom). Edge weight denotes the proximity values, only shown for pi,j ≥ 0.01. Node colors denote
term type: drug (red), medical term (blue), natural product (green), or allergen (yellow). Edge colors denote: known
DDI (red), ADR (blue), or DI (green); grey nodes denote unknown association. Edges with both ADR and DI are
shown in cyan. Darker (lighter) colors denote metric (semi-metric) edges. Plot generated with Gephi [448]. Drug
terms Lacosamide and Carbamazepine in the Instagram network, and Lacosamide and Oxcarbazepine in the Twitter
network, all used as inclusion criteria, had no connection in the networks and were therefore omitted.
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Figure B.4: Edge distribution for all analyzed networks of co-mention triads. Left. Edge proximity distribution,
pi,j . Right. Edge semi-metric distribution, si,j . Instagram networks are represented by a solid line while Twitter
networks by a intermittent dashed line. Cohorts are then separated by color, with Depression, Epilepsy, and Opioids
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Appendix C
Supplemental material for chapter 5: Temporal signals of DDI
associations from social, clinical, and scientific sources
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Figure C.1: Absolute numbers of posts in social media (from Twitter and Instagram), reports in clinical reporting
(from FAERS), and papers in the scientific literature (MedLine).
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Figure C.2: Relative numbers of posts in social media (Twitter & Instagram), reports in clinical reporting (FAERS),
and papers in the scientific literature (MedLine) for the term pair (Amphetamine, Oxycodone). Dashed and dotted
vertical lines show when Twitter and Instagram platforms were publicly released, respectively.
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Figure C.3: Relative numbers of posts in social media (Twitter & Instagram), reports in clinical reporting (FAERS),
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vertical lines show when Twitter and Instagram platforms were publicly released, respectively.
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